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Abstract 
 
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease driven 
by vascular remodelling and inflammation. Presenting symptoms of PAH are 
nonspecific, making diagnosis often late when the disease is irreversible. 
Endothelial damage occurs early in the disease progress and medial thickening 
due to proliferating smooth muscle cells in the distal arteries is the earliest known 
pathology. Circulating microparticles (MPs) are vesicles released by various cells 
and used as markers of cell activation during inflammation and vascular damage 
in various vasculopathies. Thus, the aim was to identify circulating MPs, with a 
special interest to smooth muscle MPs, to be used as biomarkers in PAH. 
Initially, I characterised smooth muscle MPs derived from growing smooth 
muscle cells in culture. Smooth muscle MPs were positive for platelet derived 
growth factor receptor-β (PDGFR-β), endoglin, intracellular cell adhesion 
molecule (ICAM-1) and neural glial antigen 2 (NG2) but negative for platelet 
endtholial cell adhesion molecule-1 (PECAM-1). High levels of 
endoglin+/ICAM-1+ and low levels of PDGFRβ+/NG2+ MPs were derived from 
human umbilical cord vein endothelial cells. PDGF, tumour necrosis factor-α, 
transforming growth factorβ, and endothelin-1 were growth factors and cytokines 
that could stimulate the release of MPs from growing smooth muscle cells. 
 
Having characterised smooth muscle MPs (SMMPs), I investigated their levels in 
plasma from pulmonary arterial hypertension patients and compared them with 
other vascular inflammatory diseases. Circulating levels of total, smooth muscle, 
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endothelial, leukocyte, and platelet MPs were elevated in PAH patients compared 
to age-matched healthy controls and in patients with myocardial ischemia and 
HIV. PAH drugs, particularly prostacyclin mimetics were effective in decreasing 
MP numbers in cell culture and in patients after long-term therapy. 
 
The function of MPs and mechanism of their release inhibition by the prostacyclin 
analogue treprostinil was investigated. MPs in plasma and cultured smooth muscle 
cells were procoagulant, as measured using a thrombin generation assay, and 
induced smooth muscle proliferation. Treprostinil inhibited SMMP release via the 
prostacyclin receptor and the prostaglandin E2 receptor, and also inhibited cell 
proliferation. Furthermore, the mimetic inhibited calcineurin/nuclear factor of 
activated T-cells (NFAT) signalling, which was partially reversed by blockade of 
peroxisome proliferator activated receptor. As calcineurin/NFAT is a driver of 
smooth muscle proliferation and remodelling, it may be a novel target through 
which prostacyclin may be signalling. 
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1. Introduction 
Pulmonary arterial hypertension (PAH) is a rare and progressive vascular 
remodelling disease which is ultimately fatal unless patients undergo lung 
transplant. Patients with PAH belong to a group having pulmonary hypertension 
(PH) which is defined as an increase in mean pulmonary artery pressure (mPAP) 
>25 mmHg at rest as assessed by right heart catheterisation (RHC). This compares 
to a normal mPAP at rest of 14±3 mmHg with an upper limit of approximately 20 
mmHg. Patients with PAH are characterised as having pre-capillary PH defined 
by a pulmonary capillary wedge pressure (PCWP) <15 and a pulmonary vascular 
resistance (PVR) >3 Wood units (WU) without the presence of other precapillary 
causes of PH brought on by other lung diseases (Hoeper et al., 2013). 
 
PAH affects people of all age groups. Without treatment, the median survival after 
diagnosis for patients is only 3 years for adults (D’Alonzo et al., 1991) and less 
than 10 months in children (Takatsuki and Ivy, 2013). In neonates and infants, the 
development of PAH most probably arises from the failure of the neonatal 
vasculature to dilate at birth (Rabinovitch, 2012). The remarkably reduced number 
of alveolar ducts and abnormally muscularised pulmonary arteries at the alveolar 
duct and wall levels are characteristic of the disease. In older infants, children and 
adults, PAH is also characterised by intimal hyperplasia, which leads to 
pulmonary artery occlusion, a rise in vascular pressure and the formation of 
plexiform lesions (Rabinovitch, 2012). The severity of PAH can be tested using 
clinical parameters that measure pulmonary haemodynamics, exercise capacity 
24 
 
and World Health Organisation (WHO) functional class, a reliable predictor of 
survival at time of diagnosis as well as during follow-up (Galie et al., 2015b). 
 
1.1 Pulmonary hypertension Classification 
Pulmonary arterial hypertension is, as mentioned before, a group of patients with 
PH. There are 5 categories or “groups” in PH under the WHO Classification of 
Pulmonary Hypertension most recently updated at the 5th World Conference in 
Nice 2013 (Simonneau et al., 2013). The first group is termed PAH and includes a 
wide variety of causes of PH that share similar vascular remodelling 
characteristics. Under PAH are 5 main classes: Idiopathic (IPAH), heritable or 
familial (FPAH), drug and toxin induced, associated pulmonary arterial 
hypertension (APAH), and persistent PH of the newborn (Table 1).  All forms of 
PAH leads to reduced survival and pathological sequelae such as plexiform 
lesions (McLaughlin and McGoon, 2006). 
 
All other groups signify pre-capillary PH in presence of other causes. Group 2 
represents PH due to left heart disease. Group 3 represents PH associated with 
parenchymal lung disease and/or hypoxia. Group 4 represents chronic 
theromboemoblic pulmonary hypertension (CTEPH), which is the obstruction of 
the pulmonary vasculature resulting from unresolved embolus masses that 
undergo fibrosis. Group 5 represents PH with unclear and/or multifactorial 
mechanisms. 
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Classification of Pulmonary Hypertension 
Group 1: Pulmonary arterial hypertension (PAH) 
1.1 Idiopathic (IPAH) 
1.2 Heritable (HPAH) 
1.2.1 BMPR2 mutation 
1.2.2 Other mutations 
1.3 Drugs or toxins induced 
1.4 Associated with: 
1.4.1 Connective tissue disease 
1.4.2 Human immunodifficiency virus (HIV) infection 
1.4.3 Portal hypertension 
1.4.4 Congenital heart disease 
1.4.5 Schistosomiasis 
1’. Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary 
haemangiomatosis (PCH) 
1’.1 Idiopathic 
1’.2 Heritable 
1’.2.1 EIF2AK4 mutation 
1’.2.2 Other mutations 
1’.3 Drugs, toxins and radiation induced 
1’.4 Associated with: 
1’.4.1 Connective Tissue Disease 
1’.4.2 HIV Infection 
1’’ Persistent pulmonary hypertension of the newborn 
Group 2: Pulmonary hypertension due to left heart disease 
2.1 Left ventricular systolic dysfunction 
2.2 Left ventricular diastolic dysfunction 
2.3 Valvular disease 
2.4 Congenital/acquired left heart inflow/outflow tract obstruction and congenital 
cardiomyopathies 
2.5 Congenital/acquired pulmonary veins stenosis 
Group 3: Pulmonary hypertension due to lung disease and/or hypoxia 
3.1 Chronic obstructive pulmonary disease (COPD) 
3.2 Interstitial lung disease 
3.3 Other pulmonary disease mixed restrictive and obstructive pattern 
3.4 Sleep-disordered breathing 
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3.5 Alveolar hypoventilation disorders 
3.6 Chronic exposure to high altitude 
3.7 Developmental lung diseases 
Group 4: Chronic thromboembolic pulmonary hypertension and other 
pulmonary artery obstructions 
4.1 Chronic thromboembolic pulnmonary hypertension (CTEPH) 
4.2 Other pulmonary artery obstructions 
4.2.1 Angiosarcoma 
4.2.2 Other intravascular tumors 
4.2.3 Arteritis 
4.2.4 Congential pulmonary arteries stenoses 
4.2.5 Parasites (hydatidosis) 
Group 5: Pulmonary hypertension with unclear and/or multifactorial 
mechanisms 
5.1 Haematological disorders: haemolytic anaemia, myeloproliferative disorders, 
splenectomy 
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
lymphangioleiomatosis neurofibromatosis 
5.3 Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid 
disorders 
5.4 Others: pulmonary tumoral thrombohic microangiopathy, fibrosing 
mediastinitis, chronic renal failure (with/without dialysis), segmental pulmonary 
hypertension 
 
  
Table 1 – Clinical classification of pulmonary hypertension. Adapted from 
(Adapted from Galie et al., 2015). 
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Functional classification of pulmonary hypertension 
Class I Patients with pulmonary hypertension without resulting limitation 
of physical activity. Ordinary physical activity does not cause 
undue dyspnoea or fatigue, chest pain or near syncope 
Class II Patients with pulmonary hypertension resulting in slight limitation 
of physical activity but comfortable at rest. Ordinary physical 
activity causes undue dyspnoea or fatigue, chest pain or near 
syncope. 
Class III Patients with pulmonary hypertension resulting in marked 
limitation of physical activity but comfortable at rest. Less than 
ordinary activity causes undue dyspnoea or fatigue, chest pain or 
near syncope. 
Class IV Patients with pulmonary hypertension with inability to carry out 
any physical activity without symptoms. Patients manifest signs of 
right heart failure. Dyspnoea and/or fatigue may even be present at 
rest. Discomfort is increased by any physical activity 
 
Table 2 - Current World Health Organisation / New York Heart Association 
Classification of functional status in patients with pulmonary hypertension. 
The severity of PAH in patients can be classified using the WHO functional class 
system. Patients with the mildest form of disease in early-stage PAH are placed in 
class I and patients with the most severe are placed in class IV. The WHO 
functional class system is helpful in aiding decision making for PAH therapy and 
serves as an accurate predictor of patient mortality. (Adapted from Galie et al., 
2015). 
  
28 
 
1.1.1 Idiopathic pulmonary arterial hypertension 
Idiopathic pulmonary arterial hypertension (IPAH) is a form of PAH where the 
cause of the disease is undetermined, thus no family history and risk factor is 
identified to be present. It is characterised histopathologically by muscularisation 
of the precapillary arterioles, medial thickening due to vascular smooth muscle 
cell proliferation, and angioproliferative plexiform lesions, which are complex 
glomeruloid-like vascular structures of endothelial cells originating from 
pulmonary arteries (McLaughlin and McGoon, 2006; Jonigk et al., 2011). There is 
also cell proliferation in the intima though their origin is not clear as they may be 
smooth muscle-like cells that could originate as stem cells, fibrocytes or transform 
from endothelial cells. IPAH is a rare disease, with incidences of 2-5 million per 
year and a male:female ratio of 1:2.7 (Pugh and Hemnes, 2010). According to the 
first US National Institutes of Health registry created in 1981, the mean age of 
patients with IPAH was 36 years. Now that PAH is diagnosed more frequently, 
the mean age of diagnosis has increased to 50-65 years in many registries. 
Moreover, survival has also improved among patients, while the female 
predominance has been variable and may not even exist in the elderly (Galie et al., 
2015b). A 2013 study recruited 32 study participants and revealed that the overall 
mean age of IPAH patients was 56±16 years at the time of symptom onset and 
59±17 years at the time of diagnosis by right heart catheter. Males were older than 
females at symptom onset as mean age was 58versus 53 years, respectively 
(Strange et al., 2013). Symptoms of the disease include dyspnea and fatigue, due 
to decreased gas exchange not only as a result of the vascular remodelling but also 
a loss of peripheral blood vessels coined “vascular pruning”. This is often 
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followed by chest pain or angina (McLaughlin and McGoon, 2006). PAH will 
lead to right ventricular hypertrophy as the heart compensates to generate enough 
force to pump blood through the pulmonary circulation against a higher pressure. 
Unremitted hypertrophy will lead to right ventricular failure and ultimately death. 
 
1.1.2 Heritable pulmonary arterial hypertension 
PAH with familial cases of identified gene mutations is known as heritable. 
Germline mutations in the gene coding for the bone morphogenetic protein 
receptor type II (BMPR2), which is a member of the transforming growth factor 
(TGF)-β signalling family, are present in up to 80% of the familial cases of PAH. 
BMPR2 mutations have also been shown to be present in up to 26% of IPAH 
(Thomson et al., 2000; Eyries et al., 2013; Austin and Loyd, 2014). Bi-allelic 
mutations in eukaryotic translation initiation factor 2 alpha kinase 4 (EIF2AK4), 
which encodes a serine threonine kinase expressed in response to amino acid 
deprivation, have been reported in all familial pulmonary veno-occlusive disease 
(PVOD) and pulmonary capillary hemangiomatosis and in 25% of histologically 
confirmed PVOD and PCH (Eyries et al., 2013). Mutations in other genes of the 
TGF-β family have also been detected in particular PAH presentations such as the 
ACVRL1 gene encoding for the TGF-β co-receptor, endoglin, a gene  that is also 
mutated in hereditary hemorrhagic telangiectasia (Harrison et al., 2003). Other 
mutations that have also been shown to be involved in PAH are the activin 
receptor-like kinase -1 (ALK-1), SMAD9, Caveolin 1 (CAV1), and the potassium 
channel subfamily K gene KCNK3 (Galie et al., 2015b). 
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1.1.3 Drug- and toxin-induced PAH 
The exposure to various prominent drugs and toxins has been found to be 
associated with PAH. In the 1960s and later in 1990s, the weight loss stimulant 
drugs aminorex and fenfluramine derivatives were closely linked with PAH 
outbreaks (Souza et al., 2008; McLaughlin et al., 2015). In 2012, benfluorex, a 
drug sharing similar structural and pharmacological characteristics as 
fenfluramine was withdrawn in the European Union due to the risk of right-valve 
disease, was also revealed to be associated with increased incidence of PAH 
(Savale et al., 2012). The anticancer drug and broad-spectrum tyrosine kinase 
inhibitor, dasatinib,  was linked with a series of cases of drug-induced PAH in 
patients with chronic myelogenous leukemia, and in most cases patients did not 
fully recover hemodynamically (Montani et al., 2012). Additionally, interferon 
therapy has also been associated to PAH development (McLaughlin et al., 2015). 
 
1.1.4 Associated pulmonary arterial hypertension 
PAH has been shown to be associated with various other diseases such as 
connective tissue disease (CTD), human immunodeficiency virus (HIV), portal 
hypertension, congenital heart disease (CHD), and schistosomiasis. 
Approximately 15-25% of total PAH cases are accounted to CTD-associated PAH 
in worldwide registries (Badesch et al., 2010). The leading causes are systemic 
sclerosis (SSc) and systemic lupus erythematosus (SLE). Moreover, the leading 
cause of SSc is PAH (Humbert et al., 2011). 30% of patients with CTD-associated 
PAH have 1 year mortality, as opposed to 15% of patients with IPAH. 
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Remarkably, cases of reversible PAH have been reported in patients with mixed 
CTD and SLE (McLaughlin et al., 2015). Patients with HIV have increased risk in 
developing PAH, with prevalence of 0.5% (Benza et al., 2012). The clinical and 
haemodynamic presentations are similar to IPAH. The USA REVEAL (Registry 
to Evaluate Early Long-term PAH Disease Management) registry showed that 
survival was at 93% at 1 year and 75% at 3 years. Both PAH drugs and highly 
active anti-retroviral drugs used in HIV have been reported to reverse PAH 
(Degano and Sitbon, 2009). Approximately 6% of patients with portal 
hypertension develop PAH independent of liver disease severity, though the long-
term prognosis is associated with both liver and pulmonary vascular disease. PAH 
associated with portal hypertension, or portopulmonary hypertension, has been 
associated with increased mortality during and after liver transplantation, 
particularly if the mPAP is higher than 35 mm Hg. With a 3 year survival of 40%, 
prognosis in portopulmonary hypertension is worse than in IPAH/HPAH with 
64% survival (Krowka et al., 2012). As disease management is improving, more 
and more children with PAH associated with congenital heart disease (CHD) are 
surviving to adulthood. Approximately 10% of adults with CHD develop PAH 
(Engelfriet et al., 2007). PH is one of the most prominent complications seen in 
schistosomiasis (Sch), an infectious disease caused by parasitic trematode worms. 
A prevalence of 4.6% of PAH among patients diagnosed with hepatosplenic 
schistosomiasis mansoni (Lapa et al., 2009), and approximately 20% of newly 
diagnosed PAH cases in endemic countries may be due to Sch-PAH. The 3-year 
mortality of patients with Sch-PAH is 15% (Dos Santos Fernandes et al., 2010) 
and it has been suggested that these patients respond well with improvements in 
functional class, 6-minute walking distance, cardiac index and pulmonary vascular 
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resistance (PVR) to PAH therapies including phosphodiesterase-5 inhibitors and 
endothelin antagonists (Fernandes et al., 2012). 
 
1.1.5 Pulmonary veno-occlusive disease, pulmonary capillary 
hemangiomatosis, and persistent PH of the newborn 
As pulmonary veno-occlusive disease (PVOD) and pulmonary capillary 
hemangiomatosis (PCH) share closer similarities to group 1 PAH than any other 
group such as the ability to carry the BMPR2 mutation and being diseases of 
vascular remodelling with the presence of lesions, they are classified as 1’ 
(Montani et al., 2009a). Significant differences in PVOD and PCH presentation 
from group 1 PAH include chest computed tomography findings showing 
pulmonary opacities, lymph node enlargement and signs of oedema, as well as 
causal homozygous EIF2AK4 mutations in heritable cases (Montani et al., 2009b; 
Eyries et al., 2013). Likewise, due to the difference and similarities, persistent PH 
of the newborn is classified as 1” (McLaughlin et al., 2015). 
 
1.2 Remodelling in PAH 
Historically, endothelial dysfunction was assumed to be responsible for the onset 
of vascular remodelling. More recently, numerous studies have suggested that 
other vessel wall cells including smooth muscle cells, fibroblasts and non-resident 
vascular cells, such as bone marrow-derived stem cells could play a major role in 
disease initiation as well (Davie et al., 2009). Five vascular abnormalities have 
been established in the remodelling process in PAH: 1) abnormal muscularisation 
33 
 
of distal precapillary arteries, 2) loss of precapillary arteries, 3) thickening of large 
pulmonary arteries, 4) neointimal formation in smaller vessels less than 100-500 
µm in diameter and 5) formation of plexiform lesions within the affected 
vasculature (Figure 1; Rabinovitch, 2012). Pathological features of PAH also 
include the formation of thrombotic lesions resulting from endothelial 
dysfunction-induced local thrombosis (Humbert et al., 2004a). Dysregulated 
endothelial proliferation may also lead to the formation of aberrant channels in the 
obliterated lumen and adventitia of vessels, perhaps as a result of apoptotic-
resistant endothelial cell expansion or circulating endothelial progenitor cell 
accumulation at areas of vascular injury (Masri et al., 2007; Rabinovitch, 2012). 
 
Indeed, a key factor in the remodelling process is enhanced pulmonary arterial 
smooth muscle (PASM) proliferation accompanied by depressed apoptosis of 
these cells (Sakao et al., 2010). Many factors are involved in driving their 
proliferation such as the BMPR-2 mutations, increased expression and activity of 
the platelet derived growth factor (PDGF) receptor and the serotonin (5-HT) 
transporter, and de novo expression of the anti-apoptotic protein survivin. In 
addition, the levels of various growth factors such as PDGF, vascular endothelial 
growth factor (VEGF) and epidermal growth factor (EGF) are also elevated, 
which all increase cell proliferation and promote remodelling (Humbert et al., 
2004b; Hassoun et al., 2009). Reduction in the expression and function of the 
voltage-gated potassium channel, Kv1.5 has been associated with vasoconstriction 
seen in PAH as well as increase of the anti-apoptotic protein, Bcl-2 (Bonnet et al., 
2007). Upregulation of remodelling-associated genes such as hypoxia-inducible 
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factor-1 α (HIF-1α), VEGF-α, VEGF-1/-2, angiopoietin-1  (ANG-1), Tie-2, 
thrombospondin (THBS1)-1, the stem cell growth factor receptor c-kit, and the 
vascular sprouting-associated markers NOTCH4 and matrix metalloproteinase 9 
are also present in PAH (Jonigk et al., 2011). 
 
Classically in PAH, there are three major pathways that have been proposed to 
cause or contribute to the remodelling: the prostacyclin (PGI2), endothelin (ET), 
and nitric oxide (NO) pathways (McLaughlin and McGoon, 2006). There is 
impaired production of vasodilator such as NO and PGI2 and prolonged 
overexpression of vasoconstrictor agents such as endothelin-1 (ET-1) and 
thromboxane A2, which results in elevated pulmonary artery pressure, cell 
proliferation and thrombosis in the lung. These pathways will be further discussed 
in later sections of this chapter. 
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1.3 Pathways in pulmonary arterial hypertension 
1.3.1 Nitric oxide pathway 
Nitric oxide (NO) is a potent vasodilator that is synthesised by NO synthase 
(NOS) via the conversion of L-arginine to NO and L-citrulline in a process 
requiring NADPH and O2 as cosubstrates and (6R)-tetrahydrobiopterin (BH4), 
FAD, FMN and iron protoporphyrin IX (haem) as cofactors (Korhonen et al., 
2005). 3 isoforms of NOS have been identified: endothelial (eNOS), inducible 
(iNOS) and neuronal (nNOS). eNOS is expressed mainly in endothelial cells 
while nNOS is expressed in the brain and peripheral nervous system. Both eNOS 
and nNOS are constitutively expressed. eNOS and nNOs are activated by 
increases in intracellular calcium levels which stabilises binding of calmodulin to 
constitutive NOS, thus leading to the production of NO. When intracellular 
calcium levels decrease, the production discontinues, thus NO production is 
transient and short-lasting. In contrast, iNOS expression is found in most resting 
cells and its gene expression in various inflammatory and tissue cells is induced 
by microbial products such as lipopolysaccharide (LPS) and double stranded 
RNA, or proinflammatory cytokines such as interleukin-1 (IL-1), tumour necrosis 
factor α (TNFα) and interferon γ (IFNγ). iNOS can produce high levels of NO for 
prolonged periods due to its tight binding to calmodulin even at low intracellular 
calcium levels. 
 
NO is an important regulator of endothelial proliferation and survival, smooth 
muscle proliferation and platelet function. High levels of the NOS inhibitor 
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asymmetric dimethylarginine (ADMA) have been shown in PAH (Pullamsetti et 
al., 2011), while low levels of cofactors such as BH4 have been shown to cause 
PH (Khoo, 2005). NO can activate cytoplasmic (soluble) guanylyl cyclase (cGC) 
which leads to the generation of cyclic guanosine monophosphate (cGMP). Cyclic 
GMP in turn stimulates protein kinase G, which through its downstream 
phosphorylation of channels, receptors, kinases and phosphatases is able to reduce 
vascular tone and cardiac hypertrophy seen in PAH (Takimoto et al., 2005; Kass 
et al., 2007). NO is also able to modulate the vasculature independent of cGMP 
through protein S-nitrosylation of thiol groups contained in proteins or nitration of 
aromatic amino acids (Kass et al., 2007). 
 
1.3.2 Endothelin pathway 
Endothelin 1 (ET-1) is a 21-amino acid peptide that is produced in vascular 
endothelial cells. It is derived from big ET-1 via the action of phosphorimidon-
sensitive metalloproteinase, endothelin converting enzyme (ECE), which is 
present in several isoforms in both vascular endothelial and smooth muscle cells. 
It is a potent vasoconstrictor and mitogen for vascular smooth muscle and thus is 
implicated in the pathology of PAH and vascular remodelling. ET-1 is able to 
mediate its effect on the pulmonary vasculature by binding to its two G-protein-
coupled receptors, ETA and ETB, which exhibit species, developmental and 
regional differences (Davie et al., 2002). Both receptors are involved in ET-1-
mediated contraction in the distal pulmonary arteries, whereas ETA is largely 
responsible for the contraction of proximal arteries (Davie et al., 2002). ETB is 
involved in the clearance of ET-1, possibly explaining why treatment with dual 
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ET-1 receptor antagonists (ERAs) actually increases ET-1 levels (Williamson et 
al., 2000). Furthermore, ETB receptors are also expressed in endothelial cells, 
which upon activation, can release vasodilator and anti-proliferative substances 
such as PGI2 and NO, which may counter the vasoconstricting effects of ET-1. 
Levels of ET-1 are raised in lungs of patients with PAH (Cacoub et al., 1997) and 
shown to be a poor predictor of survival. In rats, higher circulating ET-1 has been 
associated with increased  susceptibility to hypoxia-induced pulmonary vascular 
remodelling (Aguirre et al., 2011). In cell culture, ET-1 is a strong driver of 
growth of PASM cells (PASMCs) from fawn hooded rats (Zamora et al., 1996; 
Wort et al., 2001). ET-1 secretion from endothelial cells has been shown to be 
inhibited by prostacyclin in a dose dependent manner (Prins et al., 1994). In 
patients, epoprostenol was reported to have a beneficial effect in the homeostasis 
of ET1 by promoting its clearance (Langleben et al., 1999). 
 
1.3.3 Prostacyclin pathway 
 
Prostacyclin (PGI2) is a 20 carbon prostanoid derivative that was discovered by 
John Vane and colleagues in the late 1970s as a naturally occurring vasoactive 
regulator that works as a powerful vasodilator and inhibitor of platelet aggregation 
and cell proliferation (Takubowski et al., 1994; Gryglewski, 2008). In contrast, 
thromboxane A2, which is also derived from COX, is a potent vasoconstrictor, 
mitogen and platelet activator, and thus opposes PGI2 in regulating the cellular 
functions in the vasculature (Anderson and Nawarskas, 2010). PGI2 is synthesised 
within vascular endothelial and smooth muscle cells in response to the oxidation 
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of arachidonic acid by cyclooxygenase (COX)- 1 and -2 enzymes (Flavahan, 
2007). A 1982 study conducted by Lewis Rubin showed that intravenous PGI2 in 
primary PH patients (synonymous with IPAH) showed responsive pulmonary 
vasodilation that was dose dependent (Rubin et al., 1982; Nemenoff et al., 2008). 
An increase in cardiac output without a large fall in systemic blood pressure was 
also seen, which led to future promising studies in the field. 
 
PGI2 is very unstable and has a half-life at physiological pH and temperature of 
approximately three minutes either in vitro or in vivo (Dusting et al., 1978; Clapp 
and Gurung, 2015). Due to this, a series of compounds have been made which are 
chemically based around PGI2 that are not susceptible to hydrolysis in solution 
and hav a longer biological half-life in vivo. These prostacyclin analogues are 
further explained in section 1.6.4.  
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1.4 Biomarkers in PAH 
The diagnostic approach for PAH is based on the patient’s history and physical 
examination by echocardiogram with  confirmation by right heart catheterisation, 
the gold standard for haemodynamic evaluation despite being highly invasive 
(Bazan and Fares, 2015). Although echocardiography is less invasive, it has 
limited accuracy for estimating hemodynamic measures such as PAP (Fisher et 
al., 2009). When considering treatment decisions for PAH, echocardiography 
alone is not sufficient and RHC is required (Galie et al., 2015b). Despite advances 
in drug therapeutics, late diagnosis and a lack of indices have continued to make it 
difficult to improve the efficacy of treatments and patient survival in PAH. Many 
of the clinical and hemodynamic parameters currently used for disease 
confirmation and/or progression lack standardisation, reproducibility and are 
invasive. In an effort to bypass these limitations, a number of circulating 
biomarkers have been investigated in PAH as potential objective and non-invasive 
tools for diagnosis, prognosis, and response to therapy (Pezzuto et al., 2015). 
 
A biomarker is defined by The National Institutes of Health Biomarker Definition 
Working Group as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention” (Biomarkers Definitions Working Group, 
2001). Recently, biomarkers have also been described as disease-associated 
changes in body tissue and fluids (Poste, 2011). Ideally, a biomarker should be a 
surrogate for clinical end points that is observer independent, widely available, 
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non-invasive,  disease-specific, a sign of disease activity, a target for treatment, 
and statistically significant (Pezzuto et al., 2015). 
 
1.4.1 Microparticles 
MPs are procoagulant vesicles that are released in the circulation by various cells 
within the vasculature upon cell activation and/or apoptosis (Simak and 
Gelderman, 2006; Lacroix and Dignat-George, 2013). They are also able transport 
inflammatory components from their cells of origin as well as miRNA and bind 
and fuse to their target cells through receptor-ligand interactions and thus mediate 
inflammation and coagulation (Diehl et al., 2012). They are elevated in the 
circulation in PAH and appear to correlate with severity of disease, though their 
origin has only been characterised for endothelial cells and leukocytes (Amabile et 
al., 2008). A marker that indicates both inflammatory status as well as vascular 
remodelling and damage could be extremely useful as a biomarker in PAH. 
Indeed, MPs are pro-inflammatory, pro-thrombotic submicron phospholipid 
vesicles (mostly 100nm to 1µm in diameter) derived from eukaryotic cells that 
bleb off from the plasma membranes of various cells such as platelets, leukocytes 
and endothelial cells in response to different types of stimulation such as 
inflammatory insult by cytokines (Simak and Gelderman, 2006; Dignat-George 
and Boulanger, 2011). 
 
The most extensively studied are platelet-derived MPs (PMPs), which were 
thought to hold pathophysiological importance as they expose procoagulant 
anionic phospholipids such as phosphotidylserine on their outer surfaces. In 1946, 
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Chargaff and West demonstrated that high speed centrifugation could prolong the 
clotting of platelet poor plasma (PPP), suggesting that subcellular particles that 
were procoagulant could be present in plasma and removed by sedimentation 
(Chargaff and West, 1946). Later in 1967, Wolf was able to show that activated 
platelets shed membrane fragments which he termed “platelet dust”. These 
particles were also associated with phospholipid-related procoagulant activity in 
plasma, specifically platelet factor 3 (Wolf, 1967). 
 
By definition, MPs are procoagulant phospholipid microvesicles that contain 
certain membrane receptors as well as other proteins associated with the parent 
cells from which they were derived. Through flow cytometry, targeting cell-
specific antigens or combinations of these antigens allows the identification of 
their cellular origin. MPs may vary in size, the smallest ones being comparable to 
the size of exosomes (40-80nm), which are intracellular multivesicular bodies 
fused with the plasma membrane. A crucial distinction between the subcellular 
fragments is their source and mechanism of derivation (Orozco and Lewis, 2010). 
Unlike exosomes, MPs richly expose phosphatidylserine (PS) on their 
membranes, and the calcium-dependent phospholipid, annexin V, which has a 
high affinity for PS, can be utilised to detect MPs (Simak and Gelderman, 2006). 
The upper size limit of MPs is considered to be 1.5µm in diameter but typically in 
assays 1µm is used as larger MPs can be the same size or even larger than 
platelets, making the distinction of MPs from platelets or platelet-MP aggregates 
difficult (Simak and Gelderman, 2006). Endothelial and platelet microparticles 
have been shown to serve as transport vesicles for microRNAs which can 
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influence cardiovascular diseases such as coronary artery disease, where different 
mRNA profiles have been observed between stable and unstable coronary artery 
disease (Diehl et al., 2012). 
 
MP release from membranes is a highly controlled process, unlike the degradation 
of plasma membranes associated with necrotic cells which is random (Simak and 
Gelderman, 2006). The release could be cell specific and/or agonist/stimulant 
specific, thereby resulting in MP release from different cell types. Cell stimulation 
leads to increased intracellular calcium levels, which is essential for MP release 
from cells (Figure 1). This activates the Mg2+ ATP-independent Ca2+-dependent 
enzyme scramblase, which allows phospholipids to move randomly between both 
leaflets of the bilayer, thereby disrupting and collapsing the lipid symmetry 
regulated by the enzymes flippase and floppase (Simak and Gelderman, 2006). 
Flippase is a Mg2+ adenosine triphosphate (ATP)-dependent aminopholipid 
translocase that is responsible for the transport of phospholipids from the outer 
leaflet to the inner, while its counterpart floppase is responsible for the transport 
from the inner leaflet to the outer, thus ensuring a transmembrane enzymatic 
balance. Elevated intracellular calcium levels inactivates flippase while activating 
floppase and scramblase, thereby disrupting the membrane equilibrium and 
initiating the budding off process of the microparticle within minutes, a process 
known as “blebbing” (Zwaal and Schroit, 1997). During this stage, 
phosphatidylserine (PS) is externalised, allowing the detection of MPs using the 
annexin V protein which potently binds to PS. The increased cytosolic calcium 
also activates enzymes such as calpain which cleaves cytoskeleton filaments, 
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which leads to MP blebbing (Chironi et al., 2009; Lacroix and Dignat-George, 
2013). Caspase 3-induced Rho kinase I activation has also been implicated in the 
actin-myosin contraction and cytoskeletal restructuring seen in the blebbing 
process (Boulanger et al., 2006). Tramontano and colleagues reported that the Rho 
kinase inhibitor Y-27632 was able to inhibit TNFα-induced microparticle release 
from cultured human coronary artery endothelial cells, implicating the 
involvement of the Rho kinase pathway in the blebbing process (Tramontano et 
al., 2004). 
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Figure 1: Schematic of the microparticle formation process 
Cells undergoing activation (ie. via TNFα stimulation) or apoptosis have raised 
intracellular calcium, which can inactivate the Mg2+ ATP-dependent 
aminophospholipid flippase and activate floppase and scramblase. This leads to 
the loss of phospholipid asymmetry, which contributes to the formation of 
microparticles, a process known as blebbing. Increased calcium also activates 
calpain as well as caspase-3 and the Rho-kinase pathway, which lead to 
cytoskeleton reorganisation, cell contraction, and proliferation, and also 
contribute to microparticle blebbing. 
Abbreviations: Flip=flippase; Flop=floppase; Ca2+=calcium; TNFα=tumour 
necrosis factor α; Rho K=Rho kinase; PS=phophatidyl serine; MLC-P=myosin 
light chain phosphorylation 
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Most platelet-activating agonists such as adenosine diphosphate (ADP), 
adrenaline, thrombin, collagen, and calcium ionophores (e.g. A23187 and 
ionomycin) are able to induce PMP release with varying potency: adrenaline < 
ADP < thrombin < collagen < thrombin + collagen < A23187 (Horstman and Ahn, 
1999). Other stimuli that cause MP release from platelets, endothelial cells, and 
various other cell types include TNF-α and other inflammatory cytokines, 
bacterial lipopolysaccharides, ROS, CRP, uremic toxins, the complement 
membrane attack complex C5b9, anti-platelet antibodies, and mechanical stimuli 
such as sheer stress (Hamilton et al., 1990; Simak and Gelderman, 2006; Dignat-
George and Boulanger, 2011). 
 
MPs can communicate, initiate signalling, cell contact or transfer of receptors 
(Simak and Gelderman, 2006). Additionally, they may be involved in organ 
defense systems, specifically in inflammation, tissue regeneration and stress 
response (Tushuizen et al., 2011). It has been proposed that as PS serves as a 
marker for injured cells and helps identify these cells as being ready for removal 
by phagocytosis of the cell. By releasing PS+MPs, cells may be able to receive a 
window of opportunity for reparation in a faster manner that conserves metabolic 
energy compared to internalising the PS into their inner plasma membrane leaflet 
(Simak and Gelderman, 2006). 
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1.4.1.1 Microparticles in PAH 
Past studies have shown that microparticles correlate with PAH severity and may 
hold the potential to be a valuable tool for disease diagnosis. Bakouboula and 
colleagues reported that levels of procoagulant endoglin (CD105)+ and tissue 
factor+ MPs were elevated in the plasma of PAH patients compared to healthy 
controls (Bakouboula et al., 2008). The raised MP levels correlated with elevated 
levels of proinflammatory markers such as highly specific CRP (hsCRP) and 
MCP-1. Endothelium derived endoglin+ MPs were further increased in blood 
taken from the pulmonary artery compared to blood taken from the jugular vein, 
which may suggest an increase in production of MPs at the vicinity of the artery, a 
possible trapping in cell aggregates as seen in coronary diseases, or sequestration 
from the pulmonary vasculature (Héloire et al., 2003). Interestingly, values of the 
MP gradient across the pulmonary precapillary circulation between the occluded 
pulmonary artery and jugular vein were significantly correlated with mPAP. 
Amabile and colleagues also reported that platelet endothelial cell adhesion 
molecule (PECAM/CD31)+ and vascular endothelial (VE)-cadherin (CD144)+ 
MPs were also elevated and correlated with haemodynamic severity measured by 
mPAP in PAH patients (Amabile et al., 2008). Platelet MPs double positive for 
PECAM and the platelet surface marker CD41 were also shown to be elevated in 
PAH. 
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1.4.2 Right ventricular dysfunction/neurohormonal activation 
1.4.2.1 Natriuretic peptides 
 
Natriuretic peptides are a family of hormones that share a similar molecular 
structure involved in the regulation of blood volume and pressure through their 
action as a diuretic, natriuretic, vasodilator and inhibitor of the renin angiotensin 
aldosterone system (Yoshimura et al., 1991). Atrial and brain natriuretic peptides 
(ANP and BNP, respectively) are the major peptides involved in the natriuretic 
peptide system and are both elevated in PH associated with right ventricular (RV) 
wall stress. BNP is considered to be more sensitive to ventricular dysfunction as it 
is released by ventricular tissue whereas ANP is mainly produced by atrial 
myocytes (Maeda et al., 1998). BNP and its cleavage product pro-BNP are to date 
the only serologic markers indicated in PAH treatment guidelines for use as 
prognostic indicators (Pezzuto et al., 2015). 
 
BNP elevation has been observed in various types of PH including IPAH, PAH 
associated with CTD and congenital systemic-to-pulmonary shunts, CTEPH, PH 
associated with lung fibrosis, as well as in acute pulmonary embolism (Nagaya et 
al., 2000, 2002; Kucher, 2003; Leuchte et al., 2004; Wilkins et al., 2005). 
 
Both BNP and ANP correlate with RV overload (Nagaya et al., 1998). Elevated 
BNP resulting from RV overload correlated positively with mean PAP, PVR, 
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mean right atrial pressure, RV end-diastolic pressure, and RV myocardial mass 
index, and negatively with CO and RV ejection fraction in pulmonary 
hypertensive patients. Findings showing negative correlation with 6-minute 
walking distance (6MWD), peak oxygen uptake (VO2), and positive correlation 
with the WHO class in PAH were later observed  (Leuchte et al., 2004). PH 
patients with a supramedian level of baseline BNP (>150 pg/ml) had a lower 
survival rate than those with an inframedian (50-100 pg/ml). Plasma BNP lowered 
significantly in survivors on treatment during the follow-up but increased (>180 
pg/ml) in non-survivors (Nagaya et al., 2000). 
 
The N-terminal part of the prohormone of BNP, NT-pro-BNP, has also been 
studied in a heterogenous group of PH patients. Levels of plasma NT-pro-BNP 
levels were elevated in a cohort of 61 patients with various forms of pre-capillary 
PH, which correlated positively with hemodynamic parameters such as right atrial 
pressure, mPAP, PVR, and HR, as well as lung function VO2 (Andreassen et al., 
2006). Leuchte and colleagues also observed that sixty-six of 118 (55.9%) PH 
patients had NT-pro-BNP levels that were 2.5 fold higher than in normal patients. 
(Leuchte, 2007). Interestingly, a longitudinal study revealed that a >15% /year 
reduction in circulating NT-pro-BNP was associated with better survival in 
patients with PAH (Mauritz et al., 2011). 
 
As biomarkers, BNP and NT-pro-BNP have limitations regarding being 
influenced by demographic characteristics such as obesity, sex and age (Pezzuto et 
al., 2015). Additionally, as NT-pro-BNP is cleared by the kidneys, renal 
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insufficiency may result in high levels of the pro-hormone independently from a 
decline in pulmonary haemodynamics or RV overload (Leuchte, 2007). Indeed, 
NT-pro-BNP levels have been reported higher in scleroderma-related PAH than in 
IPAH, despite a severe haemodynamic impairment in the latter patient cohort. 
 
1.4.2.2 Other Biomarkers of myocardial injury 
Cardiac troponins are components of the thin actin filaments of cardiac muscle 
and are integral in the contraction of the heart. They consist of 3 regulatory 
proteins: troponin C (TnC), TnI (cTnI), and TnT (cTnT). High troponin levels in 
plasma are associated with myocyte damage. Cardiac troponins play a major role 
in the diagnosis and prognosis of acute coronary syndromes as well as detecting 
myocardial damage and right ventricular dysfunction in pulmonary embolism 
(Meyer et al., 2000; Antman, 2002). Unfortunately, cardiac troponins do not 
represent a sensitive early biomarker of early disease. Increases in cTnT levels 
were detected in only 14% of a heterogeneous group of 56 patients with PH (51 
with PAH and 5 with CTEPH), though these levels of cTnT were shown to be a 
strong independent marker for PVR, 6MWD and death (Torbicki et al., 2003). In 
another study, cTnT elevation was also observed but in only 27.3% of a 
hetergoenous group of PH patients (Filusch et al., 2010). 
 
1.4.3 Inflammation/oxidative stress 
Inflammation has been shown to play an active role in disease progression in 
PAH. The pulmonary vessel wall with plexiform lesions  contain inflammatory 
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cell infiltrates and are surrounded by immune cells such as T- and B- 
lymphocytes, macrophages, and mast cells in PAH (Tuder et al., 1994; Voelkel et 
al., 2014). 
 
Numerous plasma cytokines are increased in PAH such as interleukin (IL)-1α, -
1β, -2, -4, -6, -8, -10, and -12p70, tumour necrosis factor (TNF)-β, monocyte 
chemoattractant protein-1 (MCP-1), and osteopontin (OPN) (Soon et al., 2010; 
Rabinovitch et al., 2014). Transgenic mice experiments have showed that 
overexpression of IL-6 is associated with vascular remodelling, development of 
PAH, and an exaggerated response to hypoxia, while IL-6-defiency is protective 
from hypoxia-induced PAH (Savale et al., 2009). IL-2, -6 and -8, -10, and -12p70 
appear to be predictors of survival in a study involving a cohort of 60 IPAH and 
heritable PAH patients. Serum cytokines correlated better with survival than right 
heart function and 6MWD, though correlation with haemodynamic parameters 
was not seen (Soon et al., 2010). Elevated levels of epidermal growth factor and 
IL-6 has also been observed in paediatric PAH, of which the latter was 
significantly associated with adverse outcome (Duncan et al., 2012). Katsushi and 
colleagues were able to show that epoprostenol therapy led to a significant 
decrease in elevated circulating levels of MCP-1 in PAH patients (Katsushi et al., 
2004). 
 
Increased oxidative stress has been observed in PAH patients as well as in animal 
models (Cracowski et al., 2001; DeMarco et al., 2008). Interestingly, PGI2 
infusion has shown to have an anti-inflammatory effect on the lung tissue, 
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reducing oxidative stress, as measured via a decrease in the levels of arachidonic 
acid-derived metabolites 5-oxo-eicosatetraenoic acid, 5-hydroxyeicosatetraenoic 
acid, and leukotriene B4 in the lungs of PH patients (Bowers et al., 2004). The 
increased production of reactive oxygen species (ROS) was shown more recently 
to be a common consequence of BMPR2 mutations in heritable PAH in both 
human and mice cultured smooth muscle cells (Lane et al., 2011). As increased 
peroxide and superoxide production preceded RV systolic pressure elevation, it 
suggested a potential role for ROS in the pathogenesis of PAH. 
 
Isoprostanes are also markers of oxidative stress as they are products of membrane 
lipid peroxidation and have been found to regulate the bronchoconstriction and 
vasoconstriction and inflammation in the pulmonary vasculature (Montuschi et al., 
2004; Janssen, 2008). Thromboxane receptor (TP) activation and signalling via 
the RhoA/ROCK pathway as well as prostaglandin E2 receptor (EP2) activation 
have been implicated in the smooth muscle contraction caused by E-ring and F-
ring compounds of isoprostanes (Janssen and Tazzeo, 2002; Tazzeo et al., 2003). 
Isoprostanes may also stimulate smooth muscle and endothelial cells to induce 
proinflammatory cytokine release (Janssen, 2008). The elevated urinary 
isoprostane F2α levels in PAH patients that inversely correlate with pulmonary 
vasoreactivity have been noted (Cracowski et al., 2001). Moreover, baseline levels 
of F2-isoprostane in the urine were associated with mortality in PAH patients 
(Cracowski, 2012). The role of isoprostanes as markers for oxidative stress has 
been implicated in various other cardiovascular diseases (eg. atherosclerosis, 
coronary artery disease) as well as lung diseases (eg. Asthma and chronic 
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obstructive pulmonary disease), neurological diseases (eg. Alzheimer’s disease, 
Huntington’s disease), renal diseases (eg. Hemodialysis), and liver diseases (eg. 
acute and chronic alcoholic liver disease) (Montuschi et al., 2004).  
 
Increased circulating levels of C-reactive protein (CRP), a marker of inflammation 
and tissue damage, in PAH and CTEPH were observed in patients compared to 
controls (Quarck et al., 2009). In PAH patients, levels of CRP were associated 
closely with the New York Heart Association functional class, right atrial 
pressure, and 6MWD, and were higher in non-survivors that survivors. PAH 
patients with normalised CRP levels after treatment continued to have a higher 
survival rate. In CTEPH patients who had undergone enderarterectomy to 
surgically remove obstructive arterial deposits, CRP levels were significantly 
decreased after 12 months post-surgery. CRP has been widely been considered a 
non-specific bystander inflammatory marker for many diseases (eg. acute 
myocardial ischemia, atherosclerosis, and Chrohn’s disease) (Lagrand et al., 1999; 
Vermeire et al., 2005; Quarck et al., 2009). However, it also has the capability of 
activating endothelial cells to induce the expression of adhesion molecules such as 
intracellular adhesion molecule 1 (ICAM-1), and cytokines such as IL-1, -6, and 
TNFα and chemokines such monocyte chemoattractant protein -1 (MCP-1) and 
mediate inflammatory processes during atherosclerosis (Labarrere and Zaloga, 
2004). 
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1.4.4.1 Vascular remodelling and damage 
Angiopoentins are angiogenic factors important in vascular development and 
maturation and are produced by VSMCs and precursor pericytes (Brindle, 2006). 
Ang-1 downregulates excessive proliferation of endothelial cells and stabilizes 
new blood vessel formation by binding to the extracellular domain of the tyrosine 
kinase receptor Tie2 (Chu et al., 2004). Ang-2  is the primary antagonist of Ang-1 
and has been recognised as a ligand that may be involved in the pathogenesis of 
IPAH vascular hyperplasia (Augustin et al., 2009). Kumpers and colleagues 
conducted a study measuring plasma Ang-1, Ang-2, soluble Tie2 and VEGF in a 
retrospective cohort of 81 IPAH patients and a prospective cohort of 25 IPAH 
patients, which revealed elevated plasma levels of all aniogenic factors in disease 
compared with controls (Kümpers et al., 2010). Elevated Ang-2 was associated 
with elevated PVR, cardiac index, and mixed venous oxygen saturation and was 
considered an independent risk factor for mortality. After 3 months of PAH-
directed therapy, Ang-2 levels were positively correlated with increased right 
atrial pressure and PVR and inversely correlated with mixed VO2 saturation. 
Additionally, Ang-2 mRNA and protein were also found in histological samples 
of IPAH lung tissue (Kümpers et al., 2010). 
 
Osteopontin (OPN) is a pleiotropic cytokine broadly expressed in various cell 
types including fibroblasts and cardiomyocytes and is upregulated in 
inflammation, other conditions such as cancer (Rangaswami et al., 2004, 2006). 
Its expression can be induced by proinflammatory cytokines such as IL-1β and 
TNF as well as TGFβ, angiotensin II, and hyperglycaemic and hypoxic conditions. 
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It is capable of recruiting monocytes and macrophages, and T-lymphocytes to 
areas of inflammation (Hullinger et al., 2001; Lorenzen et al., 2011). Osteopontin 
induces proliferation of smooth muscle cells and is involved in monocyte 
recruitment during pulmonary arterial remodelling in sustained hypoxia (Gadeau 
et al., 1993; Burke et al., 2009). OPN gene expression has also been shown to be 
elevated in hypoxia-induced pulmonary hypertensive rats and IPAH patients 
(Hoshikawa et al., 2003, 2006) Though its origination is unclear, they may behave 
similarly like soluble cytokines to promote communication between the 
extracellular matrix and cardiomyocytes or as an immobilized constituent of the 
extracellular matrix (Rosenberg et al., 2012). Elevated levels of OPN have been 
observed in IPAH patients and been shown to be an independent marker for 
survival, correlating with disease severity (Lorenzen et al., 2014). Both in vitro 
and in vivo studies have revealed that OPN expression is increased in pulmonary 
artery adventitial fibroblasts during PH-associated vascular remodelling (Anwar et 
al., 2012). OPN was also an independent predictor of right ventricular (RV) 
dilatation and dysfunction, which was also confirmed in animal models of cardiac 
hypertrophy and failure and also patients with heart failure (Singh et al., 1999; 
Rosenberg et al., 2008). 
 
Since NO is too unstable to be measured in gaseous form in the blood, exhaled 
NO levels in bronchoalveolar lavage fluid are measured instead and shown to be 
decreased in IPAH patients compared to controls (Girgis et al., 2005). Exhaled 
NO levels were shown to be elevated following either intravenous or inhaled 
epoprostenol as well as bosentan therapy (Forrest et al., 1999; Ozkan et al., 2001; 
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Girgis et al., 2005). As biomarkers, exhaled NO presents various confounding 
variables such as sex, age, infection, atopy, and food and drug intake (American 
Thoracic Society and European Respiratory Society, 2005). 
 
A reduction in the bioavailability of NO is likely to partly result in the increased 
synthesis of the potent competitive inhibitor of NOS, assymetric dimethyl arginine 
(ADMA). Levels are  elevated in IPAH patients and are positively correlated with 
right atrial pressure and negatively with mixed VO2 saturation, stroke volume, 
cardiac index and survival (Kielstein, 2005). Garenflo and colleagues reported that 
levels of ADMA are also increased in PAH associated with CHD and CTEPH 
patients, which were decreased for CTEPH patients who underwent pulmonary 
endarterectomy (Gorenflo et al., 2001; Skoro-Sajer et al., 2007).  
 
Serotonin (5-HT) is a monoamine neurotransmitter that is thought to mediate 
pulmonary vascular remodelling in PAH by inducing cell proliferation of 
pulmonary arterial smooth muscle cells and fibroblasts and causing 
vasoconstriction. Animal model experiments revealed that exogenous 5-HT could 
promote the development of PAH in rats, while the inhibition of the serotonin 
receptors 5-HT1b and 5-HT2a inhibited this development (Eddahibi et al., 2001; 
Keegan et al., 2001; Hironaka et al., 2003). IPAH patients, 5-HT levels are 
increased and positively correlates with PVR (Hervé et al., 1995). More recently, 
Callebert and colleagues conducted a study involving 16 PAH patients, which 
showed that serotonin was neither a predictive marker for disease severity nor a 
predictor of haemodynamic improvement after epoprostenol therapy, though a 
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larger study would be necessary to firmly confirm this finding (Callebert et al., 
2015). 
 
The large multimeric glycoprotein plasma van Willebrand factor (vWF) is 
produced by endothelial cells and involved in platelet aggregation and adhesion at 
sites of vascular injury. Plasma vWF is elevated in severe PAH and shown to 
decrease following prostacyclin treatment. A study by Kawut and colleagues 
involving a cohort of 66 PAH patients demonstrated that elevated vWF at baseline 
and follow-up were negatively correlated with survival (Kawut, 2005). 
Interestingly, vWF levels decreased with long-term prostacyclin infusion 
(Friedman et al., 1997). 
 
D-dimer is a marker for cross-linked fibrin and thus may be a used to detect 
microvascular thrombosis. Elevated D-dimer is observed in IPAH and correlated 
with the New York Heart Association class, resting oxygen saturation, 6MWT and 
PAP (Shitrit, 2002; Shitrit et al., 2002). Levels negatively correlated with survival 
at 1 year. However, correlations between haemodynamic parameters and D-dimer 
plasma levels were not seen in PAH associated with systemic sclerosis 
(Kiatchoosakun et al., 2007). As D-dimer is elevated in many other diseases as 
well, its use as a marker for PAH is probably limited. 
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1.4.4.2 Endothelin-1 
PH patients have been shown to have elevated ET-1 levels in lung tissue and 
plasma as well as elevated mRNA in the endothelial cells of lung specimens 
(Giaid et al., 1993; Rubens et al., 2001). The increase in ET-1 or big ET-1 plasma 
levels were shown to be related to pulmonary haemodynamics in congestive heart 
failure and IPAH. ET-3, which is produced by various cell types including 
endothelial cells in numerous organs, has a high affinity for ETB receptors but not 
ETA (Galie, 2004). As the activation of endothelial ETB has been shown to lead 
to beneficial effects such as the release of vasodilator and anti-proliferative agents 
such as prostacyclin and nitric oxide as well as the prevention of endothelial 
apoptosis, the study of ET-3, in particular the ET-1/ET-3 ratio, was studied by 
Montani and colleagues as a prognostic factor of PAH (Hirata et al., 1993; 
Shichiri et al., 1997; Montani et al., 2007). Notably, the ET-1/ET-3 ratio was 
associated with a decline in clinical status, haemodynamics and prognosis in PAH 
patients during vasoactive drug treatments (Montani et al., 2007). 
 
Langleban and colleagues reported that epoprostenol may have a beneficial effect 
on endothelin-1 clearance and release in patients with primary (idiopathic)PH. 
82% of the group treated with epoprostenol and conventional therapy had an 
arterial/venous ET-1 level ratio <1 compared to only 29% of the control group on  
conventional therapy alone (Langleben et al., 1999). A later study showed that 
inhaled iloprost was able to decrease the transpulmonary big ET-1 ratio likely 
through increasing pulmonary clearance as levels of big ET-1 were increased in 
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the pulmonary artery and decreased in the radial artery (Wilkens, 2003). Elevated 
ET-1 was considered an independent predictor of clinical worsening in the long 
term (Vizza et al., 2008, 2013). To add, demographic features such as African 
ethnicity, male gender, and older age are associated with higher ET-1 plasma 
levels, whilst patients on angiotensin-converting enzyme inhibitors, β-blockers, 
statins, and vasodilators are associated with lower levels (Shah, 2007). Thus, 
various potential confounding factors could affect the use of ET-1 as a biomarker. 
 
1.4.5 Markers for end-organ failure 
As renal dysfunction is associated with haemodynamic impairment in PAH as 
well as an independent predictor of mortality, renal function measurements such 
as serum creatinine levels or creatinine clearance represent important prognostic 
biomarkers (Shah et al., 2008; Benza et al., 2010). This is important particularly 
when evaluating biomarkers such as NT-proBNP undergoing renal clearance. 
 
Hyponatremia has been shown to be strongly related to RV dysfunction, WHO 
functional class, and poor survival in PAH (Forfia et al., 2008). Though the 
mechanism behind hyponatremia has not yet been elucidated, increased 
neurohormonal activation induced by advanced RV dysfunction has been 
hypothesised. 
 
Elevated uric acid, which is the final oxidation product of purine metabolism and 
an endogenous free radical scavenger, has been observed in PAH and correlated 
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with disease severity (Bendayan et al., 2003). Its production in the disease is likely 
to be by ischemic lung or RV tissue (Voelkel et al., 2000). Increases in plasma 
uric acid was independently associated with mortality in IPAH, and were 
decreased following successful prostacyclin therapy (Hoeper et al., 1999). 
Unfortunately, plasma levels of uric acid is influenced by a multitude of factors 
including age, sex, renal failure, hypoxemia, allopurinol, and intake of diuretics, 
thereby limiting its potential as a biomarker. 
 
RV dysfunction seen in PAH can lead to liver congestion and low perfusion to the 
liver, and can lead to liver dysfunction. Thus, liver dysfunction has also been 
implicated as a potential marker for PAH (Richman et al., 1961). To add, the 
prognosis of heart failure was shown to be associated with elevated levels 
bilirubin and aspartate aminotransferase, which is an indicator of liver dysfunction 
(Batin et al., 1995). A 2010 study involving a cohort of 37 PAH patients 
confirmed this finding by showing that hyperbilirubinemia was associated with 
advanced right heart failure and reduced survival (Takeda et al., 2010). 
 
1.4.6 New markers of transcriptional regulation 
miRNAs are small non-coding RNA molecules that are 21-23 nucleotides and 
involved in transcriptional and post-transcriptional regulation of gene expression. 
They have been shown regulate cell proliferation and apoptosis in physiological 
processes such as cardiac fibrosis, hypertrophy, angiogenesis and heart failure 
(Catalucci et al., 2009). miRNA can be detected in fluid samples, suggesting their 
biological functions may occur outside cells through paracrine signaling (Gupta et 
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al., 2010). The miR-204 gene has been implicated in PAH as it is pro-proliferative 
and apoptotic role in pulmonary arterial smooth muscles. Its expression was 
downregulated in PASMCs from pulmonary hypertension patients which may 
have been attributed to elevated signal transducer and activator of transcription 3 
(STAT3) by circulating factors such as ET-1, PDGF, and angiotensin II 
(Courboulin et al., 2011). miR-204 suppression and STAT3 activation also led to 
increased expression of nuclear factor of activated T-cells (NFAT), which further 
drove the proliferative and anti-apoptotic processes potentially responsible for 
vascular remodelling in PAH. miR-204 expression is decreased in PAH patient 
lungs and the lungs of rodents exposed to chronic hypoxia or monocrotaline 
(Courboulin et al., 2011). Levels correlated with PVR in humans and mPAP in 
rodents as measures for disease severity. Interestingly, nebulization with a miR-
204 mimic reversed the pathology of monocrotaline-induced PAH in murine. In 
another study, miR-21 expression was increased in human PASMCs under 
hypoxic conditions but decreased in mouse monocrotaline models (Sarkar et al., 
2010) and in human lung samples from IPAH patients. miR-21 has been 
implicated as an “oncomir” because it is consistently upregulated in multiple 
cancers such as chronic lymphocyte leukemia and breast cancer and promotes cell 
proliferation, apoptosis, and metastasis (Ou et al., 2014). Another study revealed 
that TGFβ and BMP4 stimulation may rapidly induce miR-21 expression, thereby 
suggesting that impaired BMPRII receptor signalling may be associated with 
reduced miR-21 expression and thus increased vascular remodelling. In contrast 
the miR21 oncomir, miR-145, is reduced in a number of cancers including lung, 
bladder, gastric, and nasopharyngeal cancer (Xu et al., 2012). It is the most 
abundant miRNA in normal vascular walls and vascular smooth muscle cells and 
61 
 
may play a role in the regulation of smooth muscle cell proliferation and plasticity 
(Cheng et al., 2009; Cordes et al., 2009). Its expression has been shown to be 
further increased in IPAH and HPAH patient lung tissue compared to controls 
(Caruso et al., 2012). Its expression was also elevated in cultured PASMCs from 
patients with BMPR2 mutations and in wild type mice exposed to hypoxia, whilst 
miR-145 deficiency was protective from PAH development. The proto-oncogene 
encoding a serine/threonine protein kinase, PIM-1, has been recognised as a 
potential marker for PAH as it shows high specificity for vascular lesions in 
disease (Padma and Nagarajan, 1991; Paulin et al., 2011). It is expressed very low 
in healthy human tissues but plasma levels were increased in PAH and correlated 
with disease severity as measured by WHO functional class, cardia index, 6MWD, 
and NT-proBNP. PIM-1 is involved in the NFAT/STAT3 signalling pathway, 
suggesting that it may be involved in the pro-proliferative and anti-apoptotic 
phenotype characteristic of smooth muscle cells in disease (Paulin et al., 2011). 
Interestingly, after blood sample collection, PIM-1 expression in the buffy coat 
was increased in PAH unlike other inflammatory diseases such as scleroderma, 
which may indicate specificity for PAH. 
 
1.5 Therapies in PAH 
Clinically, background treatments for PAH include warfarin, digoxin, diuretics, 
and oxygen. The cardiac glycoside digoxin and diuretics provide symptomatic 
relief but fail to provide long term clinical benefit (Rich et al., 1998; Rhodes et al., 
2009). The anticoagulant warfarin, a vitamin K sparing antagonist, has been 
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shown to slightly improve survival in patients though its effect is difficult to 
estimate without a randomised clinical trial (Johnson et al., 2006). The L-type 
calcium channel blocker, nifedipine, has shown to provide some benefit and its 
treatment has shown to increase cardiac output and decrease pulmonary resistance 
in ~10-15% of IPAH patients (Tonelli et al., 2010). Unfortunately, these effects 
have not been consistent and many patients did not respond to vasodilator therapy 
(Rubin, 1985). 
 
There are three main classes of drugs for the treatment of PAH: prostacyclin (or 
stable analogues), phosphodiesterase type 5 (PDE5) inhibitors and endothelin-1 
(ET-1) antagonists. Though all of these drug classes have shown to provide 
significant improvements in symptoms clinically such as in exercise capacity, 
only prostacyclin has shown to increase survival (Barst et al., 2011; Ivy et al., 
2013). Though the disease progression can be delayed through current therapy, 
there is no cure for PAH to date. 
 
1.5.1 PDE-5 inhibitors in PAH 
The inhibition of cGMP-degrading enzyme phosphodiesterase-5 (PDE-5) leads to 
vasodilatation at sites expressing the enzyme (Anderson and Nawarskas, 2010). 
Due to the abundant expression of PDE-5 in the pulmonary vasculature, PDE-5 
inhibitors were investigated for use as therapy in PAH. Sildenafil, tadalafil, and 
verdanifil are PDE-5 inhibitors that are approved for erectile dysfunction and are 
also capable of causing significant vasodilatation in the pulmonary vasculature 
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with maximum effects observed after 60, 75-90, and 40-45 minutes, respectively 
(Ghofrani et al., 2004). 
 
Sildenafil is an orally active, potent and selective PDE-5 inhibitor. The 
randomised controlled trial Sildenafil Use in Pulmonary Arterial Hypertension 
(SUPER-1) trial performed in 278 PAH patients treated with sildenafil showed 
improved haemodynamics, exercise capacity and symptoms (Galie et al., 2005). 
Another randomised controlled trial led conducted by Barst and colleagues 
revealed beneficial effects of oral sildenafil citrate in 235 treatment naïve 
paediatric PAH patients (Barst et al., 2012). 
 
While sildenafil has a half-life of 4 hours in vivo and is dispensed thrice a day, the 
selective PDE-5 inhibitor tadalafil has a 17.5 hour half-life in vivo and is only 
dispensed once a day (Galie et al., 2009; Falk et al., 2010). The PHIRST 
(Pulmonary Arterial Hypertension and Response Trial) study on 406 PAH patients 
treated with tadalafil showed improvements in symptoms, haemodynamics, 
exercise capacity and time to clinical worsening at 40 mg once daily dosage 
(Galie et al., 2009). 
 
1.5.2 Endothelin antagonists in PAH 
Bosentan is an orally active dual ETA and ETB receptor antagonist and the first 
ERA to be synthesised. Rat experiments have shown that bosentan can reduce 
pulmonary vascular hypertrophy without inducing systemic vasodilatation (Chen 
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et al., 1995). Bosentan has been studied in PAH patients in five randomised 
control trials: Pilot, BREATHE (Bosentan Randomised trial of Endothelin 
Antagnoist THErapy)-1, BREATHE-2, BREATHE-5 and EARLY (Endothelin 
Antagonist TRial in mildly symptomatic PAH patients), which showed 
effectiveness in decreasing mPAP and PVR and increasing cardiac output while 
improving functional class in patients (III to II), time to clinical worsening, 
exercise capacity, and echocardiographic and Doppler variables (Channick et al., 
2001; Rubin et al., 2002; Humbert, 2004; Galie, 2006; Galiè et al., 2008b; Strange 
et al., 2011). Bosentan has been approved for treatment of PAH patients in WHO 
functional class II and patients with PAH associated with congenital systemic-to-
pulmonary shunts and Eisenmenger’s syndrome (Galie, 2006). 
 
Ambrisentan is a non-sulfonamide, propanoic acid-class of ERA that has a 
relatively selectivity for ETA receptors (Davie et al., 2009). A pilot study and two 
large randomised controlled trials, ARIES 1 and 2, have revealed its efficacy on 
improving exercise capacity, symptoms, haemodynamics and time to clinical 
worsening in IPAH and PAH associated with connective tissue disease and HIV 
infection (Galiè et al., 2008a). Ambrisentan has been approved for WHO 
functional class II and III patients. 
 
Sitaxentan is another ETA receptor antagonist with a greater selectivity towards 
ETA receptors than ambrisentan (ref). The  orally active drug has been evaluated 
in 2 randomised controlled trials, STRIDE (Sitaxentan To Relieve Impared 
Exercise) 1 and 2 in patients with IPAH or PAH associated with CTD or coronary 
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heart disease (CHD) in WHO functional class II and III (Barst et al., 2004, 
2006b). The trials revealed improvement in exercise capacity measured by 
predicted peak oxygen consumption and haemodynamics measured by PAP and 
PVR. Sitaxentan was initially authorised by the European Medicines Agency 
(EMA ) as Thelin (Pfizer, New York, USA) in 2006 but was later withdrawn by 
the manufacturer in 2010 from the worldwide market after 9 cases of severe 
hepatitis-like drug reactions were reported (Hoeper et al., 2011). The EMA 
withdrew marketing authorisation soon after (European Medicines Agency, 2010). 
 
1.5.3 Prostacyclin pathway 
The synthetic PGI2 Epoprostenol has a short half-life of <6 minutes and 
administration via peripheral veins also causes painful vein irritation (Steiropoulos 
et al., 2008). Thus, the need for continuous administration by infusion pump and a 
permanent tunnelled catheter is needed. Epoprostenol has been shown to improve 
symptoms in PAH, exercise capacity measured by the 6 minute walking distance 
(6MWD) and haemodynamics assessed by mean PAP, cardiac index and PVR, 
and is the only treatment known to improve survival in IPAH in a randomised 
study (Barst et al., 1996). Other prostanoids are chemically stable in solution and 
have considerably longer plasma half-lives: iloprost with 20-30 minutes, beraprost 
with 40-60 minutes, and treprostinil with 180-270 minutes (Demolis et al., 1993; 
Olschewski et al., 2004; Wade et al., 2004). Prostacyclin analogues can be 
administered via various routes of administration such as intravenous (iloprost, 
treprostinil), oral (beraprost, treprostinil), inhaled (iloprost, treprostinil), and 
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subcutaneous (treprostinil). The order of in vivo stability of the prostacyclin 
analogues is iloprost<beraprost<cicaprost<<treprostinil (Clapp and Patel, 2010). 
 
Iloprost is typically administered by inhalation with the theoretical benefit of 
being selective for the pulmonary circulation, though it is also available for i.v., 
and has a half-life of 20 to 25 minutes (Higenbottam et al., 1998; Steiropoulos et 
al., 2008; Galie et al., 2015b). The Aerosolized iloprost Randomized (AIR) study 
group trial, which was a randomized controlled trial evaluating inhaled iloprost, 
showed that daily inhalations (6-9 times, 2.5-5µg per inhalation, median 30ug 
daily) in patients with PAH and CTEPH increased exercise capacity and improved 
symptoms, PVR, and clinical events compared to placebo inhalation (Olschewski 
et al., 2002). Another randomised control trial known as the STEP (Safety and 
pilot efficacy Trial in combination with bosentan for Evaluation in Pulmonary 
arterial hypertension) trial revealed that inhaled iloprost helped increase exercise 
capacity in patients already treated with bosentan (McLaughlin et al., 2006). 
Frequent side-effects of inhaled iloprost include flushing and jaw pain, though is 
known to be well tolerated by most patients. 
 
Beraprost was the first chemically stable and orally active prostacyclin analogue 
(Galie et al., 2015b). It was revealed in a randomised controlled trial performed by 
the ALPHABET (Arterial Pulmonary Hypertension and Beraprost European) 
study group in Europe and another group in the USA of its ability to improve 
exercise capacity though only up to 3-6 months (Galiè et al., 2002; Barst et al., 
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2003). However, no significant haemodynamic benefits were observed. Common 
adverse effects include headache, flushing, jaw pain and diarrhoea. 
 
Treprostinil is a tricyclic benzidene analogue of PGI2 that is chemically very 
stable and can be administered at ambient temperature. Thus, it can be 
administered intravenously (half-life = 4.4 hours) as well as subcutaneously (half-
life = 4.6 hours) by a micro-infusion pump and a small subcutaneous catheter 
(Laliberte et al., 2004). Though patients require doses 2-3 times higher does than 
epoprostenol the superior stability of treprostinil allows greater convenience for 
patients as they can be supplied in premixed and prefilled syringes (Benedict et 
al., 2007). In 2002, Simonneau and colleagues studied the effects of treprostinil in 
a large randomised controlled trial performed in this condition and showed 
marked improvements in haemodynamics such as mean right atrial pressure, 
mPAP, cardiac index, PVR, and mixed venous oxygen saturation, as well as 
exercise capacity, and symptoms in PAH patients (Simonneau et al., 2002). Side 
effects included infusion-site pain and erythema, cough, headache, throat 
irritation, nausea, and flushing. In IPAH patients, subcutaneous treprostinil has 
been shown to improve survival over the course of 4 years compared to predicted 
survival using the National Institute of Health formula (Barst et al., 2006a). 
Recent advances have led to the development of aerosolised treatment delivered 
through an ultrasonic pulse-delivery nebuliser system, which has shown decreases 
in PVR and mPAP (Sandifer et al., 2005; Voswinckel et al., 2006; Nadler and 
Edelman, 2010). The peak effect and plasma level of treprostinil was observed at 
10-15 minutes following inhalation. The phase II randomised controlled trial 
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known as the TRIUMP (Treprostinil sodium Inhalation Used in the Management 
of Pulmonary arterial Hypertension) trial revealed that inhaled treprostinil in 
patients on bosentan or sildenafil showed mild to moderate improvements in 
exercise capacity as measured by 6MWD (Benza et al., 2011). 
 
 
1.6 Cellular targets for prostacyclin 
In 1994, the main target for PGI2 was discovered to be the seven-transmembane 
prostaglandin I (IP) receptor, which is expressed abundantly in blood vessels, 
leukocytes, and thrombocytes (Narumiya et al., 1999). The receptor is coupled to 
the stimulatory G protein, Gs, which activates adenylyl cyclase and leads to cyclic 
adenosine monophosphate (cAMP) generation (Figure 2). This second messenger 
is responsible for multiple biological effects of PGI2 through primarily activating 
protein kinase A (PKA). Cyclic AMP is broken down by specific PDEs, chiefly 
by PDE 1, 3, 4, which regulate basal levels and analogue-induced elevation in the 
lung (Phillips et al., 2005; Murray et al., 2007; Schermuly et al., 2007). 
 
Prostacyclin and its analogues can act on other prostaglandin receptors that also 
contribute to their therapeutic action. The activation of prostaglandin receptors 
EP2, EP4, and DP1 leads to elevation in cAMP as they are coupled to Gs, and leads 
to vasorelaxation. In contrast, the activation of the EP1, EP3, FP and TP receptors 
lead to a contractile effect as they are coupled to the G proteins, Gi and Gq, which 
are involved in either reducing cAMP levels and/or elevating intracellular calcium 
69 
 
levels (Woodward et al., 2011). PGI2 has been shown to have low selectivity for 
prostanoid receptors, and is  able to activate EP1, EP3, and TP receptors albeit at 
higher concentrations compared to natural ligands (15-45 fold for EP1 and EP3 and 
<100-fold for TP). (Bennett and Sanger, 1982; Kennedy et al., 1982; Lawrence et 
al., 1992). At clinical doses, however, PGI2 is likely to activate EP3 receptors. 
PGI2 analogues in general potently bind to the IP receptors, though iloprost has 
high affinity for EP1 receptors (Ki=1nM) (Abramovitz et al., 2000). This is 
consistent with EP1 receptor blockade enhancing iloprost-induced vasorelaxation 
in isolated rabbit perfused lungs and in guinea pig aorta (Clapp et al., 1998; 
Schermuly et al., 2007). Treprostinil on the other hand has low affinity for EP1 
recptor
 
(ki=212nM) but high affinity for DP1 (ki=4.4nM) and EP2 (ki=3.6nM) 
receptors (Whittle et al., 2012; Clapp and Gurung, 2015).  Thus the pharmacology 
of these two prostacyclins is distinct (Clapp and Gurung, 2015). 
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Figure 2. Schematic of prostacyclin signalling in smooth muscle cells 
Prostacyclin and its analogues are able to act on a variety of receptors, which include 
the prostacyclin (IP) receptor, and the prostaglandin receptors EP1, EP2, and EP3, and 
DP1, which are each coupled to a G-protein that enables downstream signalling. The 
activation of the IP, EP2, and DP1 receptors lead to vasodilatory and antiproliferative 
effects while the activation of the EP1 and EP3 receptors lead to vasoconstriction and 
cell proliferative effects. 
Abbreviations: PLC=phospholipase C; PIP2 = phosphatidylinositol 4,5-bisphosphate; 
IP3=Inositol triphosphate; DAG=diacylglycerol; Ca2+=calcium; 
PDE=phosphodiesterase-5; ATP=adenosine triphosphate; AC=adenylyl cyclase; 
cAMP; cyclic adenosine monophosphate; PKA=protein k
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1.5.4 Combination therapy in PAH 
The simultaneous use of more than one PAH-targeted drug coined as 
“combination therapy” has become a standard care in many PAH centres. Drug 
combinations have been shown to be safe and effective in several cases (Ghofrani 
et al., 2003; Hoeper et al., 2004). A study in 2005 showed that combination 
treatment  with either bosentan, sildenafil and iloprost significantly improved the 
survival, lung transplantation, and need for intravenous iloprost treatment in PAH 
patients compared to a historical control group (Hoeper et al., 2005). The STEP-1 
(SafeTy and pilot Efficacy trial in combination with bosentan for the evaluation in 
Pulmonary arterial hypertension) study that studied the safety and efficacy of 
inhaled iloprost and bosentan over 12 weeks of treatment showed only a slight 
improvement in the post-inhalation 6-minute walking distance (6MWD) and time 
to clinical worsening, though no improvement in haemodynamics was observed. 
A similar randomised controlled trial called the COMBI (COMbination therapy of 
Bosentan and aerosolised Iloprost in IPAH) trial however failed to show an effect 
on 6MWD or time to clinical worsening when investigating effects of inhaled 
iloprost with bosentan (Hoeper, 2006). The TRIUMPH (TReprostinil sodium 
Inhalation Used in the Management of Pulmonary arterial hypertension) trial 
studied the addition of inhaled treprostinil to either bosentan or sildenafil therapy 
in patients with PAH, and demonstrated an improvement in 6MWD, though 
improvement in functional class and time to clinical worsening did not occur 
(Benza et al., 2012). Similarly, the PACES (Pulmonary Arterial hypertension 
Combination study of Epoprostenol and Sildenafil) trial showed that the 
combination of sildenafil to epoprostenol in PAH brought improvements in 
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6MWD as well as time to clinical worsening after 12 weeks (Simonneau et al., 
2008). Most recently, the AMBITION (Ambrisentan and Tadalafil in patients with 
pulmonary arterial hypertension) trial studied the efficacy of the combination of 
the selective ETA receptor antagonist ambrisentan with the PDE-5 inhibitor 
tadalafil compared to monotherapy (ambrisentan or tadalafil). The combination of 
the two drugs provided greater reduction in pro-BNP levels, higher percentage of 
patients with satisfactory clinical response and improved the 6MWD compared to 
the pooled monotherapy group, though no significant differences in 
haemodynamics were observed (Galie et al., 2015a). A sequential approach to 
combination therapy is the most widely utilised strategy for PAH, though initial 
(upfront) combination therapy based on the known mortality of PAH is also 
recommended in the 2015 ESC/ERS guidelines for PAH (Galie et al., 2015b).  
 
 
1.6.1 Peroxisome proliferator-activated receptors in prostacyclin 
signalling 
As prostacyclin synthase (PGI2S) is expressed highly in vascular smooth muscles 
not only in the plasma membrane but also in the perinuclear region, signalling of 
PGI2 via a family of transcription factors known as peroxisome proliferator-
activated receptors (PPARs) is now recognised (Smith et al., 1983). There are 
three isoforms of the PPARs: PPARα, PPARβ/δ, and PPARγ, which are encoded 
by the genes PPARA, PPARD and PPARG, respectively. Classically, PPARs can 
form a heterodimer with the retinoid X receptor (RXR), which then associates 
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with coactivators and bind with peroxisome proliferator response elements 
(PPREs) to regulate the expression of target genes. As the name suggests, PPARs 
are involved in the function of peroxisomes, which are small organelles involved 
in fatty acid metabolism (Reddy et al., 1973) . but they are also involved in 
regulating various other processes such as insulin sensitivity, glucose homeostasis, 
fatty acid oxidation, inflammation, cell proliferation, apoptosis, cytokine 
production and vasculoprotection (Hamblin et al., 2009). PPARs are most 
commonly activated by ligand binding and contain a central DNA-binding domain 
that recognises response elements in the promoter regions of their target genes. 
Endogenous ligands include prostaglandins (e.g. 15-Deoxy-delta 12, 14- PGJ2), 
fatty acids, lipoxygenase metabolites (e.g. 8-HETE) and a variety of synthetic 
agents (Forman et al., 1995). PGI2 analogues iloprost and carbacyclin can act as 
PPAR ligands by directly binding and inducing gene transcription of PPAR-α and 
PPAR-δ (synonymous with PPAR-β ) in vitro,  activating them as efficiently as 
endogenous and synthetic ligands. (Forman et al., 1997). The structural basis for 
the binding of iloprost to PPAR-α and -β was confirmed through crystal structures 
of the ligand binding domain (Jin et al., 2011). Treprostinil and carbacyclin, have 
also been shown to activate PPARγ in an IP receptor-dependent manner (Falcetti 
et al., 2007). 
 
All three isoforms of PPARs are highly expressed in endothelial cells and to 
varying degrees in other cell types, with PPAR-β having the most widespread 
expression (Hamblin et al., 2009). Message levels for the three isoforms are 
reported in normal pulmonary smooth muscle, while reduced staining of PPAR-γ 
74 
 
was reported in IPAH lungs (Li et al., 2012). Reduced PPAR-γ expression was 
shown in the lungs of rodents with hypoxia-induced PH and in vascular lesions in 
a rat model of severe PAH caused by hypoxia in the presence of the VEGF 
blocker, sugen (Ameshima et al., 2003). PPARγ expression in endothelial cells 
and proliferating cells within the intima and plexiform lesions was non-existent 
(Falcetti et al., 2007) PPARγ knockdown in endothelial cells in vitro resulted in an 
abnormal, proliferating, apoptosis-resistant phenotype, while in vivo experiments 
in mice led to the development of PAH and muscularisation of distal pulmonary 
arteries (Ameshima et al., 2003; Guignabert et al., 2009). The loss of function 
mutation in BMPR-2, which normally suppresses cellular growth in the 
vasculature, is prominent in heritable PAH and has shown to decrease endogenous 
PPARγ activity whilst enhancing pathways such as the PDGF/mitogen activated 
protein kinase (MAPK)-mediated extracellular-signal-regulated kinase (ERK) 
pathways associated with vascular remodelling (Hansmann and Zamanian, 2009). 
This would suggest that the lack or loss of PPARγ, the IP receptor and PGI2S  
may be responsible for the hyperproliferative cellular phenotype displayed in 
PAH. Interestingly, though targeted deletion of PPARγ in smooth muscle was 
shown to cause PAH, its expression was shown to be distinctly increased in the 
medial layer of distal pulmonary arteries from PAH patients on various treatments 
(Falcetti et al, 2010). Additionally, in this study, its expression was not dependent 
on drug treatment, unlike the IP receptor. Upregulation of PPAR in smooth 
muscle cells may serve as a compensatory mechanism, through which progression 
in remodelling in PAH might be limited. 
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1.6.2 NFAT and calcineurin and their cellular functions 
PPARs can also act to negatively regulate gene expression through recruitment of 
corepressors and transrepression of various pro-inflammatory and pro-
proliferative transcription factors including nuclear factor kappa B (NFκB), Smad-
3, activator protein-1 (AP1), signal transducers and activators of transcription 
(STAT) proteins, and nuclear factor of activated T cells (NFAT) (Macian, 2005; 
Ricote and Glass, 2007). NFAT is a key player in the mechanism of the 
proliferation of smooth muscle that leads to the remodelling in PAH (de Frutos et 
al., 2007a, 2010). The NFAT family consists of 5 members: NFAT1 (NFATc2), 
NFAT (NFATc, NFATc1), NFAT3 (NFATc4), NFAT (NFATc3) and NFAT5 
(Musson et al., 2012). They all share an NFAT homology region in the N-terminal 
of the protein that mediates regulatory functions such as the binding to the Ca2+-
dependent phosphatase protein, calcineurin which dephosphorylates NFAT and 
promotes its translocation into the nucleus (Nilsson et al., 2007). The homology 
region also consists of nuclear localisation and export sequences, and 
phosphorylation sites containing localised serine-rich region and 3 serine-proline 
repeats for various serine/threonine kinases to activate nuclear export (Hill-
Eubanks et al., 2003). Multiple reports have shown that PKA can also 
phosphorylate NFAT and engage in the nuclear export of NFAT (Chow and 
Davis, 2000; Sheridan et al., 2002). The C-terminal region of NFAT contains a 
DNA binding domain that is moderately homologous to binding domains of the 
Rel-family proteins such as the transcription factor NFκB (Hill-Eubanks et al., 
2003). NFAT consists of a 59kDa catalytic A subunit, which contains a 
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calmodulin binding domain and an autoinhibitory region, and a 19kDa calcium 
binding regulatory B subunit. Calcineurin is ubiquitously expressed, though it is 
present at approximately 10-fold higher concentrations in brain and muscle than 
other tissues types (Olson and Williams, 2000). Separate mammalian calcineurin 
A (CnA) catalytic genes give rise to three isoforms, CnAα (PPP3CA), CnAβ 
(PPP3CB), CnAγ (PPP3CC).  Two separate B subunit regulatory genes B1 and B2 
have been identified in vertebrates. CnAα, CnAβ, and B1 gene products are 
ubiquitously expressed throughout the body, while calcineurin Aγ and B2 are 
expressed more locally in specific tissues such as the brain and testes (Molkentin, 
2004). CnAα has been shown to regulate vascular ATP-sensitive potassium 
channels by inhibiting PKA-dependent phosphorylation of the channel as well as 
the catalytic subunit (RII ) of PKA itself, thereby opposing the vasodilatory action 
of the potassium channel (Orie et al., 2009). PDGF, a key driver of smooth muscle 
cell proliferation in PAH, has been shown to activate CnAβ and induce the nuclear 
translocation of NFATc3 from the cytosol and contribute to smooth muscle 
proliferation in rat aorta (Jabr et al., 2007). 
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Hypothesis: 
Circulating microparticles (MPs) derived from smooth muscle cells are elevated in 
PAH and can serve as biomarkers of vascular remodelling and inflammation. 
Measurement of MP levels in plasma may serve to indicate disease severity as 
well as allow the assessment of the impact of front-line therapy in patients. 
Furthermore, these MPs are procoagulant vesicles that can promote inflammation 
and play a part in vascular damage and remodelling. 
 
Aims and Objectives: 
• Pulmonary arterial smooth muscle cells and their MPs from patients with 
pulmonary arterial hypertension and healthy donors will be grown in 
culture and characterised. In parallel, human umbilical cord endothelial 
cells and their MPs will also be characterised. This will help elucidate cell 
surface markers that are smooth muscle specific and aid in the 
identification of smooth muscle MPs in plasma. 
• Smooth muscle, endothelial, and leukocyte MP levels will be measured in 
plasma collected from PAH patients before and after long-term therapy. 
These MP levels will be compared with plasma from age and sex matched 
controls as well as from patients with coronary artery disease and HIV. 
• The procoagulant function of MP from PAH patients and cultured smooth 
muscle cells samples will be investigated. Additionally, the mechanism of 
prostacyclin therapy on inhibiting MP release will be studied. 
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80 
 
2. Methods 
2.1 PAH patient characteristics 
Human pulmonary arterial smooth muscle cells (PASMCs) were isolated from the 
lungs of children and adults with IPAH who had undergone transplantation after 
failed treatment or who had died and control adults. Human lung tissue was taken 
after obtaining patient/relative consent with ethical approval from Great Ormond 
Street Hospital (ICH & GOSH REC 05/Q0508/45), Papworth Hospital (REC 
H00/531/T), the Assistance Public - Hôpitaux de Paris (Institutional Review 
Board IRB00006477, agreement No. 11-045) or Brompton & Harefield Trust 
(NHLI REC 01-210) through Dr. John Wharton at Imperial College London. 
Child patients had received epoprostenol and bosentan therapy for 1.34 years and 
adult patients had received varying prostacyclin therapy for a minimum of 1.2 
years with either bosentan or sildenafil or a combination. 
Control PASMCs were isolated from donor lungs unsuitable for transplantation 
but were otherwise histologically normal or were from lung parenchymal strips 
cut from the macroscopically normal regions of the diseased lungs taken as far as 
possible away from the tumour as possible. 
HUVECs were isolated from healthy babies after delivery with ethical approval 
from West Middlesex Hospital Maternity following written parental consent. 
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2.2 Cell Isolation 
2.2.1 Isolation of PASMCs 
PASMCs were enzymatically isolated from distal pulmonary arteries using a 
modified method (Falcetti et al., 2010). Distal pulmonary arteries were dissected 
at room temperature using a phase contrast microscope (Olympus, CK2) from the 
lungs of PAH patients and normal donors and kept in cold (4oC) normal 
physiological saline solution. The saline solution contained 112mM NaCl, 5mM 
KCl, 1mM MgCl2, 25mM NaHCO3, 0.5mM KH2PO4, 0.5 mM Na2HPO4, 10mM 
glucose, and 1.8mM CaCl2 (all chemicals from Sigma-Aldridge, Dorset, Poole, 
UK). The segments of arteries were left to sterilise in 3% penicillin/streptomycin 
(Invitrogen, Paisley, UK) and 1.5µg/ml gentamycin solution (Sigma-Aldridge, 
Poole, Dorset, UK) for 30 minutes at 4oC. The arteries were then dissected into ~3 
mm wide pieces in a flow hood and placed in a 50 ml falcon tube with 1ml aliquot 
of dissociation cocktail and incubated at 37oC with continuous shaking for 30 
minutes. Aliquots  of the dissociation cocktail were prepared by adding 
0.125mg/ml elastase (Lorne Laboratories, Reading, UK), 10 mg/ml collagenase 
(Sigma-Aldridge, Poole, Dorset, UK), 0.06mg/ml trypsin inhibitor (Sigma-
Aldridge, Pool, Dorset, UK), 3.75 mg/ml bovine serum albumin (Sigma-Aldridge, 
Poole, Dorset, UK), 100µl MEM vitamins (GIBCO, Invitrogen, Paisley, UK) and 
3 ml DMEM/Ham’s F12  media (Life Technologies, Paisley, UK) to 10ml 
DMEM/F12 HEPES (GIBCO, Invitrogen, Paisley, UK)  Following the incubation, 
the tissue was then passed through a 40µm cell strainer into a 50ml falcon 
containing 10 ml of growth medium with the following composition: DMEM/F12 
containing with 10% foetal bovine serum (FBS) (GIBCO, South American Breed, 
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Invitrogen, Paisley, UK) and 1% penicillin/streptomycin (GIBCO, Invitrogen, 
Paisley, UK). The cell suspension was centrifuged at 180g for 5 minutes at room 
temperature to pellet cells, which was then resuspended in 10 ml of fresh growth 
medium by gentle agitation to disperse cells into a homogeneous suspension. Cells 
were transferred into a T-25 flask and cultured in a humidified atmosphere at 37oC 
and 5% CO2. Growth media was changed every 3 days until cells reached 80% 
confluence, after which they were frozen down to maximise the viability of these 
cells and cryo-preserved in liquid nitrogen at -170oC until used for experiments. 
 
2.2.2 Isolation of human umbilical vein endothelial cells (HUVECs) 
Umbilical cords were collected from healthy babies at delivery and human 
umbilical vein endothelial cells (HUVECs) were isolated within 7 days using a 
modified method (Baudin et al., 2007). Blood was removed from the fresh 
umbilical cords, which were then submerged in sterile RPMI 1640 medium (Life 
Technologies, Paisley, UK) to wash any excess blood. The ends of the cords were 
cut off to remove bacteria and then closed using clamps. RPMI 1640 medium 
(Life Technologies, Paisley, UK) was syringed into the cord vein until taut (with 
10-20ml of media) and left in a sterile hood for 5 minutes. The spiralled end of the 
cords was unclamped to allow the removal of RPMI and the edge of the umbilical 
cord cut off, again to avoid infection then re-clamped. 10-30 ml of 20mg/ml of 
collagenase I (Life Technologies, Paisley, UK) reconstituted in RPMI was 
syringed into the cord veins until taut and the umbilical cords incubated at 37oC 
and 5% CO2 for 15 minutes. The cords were massaged so as to manually dislodge 
the HUVECs from the basal lamina. To inactivate the collagenase, 10-30 ml of 
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RPMI containing 20% foetal bovine serum (FBS) (GIBCO, Invitrogen, Paisley, 
UK) was then syringed into the cord veins until taut. The end was unclamped and 
the collagenase solution containing endothelial cells was collected in a 50 ml 
falcon tube and then centrifuged (type, manufacturer) at 5,000g for 5 minutes. The 
supernatant was decanted and 5 ml of MCDB 131 medium (Life Technologies, 
Paisley, UK) was added to the pellet and pipetted up and down to obtain a 
homogenous cell mixture. This was then transferred into a T-25 flask and cells 
incubated at 37oC under 5% CO2. The media was replaced after cell attachment to 
endothelial basal medium (LONZA, Walkersville, Maryland, USA) with 10% 
FBS, which was changed with fresh media every 3 days. Upon reaching 80% 
confluence (Figure 3), the cells were split (as explained in the next section) to be 
used for experiments as well as frozen down and cryo-preserved at -170oC for 
long term storage. 
 
 
 
 
 
 
 
  
Figure 3. Cultured human umiblican vein 
endothelial cells (HUVECs) 
Image shown are cultured endothelial cells 
isolated from the umbilical cord of a healthy 
baby after delivery examined under a phase 
contrast microscope. 
10x magnification 
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2. Subculture of human cells 
Frozen cryo-vials containing either PASMCs, PAECs or HUVECs were rapidly 
thawed at 37oC in a water bath to minimise ice crystal formation which may 
damage cell viability. These cells were seeded in a T-75 flask containing 10ml of 
their respective growth media. The growth media for smooth muscle cells 
consisted of DMEM/Ham’s F-12 containing 10% FBS and 1% 
penicillin/streptomycin, while the growth media for endothelial cells consisted of 
EBM containing 10% FBS and 1% penicillin/streptomycin. Cells were incubated 
at 37oC and 5% CO2 in a humidified atmosphere for 24 hours to allow attachment 
to the flask botton, after which the media was replaced by fresh growth media. 
The growth media was changed every 3 days and cells grown until reaching 80% 
confluence Once the cells reached this level of confluency, they were then ready 
for subculture. This was done by first washing cells with 5ml of warm PBS 
(Invitrogen, Paisley, UK) twice, removing it and then adding 5ml of 0.05% 
Trypsin-EDTA (GIBCO). Incubation at 37oC/5% CO2 for ~2 minutes allowed the 
adhered cells to detach from the flask. 10 ml of growth media containing 10% 
FBS was immediately added to neutralise the trypsin to stop digesting the cell 
surface. The cell suspension was then transferred into a 50 ml falcon tube and 
centrifuged at 180g for 5 minutes at room temperature to obtain a cell pellet. The 
supernatant was removed and the pellet was resuspended in 3 ml of growth media, 
which was followed by gentle up and down pipetting to obtain a homogenous 
suspension of cells. The cells were counted using an automated cell counter 
(ADAM; Digital Bio, Seoul, Korea). This technique implements the use of 
propidium iodide (PI) – a dye that stains cellular DNA. 20µl of the cell solution 
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was pipetted into two 600µl Eppendorf tubes, one containing AccuStain solution 
‘T’ and the other solution ‘N.’ Solution T contained PI and a cell lysis solution 
which would thus stain all cells and thus represent the total cell count. Solution N 
only contained PI, and thus would only stained damaged cells without intact 
plasma membranes giving the non-viable cell count. After gently vortexing the 
tubes, 100µl of solution from each tube was loaded into a microchip, which was 
then inserted into the cell counter. By subtracting the total cell count from the 
non-viable cell count, the viable cell count was obtained and used to calculate the 
volume of cell suspension needed to plate at the desired cell density. 
 
2.3 Characterisation of PASMCs 
Confocal microscopy was used to characterise PASMCs by staining for the 
cytoskeletal smooth muscle markers, α smooth muscle actin (αSMA) and smooth 
muscle 22 α (sm22α) (Figure 4B-D). PASMCs were plated at a density of 1x104 
cells per well in eight-chambered slides (BD Bioscience, Oxford, UK) containing 
500µl DMEM/F-12 with 10% FBS per well and grown for 2 days, at which time 
cells normally were at e60% confluency. To prepare for staining, cells were first 
fixed with 500µl of 4% paraformaldehyde (Sigma-Aldridge, Poole, Dorset, UK), 
prepared in PBS placed in the appropriate wells for 20 minutes. After this, cells 
were washed three times with 500µl PBS for 5 minutes, before being 
permeabilised with 500µl of 1% triton X-100 solution made up in  PBS. The cells 
were washed three more times with 500µl of PBS, after which a blocking solution 
of 2% bovine serum albumin (BSA; Sigma-Aldridge, Poole, Dorset, UK) and 
86 
 
0.01% triton X-100 (Sigma-Aldrich, Poole, Dorset, UK) dissolved in PBS was 
added to the chambers and left to incubate at room temperature for 20 minutes. 
The blocking solution was then replaced with 100µl of primary antibody. Mouse 
monoclonal anti- αSMA (Sigma Aldridge, Poole, Dorset, UK) and mouse 
polyclonal anti-sm22α (Invitrogen, Paisley, UK) were prepared by diluting in 
fresh blocking solution both at a 1:500 dilution before being applied to the cells. 
The slides were then incubated at room temperature for 2 hours on a slow shaker. 
The cells were then washed 3 times with 500µl PBS, each for 5 minutes. 100µl of 
the fluorescent secondary antibody anti-mouse Alexa 555 (Invitrogen, Paisley, 
UK) and anti-sm22α, both prepared at 1:1000 dilution in blocking solution, were 
used for both α-SMA and sm22 staining. The slides were left to incubate with the 
secondary at room temperature for 2 hours on a slow shaker kept in the dark. The 
cells were washed for a final time with 500µl PBS in each well for 5 minutes, 
before the slides were detached from the chamber walls. 10µl of mounting reagent 
with 4’, 6-diamino-2-phenylindole (DAPI) (Vector Laboratories, Inc., 
Burlingame, CA, USA), which binds strongly to the A-T rich regions in DNA and 
stains the nucleus blue, was pipetted onto each slide. A glass coverslip was placed 
on top and sealed in place with a layer of commercially available nail varnish 
(Boots, UK). The slides were stored at -20oC in the dark until they were ready to 
be examined under a confocal microscope (Leica TCS SPE) preferably within 3 
days. The negative control was acquired through exclusion of the primary 
antibody. 
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Figure 4. Confocal imaging of pulmonary arterial smooth muscle cells 
(PASMCs) stained with smooth muscle biomarkers 
A) Human PASMCs isolated from distal pulmonary arteries from a child diagnosed 
with PAH were grown to 70% confluence in culture and observed under a phase 
contrast microscope. The classic hill and valley morphology characteristic of smooth 
muscle cells can be seen. B) PASMCs stained with only the nuclear marker, DAPI. 
C) PASMCs were stained with mouse monoclonal anti-αsmooth muscle actin 
(αSMA) primary antibody at a 1:500 dilution and visualised with the anti-mouse 
Alexa 555 secondary antibody (1:1000 dilution). Positive staining of αSMA is seen 
in red and the DAPI staining of the nucleus is in blue. D) PASMCs were stained with 
rabbit polyclonal anti-sm22α primary antibody at 1:500 dilution and visualised with 
anti-rabbit Alexafluor-488 secondary antibody (1:1000 dilution). Positive staining of 
sm22α is seen in green and the DAPI staining of the nucleus is blue. 
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2.4 Flow cytometric analysis of cell surface receptors 
 
PASMCs and HUVECs were analysed by flow cytometry where cell surface 
receptors were labelled with antibodies conjugated to fluorescent dyes. This 
would serve two purposes: 1) It would allow the characterisation of the cells 
through the level of expression of various cell surface receptors and 2) the 
receptor expression profile on the cell surface plasma membrane. The latter would 
enable to define the profile of cell specific receptors that ought to be present on 
microparticle (MP) membrane from known derived primary cell lines of smooth 
muscle and endothelial cells. Such characterisation was utilised not only for MP 
detection in the culture supernatant, but also to confirm the cell origin of MPs 
cells in the whole blood. 
 
The cells were grown in 6 well plates until 80% confluency. 0.5 ml trypsin-EDTA 
was added and the cells were left to incubate at 37oC and 5% CO2 for 1-2 minutes 
to detach the cells from the flask bottom. After detachment, growth media 
containing 10% serum was added to neutralise the action of trypsin. The cells 
were then collected into 15 ml falcon tubes and centrifuged at 180g for 5 minutes 
and the trypsin containing media was decanted. The cell pellet was resuspended in 
PBS (1 ml) by pipetting up and down several times. The cell suspension was then 
divided into 100µl aliquots in 600µl Eppendorf tubes for antibody labelling at a 
1:50 dilution. Mouse monoclonal anti-human antibodies conjugated with 
phycoerythrin (PE) or allophocyanin Cy-7 (APC-Cy7) were used to stain for cell 
surface receptors. These antibodies were anti-platelet derived growth factor 
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receptor (PDGFR) α and β (R&D Systems Abingdon, UK), anti-endoglin/CD105 
(BD Pharmingen), anti-neural glial antigen 2 (R&D Systems), anti-intracellelular 
adhesion molecule (ICAM1)/CD54 (BD Pharmingen), vascular cell adhesion 
molecule (VCAM)/CD106 (BD Biosciences, New Jersey, USA), anti-E-selectin 
(CD62E) (BD Biosciences), platelet endothelial cell adhesion molecule 
(PECAM)/CD31 (BD Biosciences), and mesenchymal cell adhesion molecule 
(MCAM)/CD146 (BD Pharmingen). Isotype control antibodies anti-mouse IgG1 
PE (R&D), anti-mouse IgG1,k (BD Pharmingen), anti-mouse IgG1 FITC (R&D), 
and IgG1,k APC-Cy7 (BD Pharmingen) with equal protein:fluorochrome ratios 
were also used for cell staining to examine non-specific staining. The cells were 
pipetted up and down to mix and left to incubate at 4oC for 30 minutes in the dark, 
after which they were centrifuged (Eppendorf Centrifuge 5415R, Stevenage, UK) 
at 3,000g for 3 minutes to decant unbound antibodies in the PBS. 200µl of PBS 
was then added into each tube and after pipetting up and down several times, the 
cells were transferred to a 96 well plate to be read by a FACSArray  
BioAnalyzerTM flow cytometer. The gating was set by running unstained and 
isotype control stained cells through the cytometer and toggling the forward and 
side scatter settings on a linear scale (Figure 5A) while the colour channels were 
set to logarithmic (Figure 5B-C). A minimum of 5,000 gated cells were acquired 
through the cytometer to provide enough event count. Single colour controls 
ensured that compensation could be performed during analysis with the FlowJo 
software (version 8.3.3; Tree Star, Inc., OR, USA). 
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Figure 5. Flow cytometric analysis of PASMC surface receptor expression 
PASMCs were prepared in PBS and characterised using fluorophore conjugated 
antibodies against cell surface receptors and analysed via flow cytometry. A) A dot 
plot was obtained with side scatter (granularity) and forward scatter (size) on linear 
scales established the gating of the smooth muscles. B) The number of events of 
cells were plotted against the fluorescent intensity of the phycoerythrin (PE) 
fluorescent colour. PASMCs stained with anti-platelet derived growth factor β 
(PDGFRβ) conjugated to PE showed a shift to the right of the red histogram 
compared to PASMCs labelled with the isotype control antibody (black) and 
unstained PASMCs (Blue). This indicates positive expression of PDGFRβ on the 
cell surface. C) Staining of PASMCs with  phycoerythrin (PE) conjugated to 
PECAM1 did not result in a rightward shift (Red) indicating negative expression of 
PECAM1 on the cell surface of PASMCs when compared to either the isotype 
antibody staining (black) or non-staining (Blue). 
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2.5 Preparation of supernatants from cultured cells for 
microparticle analysis 
HUVECs and PASMCs were plated at a density of 104 cells/ml in 6 well plates 
and grown in their respective growth media (endothelial basal medium with 10% 
FBS for HUVECs and DMEM/ F12 with 10% FBS for PASMCs) at 37oC in a 
humidified atmosphere of 5% CO2. When cells reached 70-80% confluence, either 
arrest media (0.1% FBS), growth media (10% FBS), or growth media in 
combination with either 20ng/ml tumour necrosis factor α (TNFα), 20ng/ml 
platelet derived growth factor (PDGF)-BB, 5ng/ml transforming growth factor 
(TGF)-β, or 10nM endothelin-1, were administered to each well, and the release 
of microparticles (MPs) from the plasma membrane assessed. 1ml of supernatant 
from cultured arrested to growing cells was collected from each 6 well plate and 
placed into autoclaved 1.5 ml Eppendorf tubes. This supernatant was spun at 
2,000g for 5 minutes at room temperature. The top 600µl was collected, so as to 
avoid picking up intact cells and/or cell debris and immediately transferred to a -
80oC freezer for storage. 
 
2.6 Identification of microparticles (MPs) from cell 
culture supernatants 
Microparticles are released from the surface of various cells that are activated or 
undergoing apoptosis through a process known as “blebbing”. The MPs 
externalise phosphatidylserine on their surfaces in a calcium-dependent manner. 
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Annexin V is a protein that can be conjugated to a fluorescent dye and used 
experimentally to bind to the phosphatidylserine and thus identify microparticles 
in platelet poor plasma through flow cytometry. 
 
To assess total microparticle count, anti-annexin V antibody conjugated to 
fluorescein isothiocyanate (FITC) or to phycoerythrin (PE) was diluted in annexin 
V buffer (BD Pharmingen) at a 1:10 dilution and 5µl was added to the appropriate 
wells of a 96-well U-bottom multiplate (Greiner Bio-One Ltd., Stonehouse, UK). 
Monoclonal mouse anti-human antibodies against cell surface markers were used 
to characterise MPs. These antibodies were anti-platelet derived growth factor 
receptor (PDGFR) α (R&D, Abingdon, UK), PDGFRβ (R&D), anti-
endoglin/CD105 (BD Pharmingen, Oxford, UK), anti-neural glial antigen 2 
(R&D), anti-intracellelular adhesion molecule (ICAM1)/CD54 (BD Pharmingen), 
vascular cell adhesion molecule (VCAM)/CD106 (BD Biosciences, Oxford, UK), 
anti-E-selectin (CD62E) (BD Biosciences), platelet endothelial cell adhesion 
molecule (PECAM)/CD31 (BD Biosciences), and mesenchymal cell adhesion 
molecule (MCAM)/CD146 (BD Pharmingen). Relevant isotype control antibodies 
included anti-mouse IgG1 PE (R&D), anti-mouse IgG1,k (BD Pharmingen), anti-
mouse IgG1 FITC (R&D), and IgG1,k APC-Cy7 (BD Pharmingen) with equal 
protein:fluorochrome ratios and were used to examine non-specific staining. The 
96 well-plate was covered with aluminium foil to shield from light and incubated 
at room temperature on a plate shaker for 15 minutes, after which 200µl of 
annexin V buffer was added to each well to dilute the samples and terminate the 
staining. 
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2.7 Microparticle analysis in patient blood 
The levels of annexin V+ microparticles were studied in the blood taken from 
patients with PAH as well as other cardiovascular and inflammation driven 
diseases. Twenty patients presented with PAH from multiple centres in Rome, 
Italy were recruited with the approval from the local ethics committee of each 
centre (EC 340/12). Twenty-seven patients with coronary artery disease were 
recruited through Dr. Crysostomos Mavroudis and Dr. Sudheer Koganti at the 
Royal Free Hospital, with ethical approval granted from the local ethics 
committee at Royal Free Hospital (REC 14/LO/0387). Twenty-four patients with 
HIV were recruited at Queen Elizabeth Central Hospital (Blantyre, Malawi) and 
twenty-four HIV negative patients were recruited from the Voluntary Testing and 
Counselling clinic in Blantyre, Malawi through Dr. Christine Kelly. Ethical 
approval was granted from the independent scientific and ethics committee 
COMREC of the University of Malawi (REC P.02/12/1180).  In all cases, 
informed written consent was provided by all patients. 
 
2.7.1 Pulmonary arterial hypertensive patient recruitment for MP 
characterisation 
The inclusion criteria were: diagnosis of PAH confirmed by haemodynamic 
assessment, either treatment naïve or already on prostacyclin analogue, endothelin 
atagonist, phosphodiesterase 5-inhibitor or a calcium channel blocker therapy, and 
planning to undergo therapy continuously for a minimum of 4 months. Of the 
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twenty patients recruited, ten were diagnosed with IPAH, seven with unclassified 
PAH, one with PAH associated with scleroderma, one with PAH associated with 
HIV, and one with pulmonary obstructive PAH. They were eleven male and nine 
female patients within the age of thirty and eighty-one years. At the time of 
recruitment, twelve out of twenty patients were not on any treatment (i.e. 
treatment naïve), while the rest were either on a PDE-5 inhibitor, endothelin 
antagonist or in combination with a prostacyclin analogue. After recruitment, they 
were put on a monotherapy either a prostacyclin (treprostinil or iloprost), an 
endothelin antagonist (bosentan or ambrisentan), a PDE-5 inihibitor (sildenafil or 
tadalfil), a calcium channel inhibitor (amlodipine) or a combination over a period 
of 4-26 months. Throughout the study, haemodynamic measurements such as the 
mean pulmonary artery pressure were recorded. 20 age and sex-matched healthy 
control volunteers were also recruited from whom blood was collected. 
 
2.7.2 Preparation of platelet poor plasma (PPP) from PAH and 
control patients 
As whole blood contains many different cells including erythrocytes, leukocytes, 
lymphocytes and platelets which can make the study of microparticles 
problematic, double centrifugation was applied to obtain platelet poor plasma 
(PPP) using an adapted protocol (Brogan et al., 2004) 
 
Blood (4 ml) was collected from patients in lavender EDTA vacutainer K2EDTA 
tubes (BD, Oxford, United Kingdom). Within 2 hours, platelet poor plasma (PPP) 
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was obtained by a double centrifugation step. First the blood was centrifuged at 
3,000g for 15 minutes to obtain plasma, which was then stored in 1.5 ml 
Eppendorf tubes at -80oC until further use. For batch analysis, the plasma was 
rapidly thawed in a 37oC water bath and centrifuged a second time at 5,000g for 5 
minutes to remove most platelets. This would ensure that the PPP would mostly 
consist of microparticles from cell types other than platelets, enabling for clearer 
analysis via flow cytometry. 100µl aliquots of PPP of each sample were 
transferred to new 1.5 eppendorf tubes and centrifuged at 17,000g for 60 minutes. 
Most of the supernatant was decanted leaving approximately 20µl with the 
microparticle pellet. The MP pellet was then reconstituted in 490µl of annexin V 
buffer (BD Pharmingen, Oxford, United Kingdom), divided into 35µl aliquots and 
plated into a 96 well U-bottomed polypropylene plate. 
 
2.7.3 Coronary heart disease patient recruitment 
Ten patients with ST-elevated myocardial infarction (STEMI) and thirteen 
patients with non-STEMI were recruited for the study. 
 
The diagnosis of STEMI was performed by following the standard diagnosis 
criteria according to current guidelines. All acute STEMI patients were treated 
with primary percutaneous coronary intervention (PCI), also known as coronary 
angioplasty, for treatment of myocardial infarction. These patients were given 
300mg of the COX-inhibitor, aspirin by ambulance paramedics and 600mg of the 
antiplatelet drug, clopidogrel upon arrival to the catheterisation laboratory. 
Patients were given intravenous morphine to alleviate chest pain symptoms as 
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necessary and weight adjusted unfractionated heparin to maintain the activated 
clotting time (ACT) at 200-250 seconds. 
 
The diagnosis of NSTEMI was based on the patients’ history of cardiac chest pain 
at rest or without ECG changes and elevated 12 hour troponin levels >0.03 ng/l. 
All patients were treated with 300mg aspirin, 600mg clopidogrel and weight 
adjusted unfractionated heparin (enoxaparin 1mg/kg twice per day). Within 72 
hours of chest pain, the patients underwent angiography. In the catheterisation 
laboratory before PCI, weight adjusted unfractionated heparin was administered to 
each NSTEMI patient to achieve an ACT at 200-250 seconds. 
 
Patients with renal failure prior to undergoing coronary bypass graft, or those 
patients who received the anti-platelet agents glycoprotein IIb/IIIa inhibitors prior 
to sampling, were excluded. 
 
2.7.4 Blood sampling and preparation of platelet poor plasma 
from coronary heart disease (CHD) patients 
Blood samples were collected from the coronary artery and forearm vein from 
patients with CHD. Diagnostic coronary angiography and PCI were performed 
according to current guidelines. A 6F venous sheath was inserted into the femoral 
vein, which allowed the passage of a 5F multipurpose catheter (5F, Cordis®, 
internal diameter 0.22cm) to be placed in the right atrium. A Judkin’s left 4 
diagnostic catheter (Cordis®, internal diameter 0.11cm) and a Judkin’s right 4 
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diagnostic catheter (Cordis®, internal diameter 0.11cm) were used to perform left 
and right coronary angiography, respectively. Blood samples were aspirated 
carefully through the catheters of similar internal diameter to minimise shear 
stress. Blood samples were also taken from the cephalic or antecubital vein on the 
arm using a 19G needle. All samples were taken before patients were treated with 
glycoprotein IIb/IIIa inhibitors.Whole blood (3.5 ml) was collected from the 
coronary artery and forearm vein in 3.2% tri-sodium citrate tubes (BD, Oxford, 
UK) and centrifuged at 5,000g for 5 minutes to isolate plasma. A second spin at 
5,000g for 5 minutes was performed to obtain PPP, which was then stored at -
80oC until analysed. 
 
2.7.5 Human immunodifficiency virus (HIV) patient recruitment 
and sample preparation 
Twenty-four adult HIV-infected patients with low CD4 counts (<100 cells/ml 
blood) in the Queen Elizabeth Central Hospital (QECH), Blantyre Malawi, were 
recruited for the study. At recruitment, prior to initiating anti-retroviral therapy, 
blood was collected  from the brachial vein together eand the carotid-femoral 
pulse-wave velocity (PWV) with patient history. The PWV was measured using a 
vicorder system, which involved placing a sensor on the patient’s neck and a cuff 
around the thigh and the distance between the two areas measured. Age, sex and 
PWV-matched twenty-four HIV-negative control patients were also recruited 
from the Voluntary Testing and Counselling clinic for comparative blood samples. 
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Whole blood (7 ml) was collected in 3.2% tri-sodium citrate tubes,  transferred to 
1.5 ml Eppendorf tubes and centrifuged at 1,500g for 10 minutes at 4oC to obtain 
plasma. This was stored at -80oC in 1.5ml aliquots in cryo-vials until used for 
experiments. After rapidly thawing at 37oC in a water bath, the plasma samples 
underwent a second centrifugation at 5,000g for 5 minutes to obtain the PPP 
which was stored in 1.5ml tubes and analysed immediately via flow cytometry. 
 
2.8 Identification of microparticles from platelet poor 
plasma 
Anti-annexin V antibody conjugated either to fluorescein isothiocyanate (FITC) or 
to phycoerythrin (PE), was diluted in annexin V buffer (BD Pharmingen) at a 1:10 
dilution and 5 µl was added to appropriate wells of a 96-well U-bottom multiplate 
(Greiner) to assess total microparticle count. Monoclonal mouse anti-human 
antibodies against cell surface markers were used to characterise the origin of cells 
for MP derivation. For identifying of smooth muscle microparticles (SMMPs), 
samples were incubated with mouse PE-conjugated anti-human PDGFRβ, mouse 
PE-labelled anti-human endoglin/CD105, mouse PE-labelled anti-human neural 
glial antigen 2 (NG2), mouse PE-labelled anti-human intracellular cell adhesion 
molecule (ICAM)/CD54, and mouse (PE) anti-human vascular cell adhesion 
molecule (VCAM)/CD106. For identifying endothelial microparticles (EMPs), 
samples were incubated with mouse (PE) anti-human E-selectin/CD62E and 
mouse (APC-Cy7) anti-human platelet endothelial cell adhesion molecule 
(PECAM)/CD31 (BD Pharmingen). For identifying leukocyte microparticles 
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(LMPs), samples were incubated with mouse (PE) anti-human carcinoembryonic 
antigen-related cell adhesion molecule 8 (CEACAM8)/CD66b (BD Pharmingen), 
mouse (FITC) anti-human tissue factor (CD142) (Sekisui Diagnostics, Lexington, 
MA, USA) and mouse (APC-Cy7) anti-human CD14. For identifying platelet 
microparticles, samples were incubated with mouse (PE) anti-human glycoprotein 
IX (GP9)/CD42a. Relevant isotype control antibodies were also used on all 
samples to distinguish non-specific staining (Figure 7). Single colour control 
staining by annexin V-FITC, PE-annexin V, and PECAM1-APC-Cy7 were used 
to compensate digitally during analysis on the FlowJo software after sample 
acquisition. The method of compensation is essential during multi-colour flow 
cytometric analysis, as it corrects for spillover, which happens when the 
fluorescent emission of a fluorochrome is detected by a detector designed to 
measure the signal of another fluorochrome. All antibodies were diluted in PBS 
containing 0.01% FBS and used at final dilutions (1:50 or 1:100) as listed in the 
table below. The 96 well plate was covered with aluminium foil to shield from 
light and incubated at room temperature on a plate shaker for 15 minutes, after 
which 200µl of annexin V buffer was added to each well to dilute the samples and 
terminate the staining. 
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Antibodies used for flow cytometric analysis 
Specificity Isotype Conjugate Company Clone Dilution 
Annexin V - FITC BD 
Pharmingen 
-- 1:100 
Annexin V - PE BD 
Pharmingen 
-- 1:100 
PDGFRβ IgG1 PE R&D 
Systems 
PRa292 1:50 
Endoglin/CD105 IgG1,k PE BD 
Pharmingen 
266 1:50 
NG2 IgG1 PE R&D 
Systems 
11711 1:50 
ICAM/CD54 IgG1,k PE BD 
Pharmingen 
HA58 1:50 
VCAM/CD106 IgG1,k PE BD 
Pharmingen 
51-10C9 1:50 
E-Selectin 
/CD62E 
IgG1,k PE BD 
Pharmingen 
68-5H11 1:50 
PECAM/CD31 IgG1,k APC-Cy7 BD 
Pharmingen 
WM59 1:100 
CD66b IgM,k PE BD 
Pharmingen 
G10F5 1:50 
TF/CD142 IgG1 FITC Sekisui 
Diagnostics 
V1C7 1:50 
CD14 IgG2b,k APC-Cy7 BD 
Pharmingen 
MɸP9 1:50 
CD42a IgG1,k PE BD 
Pharmingen 
ALMA 16 1:50 
CD146 IgG1,k PE BD 
Pharmingen 
WM59 1:50 
IgG1 Isotype 
control antibody 
IgG1 PE R&D 
Systems 
11711 1:50 
IgG1k Isotype 
control antibody 
IgG1,k PE BD 
Pharmingen 
MOPC-21 1:50 
IgG1 Isotype 
control antibody 
IgG1 FITC R&D 
Systems 
11711 1:50 
101 
 
IgG1,k Isotype 
control antibody 
IgG1,k APC-Cy7 BD 
Pharmingen 
MOPC-21 1:50 
IgGM,k Isotype 
control antibody 
IgM,k PE BD 
Pharmingen 
G155-228 1:50 
IgG1,k Istoype 
control antibody 
IgG2b,k APC-Cy7 BD 
Pharmingen 
MOPC-21 1:50 
 
Table 3. Fluorochrome conjugated antibodies and reagents used for flow 
cytometry analysis of cells and microparticles. Antibodies conjugated to various 
fluorescent dyes were diluted in PBS containing 0.1% FBS at either a 1:50 or 1:100 
dilution before incubating with cells or microparticles and running through the flow 
cytometry. As annexin V is a protein and not an antibody, FITC-annexin V does not 
have a clonal origin, unlike the antibodies used to label receptors and their respective 
isotype control antibodies.  
 
Abbreviations: 
FITC: Fluroscein isothiocyonate; PE: phycoerythrin;  APC-Cy7: allophocyanin-Cy7. 
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 1 2 3 4 5 6 7 8 9 10 11 12 
A PDGFRβ 
PECAM 
AnV+ 
Endoglin 
PECAM 
AnV+ 
NG2 
PECAM 
AnV+ 
ICAM1 
PECAM 
AnV+ 
VCAM1 
PECAM 
AnV+ 
E-Selectin 
AnV 
CD66b 
AnV+ 
TF 
CD14 
AnV+ 
PECAM 
AnV+ 
MCAM 
PECAM 
AnV+ 
Un-stained IgG1-PE 
Isotype 
B           FITC 
control 
IgG1k FITC 
Isotype 
C           PE control IgG1 FITC 
Isotype 
D           APC-Cy7 
control 
IgG1k 
APC Cy7 
Isotype 
E             
F             
G            1.1uM beads 
H            3uM beads 
Table 4. 96 well plate plan of antibody staining of microparticles (MPs) from platelet poor plasma (PPP) 
PPP was isolated after double centrifugation of whole blood at 5,000g x 5 min and MPs were obtained after a high speed centrifugation at 17,000g x 60 
mins at 4oC. The MPs were reconstituted in annexin V binding buffer and plated to appropriate wells. The fluorescent dye fluorescein isothiocyanate 
(FITC) or phycoerythrin (PE) conjugated to annexin V (AnV+) was used to label phosphatidylserine on MP surfaces to obtain total MP count.  
Fluorochrome conjugated antibodies were used to stain against surface receptors platelet derived growth factor β (PDGFRβ), platelet endothelial cell 
adhesion molecule (PECAM), Endoglin, neural glial antigen 2 (NG2), intracellular adhesion molecule 1 (ICAM1), vascular adhesion molecule 1 
(VCAM1), E-selectin, carcinoembryonic antigen-relat cell adhesion 8 (CAECAM9)/CD66b, Tissue factor, CD14, glycoprotein IX (GP9)/CD42a, and 
melanoma cell adhesion molecule (MCAM)/CD146. Double and triple staining was used in the appropriate wells of the 96 well plate. The unstained well 
contained MPs without any labelling. Single colour controls for fluorochromes FITC, PE and APC-Cy7 were used for compensation. Isotype control 
antibodies were used to determine non-specific antibody binding. 1.1µM and 3µM latex beads were used for size gating and MP enumeration, 
respectively. 
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2.10 Flow cytometric analysis of microparticles from PH 
and CHD patients 
 
Analysis of MPs was performed on the digital FACSArrayTM Bioanalyzer flow 
cytometer (BD Biosciences). To optimise the forward (FSC) and side scatter 
(SSC) settings, 1.1µm latex beads (Sigma-Aldridge, Poole, Dorset, UK) were run 
and logarithmic FSC and SSC plots obtained (Figure 6). The gates were set to 
obtain particles smaller than approximately 1.1 µm in diameter. When MPs were 
run through the cytometer, 100 µl of each sample was run at a medium flow rate 
of 2 µl/sec. As annexin V is a constitutive marker for MP, total MP were defined 
as particles <1.1 in size and annexin V+. Double and triple staining were used to 
define MP subpopulations to identify their cellular origin.  
 
Data was collected and analysed with FlowJo computer programme (version 
8.8.3; Tree Star, Inc., Oregon, USA). Optimal compensation was set for the 
appropriate channels detecting FITC, PE, and APC-Cy7 using single stained 
controls acquired on the analysis software as the data was collected digitally. 3µm 
beads (Sigma-Aldridge, Poole, Dorset, UK) were also run as an internal standard 
for enumeration (see next section). 
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Figure 6. Optimisation of MP gating strategy using 1.1µm latex beads 
A) 1.1µm beads were diluted in 0.22µm syringe filtered deionized water and analysed by 
flow cytometry. Data is presented as side scatter (depicting particle granularity) versus 
forward scatter (depicting particle size). B) Histogram indicates that the average size of the 
1.1µm beads was 1.5x103 as depicted by the peak on the forward scatter scale, which was 
used as the maximum size cut-off limit when gating for MPs in experiments. 
 
105 
 
  
101 102 103 104 105
Forward Scatter (size)
101
102
103
104
105
0.034
101 102 103 104 105
Forward Scatter (MP size)
101
102
103
104
105
An
ne
xin
 
V+
19.5
101 102 103 104 105
101
102
103
104
105
0.033 0
1.9198.1
101 102 103 104 105
Phycoerythrin (PE) isotype control
101
102
103
104
105
Al
lo
ph
o
cy
a
n
in
 
(A
PC
)-C
y7
0.13 0.016
0.4499.4
101 102 103 104 105
CD42a
101
102
103
104
105
PE
CA
M
1
101 102 103 104 105
Endoglin
101
102
103
104
105
PE
CA
M
1
CD42a - PE 
A
n
n
e
x
in
 V
 -
 F
IT
C
 
P
E
C
A
M
1
 -
 A
P
C
-C
y
7
 
P
E
C
A
M
1
 -
 A
P
C
-C
y
7
 
P
E
C
A
M
1
 -
 A
P
C
-C
y
7
 
P
E
C
A
M
1
 -
 A
P
C
-C
y
7
 
Endoglin  - PE 
A
n
n
e
x
in
 V
 -
 F
IT
C
 
CD42a - PE CD42a - PE 
Forward Scatter (MP size) Forward c tter (MP size) 
A B 
C D 
F E 
Figure 7. Flow cytometry analysis of MPs from platelet poor plasma (PPP) 
A) Unstained control well shows events that were not stained for annexin V, thus 
representing background. This is useful to use in combination with 1.1µm latex 
beads for determining the gating of annexin V+ MPs. B) Annexin V+ MPs 
acquired from platelet poor plasma of a PAH patient. C) The IgG1k isotype 
control antibody conjugated to the allophocyanin Cy-7 (APC-Cy7) fluorochrome 
was used to determine nonspecific binding, indicated by low intensity values on 
the y-axis. D) The IgG1 isotype control antibody conjugated to the phycoerythrin 
(PE) fluorochrome was used to determine nonspecific binding, indicated by the 
low intensity values on the x-axis. E-F: Double antibody staining for PECAM1 
with glycoprotein IX (CD42a) and endoglin (blue). A rightwards shift or 
upwards shift in intensity further away from the isotype control cut-off in 
intensity staining indicates presence of microparticles positive for the respective 
receptors. 
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2.11 Determination of microparticle number per ml of 
plasma 
As the number of microparticle events analysed via flow cytometry could vary 
depending on variables such as the amount of plasma analysed, forward and side 
scatter parameters, and the type of cytometer used, it was important to enumerate 
the microparticle count in a standardised fashion. The use of latex beads as an 
internal standard was first introduced by Combes and colleagues (Combes et al., 
1999), where the number of MPs per plasma or supernatant was determined by 
using the proportion of 3 µm beads counted and the volume of plasma from which 
the MPs were analysed. A predetermined number (200,000) of the 3 µm latex 
beads (Sigma-Aldridge, Poole, Dorset, UK) was calculated according to the 
manufacturer’s recommendations (see below) and added to a well in the 96-well 
plate. 
 
Equation for calculating number of latex beads: 
Number of beads per ml = (1.828x1011)/d3 
d=diameter of beads (µm) 
 
Thus, to achieve this approximately, 6µl of 3µm latex beads was diluted in 2ml of 
deionised water (dH20) that had first been filtered through a 0.22µl syringe filter. 
10µl was added into a 96-well plate well with 240µl filtered dH20 and run through 
the flow cytometer in the exact same manner as the MP analysis for PPP (Figure 
8). 
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The latex beads were acquired using the flow cytometer and gated using the 
forward scatter (size) and side scatter (granularity) settings on a logarithmic scale. 
The total events count was recorded and used to calculate the number of 
microparticles per ml of plasma. 
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Figure 8. Detection of 3µm latex beads 
A fixed number (200,000) of 3µm latex beads were prepared in filtered deionized 
water and added to wells of a polypropylene u-bottomed 96 well plate. They were 
acquired in the same manner as the MP samples via flow cytometry. The number of 
beads used and acquired was used as an internal standard for the conversion of the 
total number of MP events acquired to the number of MPs counted per ml of plasma. 
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The following equation (Figure 9) was adapted from Brogan et al. (Brogan et al., 2004), which converts flow cytometer events to an estimated 
count of MPs per ml of plasma. 
Total number of MP/ml of plasma 
 
=  200,000  /  number of beads counted   X  number of MP counted per well X  number of wells per sample 
    Number of ml of plasma 
 
Number of 3µm 
beads added to 
well of 96-well 
Usually 50,000 
Number of wells the 
sample was divided 
in 96 well plate 
Usually 100 µl 
Figure 9. Conversion equation for MP number per ml of plasma calculated from flow cytomter event counts 
The enumeration of microparticles from raw flow cytometry events count required a fixed number (200,000) of 3µm latex beads per well 
of the 96 well plate used, number of beads counted as raw events after acquisition, number of ml of plasma (100µl) used per platelet poor 
plasma to obtain the MPs, and the number of wells the sample was divided to during plating in the 96 well plate 
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2.12 Flow cytometric analysis of HIV-infected patient 
microparticles 
Flow cytometric analysis of HIV-infected patient MPs were performed in a 
category III laboratory in the College of Medicine, Blantyre, Malawi using a 
CyAn ADP flow cytometer (CyanTM ADP Analyzer, BD). As this cytometer did 
not have a 96-well plate reading function, samples were read in individual 
polypropylene FACS tubes. 
 
100 µl of PPP sample was pipetted into a 1.5 ml tube and centrifuged at 17,000g 
for 60 minutes at 4oC. The MP pellet was isolated and prepared for staining using 
the identical method as stated above for PAH and CHD samples. The samples 
were then transferred from the wells of polypropylene 96-well U-bottomed plates 
to individual FACS tubes. An additional 400 µl of annexin V buffer was added to 
every tube prior to running the MPs through the flow cytometer, making a total 
volume of 650 µl per FACS tube. The samples were run at a medium speed and 
stopped after collecting a fixed volume of 300 µl. A fixed number (200,000) of 
latex beads was calculated using the manufacturer’s instructions and pipetted into 
650 µl of 0.22 µm syringe filtered distilled water. A fixed volume of 300 µl also 
was run through the cytometer in the same manner as the samples. Data was 
collected and compensation and analysis was performed digitally on the FlowJo 
8.3.3 software. 
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2.13 The effect of prostacyclin on SMMP release 
PASMCs isolated from child IPAH patients were grown to 70-80% confluency in 
6 well plates. To assess the differential effects on microparticle release by 
different agents, 2ml of fresh growth media (DMEM/F12 containing 10% FBS) 
with and without 20ng/ml TNFα (Peprotech, Rocky Hill, New Jersey, USA) , 
20ng/ml PDGFR-BB (Peprotech, Rocky Hill, New Jersey, USA), 5ng/ml 
transforming growth factor β (TGFβ) (Peprotech, Rocky Hill, New Jersey, USA), 
and 10nM endothelin-1 (ET-1) (Enzo Life Sciences, Exeter, UK) was 
administered to cells. The agents were also administered in the presence and 
absence 1µM treprostinil (gift from United Therapeutics, Chertsey, Surrey, UK) to 
assess the effect of the prostacyclin alalogue to inhibit SMMP release. A 
concentration- response study was also conducted whereby cells were treated with 
10% FBS and 20ng/ml PDGF-BB alone and in the presence of either 1nM, 10nM, 
30nM, 100nM, 1µM, and 10µM treprostinil. The role of the IP and EP2 receptors 
were also studied by treating PASMCs with 20ng/ml PDGF-BB in combination 
100nM treprostinil and 1µM of the EP2 receptor antagonist PF-04418948 (Tocris, 
Bristol, UK) or 1µM of the IP receptor antagonist, RO1138452 (Tocris, Bristol, 
UK), Dallas, Texas, USA) or the two antagonists together. Given drugs were 
dissolved in the solvent DMSO, 0.03% DMSO (highest dilution that would 
otherwise be used) was added to all wells throughout the study. 
After 24 hours of incubation, 1ml of supernatant was collected in 1.5 ml 
Eppendorf tubes from each well and centrifuged at 2,000g for 5 minutes at room 
temperature. The top 600µl was collected in new 1.5 eppendorf tubes and the 
bottom 400µl left to decant apoptotic bodies and cellular debris. The supernatants 
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were then spun at 17,000g for 60 minutes at 4oC to obtain MP pellets. 350µl of 
annexin V was added to each tube, which was vortexed and labelled with annexin 
V-FITC. MPs were assessed through flow cytometry in a similar manner as 
explained previously and analysed by the FlowJo software version 8.3.3. 
 
2.14 Thrombin Generation Assay (TGA) 
MPs have phosphatidylserine (PS) rich areas on the surface membrane that are 
able to assemble and activate coagulation enzymes and give MPs their 
characteristic prothrombotic property (Morel et al., 2006). Moreover, some MPs 
externalise tissue factor on their surfaces, which is able to initiate blood 
coagulation (Gilbert et al., 1991; Sabatier et al., 2009). As thrombin is the 
endpoint of a series of proteolytic reactions in the coagulation cascade following 
vessel wall injury, and causes the conversion of fibrinogen to fibrin, the amount of 
active thrombin produced in plasma was measured by a thrombin generation assay 
(TGA) (Sabatier et al., 2009). When thrombin is generated, it cleaves a calcium-
fluorogenic substrate (0.5 mM/L of Z-G-G-R-AMC and 7.5 mM/L of calcium 
final reagent concentrations, Pathway Diagnostics) which can be monitored by the 
assay (TECHNOTHROMBIN® TGA). The concentration of thrombin can be 
calculated with the aid of a calibration curve which was first obtained using the 
following protocol: 
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The thrombin calibrator was diluted with the TGA buffer into 1.5µl Eppendorf 
tubes in the following manner: 
1st dilution (1:2) (STD 1): 200µl thrombin calibrator + 200µl TGA buffer 
2nd dilution (1:4) (STD 2): 100µl 1st dilution + 100µl TGA buffer 
3rd dilution (1:20) (STD 3): 20µl thrombin calibrator + 380µl TGA buffer 
4th dilution (1:200) (STD 4): 20µl 3rd dilution + 180 µl TGA buffer 
To obtain the calibration curve, 40µl of the calibrator dilutions (STD 1 – STD 4) 
and 50µl of the TGA substrate were pipetted into the wells of a microtiter plate in 
(NUNC Maxisorp 475515) in duplicates. The plate was run immediately after 
pipetting the substrate on a BMG Labtech FLUOstar OPTIMA fluorescence 
reader with filters 360nm and 460nm (excitation/emission). Thrombin was 
measured for 10 minutes in 30 second intervals for at 37oC (Figure 10). 
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Thrombin Generation Assay Calibration Curve 
 
Dilution nM 
Thrombin 
Delta 
RFU/30 
sec (W1) 
ok Delta RFU/30 
sec (W2) 
ok AV 
Calculated 
1:2 447.5 2197.2  2972.0  2584.6 
1:4 223.75 1622.7  1578.4  1600.5 
1:20 44.75 477.4  460.8  469.1 
1:200 4.475 47  47.7  47.3 
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Figure 10. Thrombin assay calibration curve 
A standard curve was generated for the thrombin assay  using known thrombin 
concentrations (nM) as indicated and plotted as raw ∆ relative fluorescence units 
(RFU) obtained by a fluorescence reader. A best fit line was generated to calculate 
thrombin concentration (nM) from ∆ RFU values. 
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To conduct the TGA assay, 100µl of PPP samples were rapidly thawed at -37oC 
and centrifuged at 17,000g to obtain MP pellets, as previously described. ~50ml 
blood from healthy volunteers was centrifuged twice at 5,000g for 5 minutes to 
obtain platelet poor plasma and centrifuged a second time at 17,000g to decant the 
remaining MP pellet and obtain MP free plasma. MP pellets were then 
resuspended in 80µl of microparticle free plasma (MPFP), which was obtained 
from healthy volunteers. 40µl of the MPs mixed in MPFP were then transferred to 
2 plate wells so as to obtain duplicate readings per sample. The fluorogenic 
substrate was added and the plate was run immediately for 90 minutes in 1 minute 
measurement intervals. Measures of peak thrombin, lag time, velocity index, and 
endogenous thrombin potential were recorded (Figure 11). 
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2.15 Proliferation Assay 
To assess the effect of prostacyclin on mediating growth inhibition of PASMCs, a 
proliferation assay was conducted. This assay would serve two purposes: 1) 
examine the inhibition on cell proliferation caused by treprostinil and 2) 
investigate whether it may be doing so via inhibiting the nuclear factor of 
activated T-cells (NFAT)/calcineurin Aβ (CnAβ) pathway. 
0 10 20 30 40 50 60 70 80 90
Peak thrombin 
Endogenous thrombin 
potential =Area under the 
curve (AUC 
Velocity index = thrombin 
Lag time 
Figure 11. . Thrombin generation assay curve 
Thrombin generation was determined and plotted against time to generate a curve. 
Measures of peak height in nM, lag time (=time required until thrombin 
generation onset) in minutes, velocity index (=rate of thrombin generated) in nM x 
min-1, and endogenous thrombin potential (=area under the curve) in nM x min 
were recorded. 
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PASMCs from IPAH patients were plated into 6-well plates in growth medium 
(DMEM/F-12 containing 10% FBS, and 1% penicillin streptomycin) at a density 
of 104 cells per ml. After 24 hours of incubation at 37oC and 5% CO2, cells were 
growth arrested in media DMEM/F12 containing 0.1% FBS for 48 hours. This 
period of time should be sufficient for the majority of the cells to reach the 
quiescent G0 phase of the cell cycle. Following this, appropriate drugs 
combinations were prepared in growth medium: 100nM treprostinil, 1µM 
treprostinil, 1µM of the calcineurin inhibitor cyclosporine, 1µM treprostinil + 
1µM cyclosporine, 0.02% DMSO (Sigma-Aldridge, Poole, Dorset, UK). After 
addition of drugs the cells were incubated at 37oC and 5% CO2 for 96 hours, after 
which they were washed with 1ml of warmed calcium and magnesium free PBS 
per well to remove residual serum. Cells were then trypsinised by replacing PBS 
with 0.5 ml of 0.05% trypsin-EDTA and incubating cells at 37oC for ~2 minutes. 
Growth media (0.5ml) was then immediately added to neutralise the trypsin and 
the cell suspension pipetted up and down several times to achieve a homogenous 
cell distribution. The cells were counted using the ADAM cell counter as already 
detailed. Data was analysed using GraphPad Prism (GraphPad Software, San 
Diego, CA) and cell proliferation expressed as the cell number per ml and as the 
% change in cell proliferation relative to the growth response induced by 10% 
FBS alone (100%). 
 
2.16 Confocal microscopy of calcineurin Aβ 
The mechanistic basis behind the effect of treprostinil on PASMC proliferation 
was examined through studying the roles of calcineurin Aβ (CnAβ) and PPARγ. 
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This was done via staining PASMCs for CnAβ and studying its expression and 
activation through nuclear translocation via confocal microscopy after treprostinil 
treatment. 
 
To prepare the staining of calcineurin Aβ, the PASMCs cells were plated at a 
density of 2 x 104 cells/ml in eight chambered slides (BD Bioscience,) containing 
500µl growth media (DMEM/Ham’s F-12 with 10% FBS and 1% 
penicillin/streptomycin) for 2 days until reaching 50-60% confluence. The cells 
were then gently washed once with 500µl PBS in each well and serum starved 
with 500µl of DMEM/Ham’s F-12 containing 0.1% FBS and 1% penicillin 
streptomycin for 48 hours. The cells in the different chambers were treated with 
the following drug treatments prepared in DMEM/F-12: Basal (0.1% FBS), 10% 
FBS, 1µM treprostinil with 10% FBS, 1µM rosiglitazone with 10% FBS, 1µM 
GW 9662 with 10% FBS, 1µM GW9662 with 1µM treprostinil and 10% FBS, 
1µM T0070907 with 10% FBS, and 1µM T0070907 with 1µM treprostinil and 
10% FBS. The cells were pre-treated with the PPARγ antagonists GW9662 and 
T0070907 in arrest media for 1 hour at 37oC and 5% CO2 prior to co-treatment 
with treprostinil and 10% FBS. 
 
The PASMCs were prepared in the chamber slides for confocal microscopy in the 
same manner as explained in section for the characterisation of smooth muscle 
cells. 100µl of rabbit polyclonal anti-calcineurin (Cn) Aβ (Millipore, Watford, 
Hertfordshire, UK), diluted at 1:200 blocking solution consisting of 2% BSA and 
0.01% triton x-100 dissolved in PBS, was added to each well and the cells 
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incubated for 2 hours at room temperature on a slow shaker. The cells were 
washed 3 times with 500µl PBS for 5 minutes each before a 100µl of the 
secondary antibody anti-mouse Alexa 488 (Invitrogen, Paisley, UK),  prepared at 
1:200 dilution in blocking solution, was used to stain CnAβ. After 2 hours of 
incubation at room temperature on a slow shaker in the dark, the slides were 
washed a final time with 500µl PBS per well and the walls of the chamber 
detached. 10µl of mounting reagent containing 4’, 6-diamino-2-phenylindole 
(DAPI) (Vector Laboratories, Inc., Burlingame, CA, USA), which binds strongly 
to the A-T rich regions in DNA and stains the nucleus blue, was pipetted to the 
wells of each slide. A glass coverslip was placed on top and sealed in place with a 
layer of commercially available nail varnish. The slides were stored at -20oC in 
the dark until they were ready to be examined under a Leica TCS SPE confocal 
microscope preferably within 3 days. 
 
Confocal images of PASMCs were taken from a focal plane from the middle of 
the cell using a z-stack of 10 images with 0.10 µm spacing. Nuclear colocalisation 
of calcineurin Aβ was quantified using the ImageJ software where at least 8 
different cells per treatment from 3 patients were analysed.  
 
2.17 The effect of SMMP on proliferation 
Normal control PASMCs were plated at a density of 1x104 into the wells of a 96-
well flat-bottomed plate in  growth media (100µl) containing DMEM/F-12, 10% 
FBS, and 1% penicillin/streptomycin (50 units/ml) and incubated at 37oC in a 
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humidified incubator for 24 hours. The cells were then washed with 200µl of PBS 
twice and growth arrested in 0.1% FBS in DMEM/Ham’s F-12 media containing 
1% penicillin/streptomycin for 48 hours. The media was replaced with fresh arrest 
which was added to each well in the absence and presence of 10% FBS, 20ng/ml 
platelet derived growth factor (PDGF-BB), 105 smooth muscle MPs derived from 
a? PAH patient(s) or 5ng/ml transforming growth factor β (TGFβ). The different 
treatments were administered into the wells in replicates of five. The cells were 
incubated for 96 hours and the changes in proliferation were compared to the cells 
in arrest media. 
 
The CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, 
Southhampton, UK) was used to examine the changes in proliferation of the 
smooth muscle cells caused by the different treatments. This assay utilises a 
colorimetric method to determine the number of viable cells. It is composed of 
two chemicals: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) and phenazine methosulfate. MTS 
is cleaved by dehydrogenase enzymes into aqueous, soluble formazan in 
metabolically active cells. The quantity of formazan product measured by the 
absorbance at 490nm is directly proportionate to number of viable cells in culture 
media. 
 
Twenty-one ml of Dulbecco’s PBS was added to a container wrapped in foil for 
protection from light, into which 42mg of MTS reagent powder was added 
according to the manufacturer’s instruction. The MTS was completely dissolved 
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by mixing on a magnetic stir plate for 15 minutes. The pH was adjusted to 6.0-6.5 
and the mixture filter sterilised by passing through a 0.22µl filter into 15ml falcon 
tubes and stored at -20oC in a container shielded from light. The MTS solution 
was thawed and 2ml was mixed with 100µl of PMS solution in a 15ml falcon 
using asceptic technique. After gentle swirling, the MTS/PMS solution was 
diluted in arrest media at a 1:6 dilution, and 120µl of the solution was used to 
replace the media containing the cells in the wells of the 96-well plate. The plate 
was incubated for 3 hours at 37oC and 5% CO2, after which absorbance was read 
at 490nm using an ELISA plate reader  
 
2.18 Statistical analysis 
All statistical analysis was carried out on GraphPad Prism 6 software (Jandel 
software, La Jolla, USA). The MP data is expressed as median ±interquartile 
range. The differences in MP levels between controls and diseased patient samples 
were examined using the Mann Whitney U test. The differences in MP levels in 
PAH patients before and after therapy was examined using the Wilcoxen matched 
pairs test. All in vitro assay data are expressed as mean ± standard error mean 
(S.E.M.) and the differences between more than two groups were determined 
using one-way analysis of variance (ANOVA) with Bonferroni, Dunnett’s or 
Neuman Keuls multiple comparisons test where appropriate. Logistic regression 
analysis was used to examine the relationship between biomarker levels (ie. 
microparticle level vs. peak thrombin) and results are expressed using Spearman’s 
rank correlation coefficient and odds ratios (OR) with corresponding 95% 
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confidence intervals (CI) and P-values. Receiver operator characteristic (ROC) 
curves, sensitivity, specificity, positive and negative predictive values, and 
likelihood ratios were calculated to examine the diagnostic characteristics of 
indices described. The ROC curve is a valuable tool for evaluating diagnostic 
tests, in particular to this project, circulating microparticle levels and MP-induced 
thrombin generation. ROC curve were reported as area under the curve (AUC) 
and 95% confidence intervals (CI) to measure how well a parameter could 
distinguish between the two diagnostic groups (ie. diseased and normal). The plot 
is indicated as the true positive rate (=sensitivity) in function of the false positive 
rate (100%-specificity) for the different cut-off points of a parameter. The points 
on ROC curves represent sensitivity/specificity pairs corresponding to decision 
thresholds held at those specific points. Statistical significance was regarded when 
P values were less than 0.05 (two sided).  
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Chapter 3 
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3. Identification of smooth muscle microparticles 
3.1 Introduction 
 
PAH is a severe disease of the small pulmonary arteries characterised by 
narrowing of the lumen, increased inflammation, and vascular remodelling, which 
leads to elevated pulmonary artery pressure (PAP) and ultimately right heart 
failure. Due to nonspecific presenting symptoms, often delayed diagnosis by an 
average of 2 years, and an invasive definitive diagnosis via right heart 
catheterisation, the need for early biomarkers is much needed in PAH (Warwick et 
al., 2008). A wide array of biomarkers has been explored and can be divided into 
5 major groups: markers of vascular dysfunction (e.g. endothelin-1, assymetric 
dimethylarginine (ADMA), angiopoietins, von Willebrand factor), markers of 
inflammation (e.g. pro-inflammatory cytokines such as IL-6, C-reactive protein, 
chemokines), markers of myocardial stress (BNP/NT-proBNP, ANP, troponins), 
markers of low carbon dioxide and/or tissue hypoxia (i.e. osteopontin, uric acid, 
growth factor 15 (GDF15), PCO2), and markers of secondary organ damage (e.g. 
bilirubin, creatinine) (Galie et al., 2015b). Though this list is growing, BNP and 
NT-proBNP, biomarkers for myocardial dysfunction, are the only plasma markers 
used widely in PH centres and clinical trials. However, they are not necessarily 
specific for PH as they are elevated in most heart diseases and tend to have high 
variability, and thus should only be interpreted in the clinical context of the 
patients. A biomarker that plays a role in both vascular dysfunction leading to 
remodelling and inflammation are microparticles (MPs), which are submicron 
pro-inflammatory, thrombogenic vesicles released by
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(Simak and Gelderman, 2006; Dignat-George and Boulanger, 2011). Circulating 
MPs of different cellular origin including platelets, erythrocytes, leukocytes, and 
endothelial cells are detectable in healthy subjects, but are elevated in a wide 
variety of cardiovascular diseases including atherosclerosis, heart failure, 
arrhythmias and inflammatory vascular diseases (Amabile et al., 2013). 
 
Endothelial dysfunction plays a prominent role in the development and 
progression of PAH. An imbalance caused by increased proliferation and 
decreased apoptosis of endothelial cells has been reported in idiopathic PAH 
(IPAH)  (Masri et al., 2007). Increased endothelial apoptosis at the initial stages of 
PAH and decreased apoptosis in later stages appears to contribute to the disease 
progression (Sakao et al., 2005). Additionally, primary pulmonary endothelial 
cells isolated from PAH lung specimens have a pro-proliferative, apoptotic-
resistant phenotype (Eddahibi et al., 2006). Amabile and colleagues have shown 
that circulating endothelial MPs expressing the surface markers platelet and 
endothelial cell adhesion molecule (PECAM), vascular endothelial cadherin (VE-
cadherin) and E-selectin were increased in subjects with PH compared to control 
subjects (Amabile et al., 2008). Levels of PECAM+/CD41- and VE-cadherin+ 
MPs correlated positively with mean PAP (mPAP), pulmonary vascular resistance 
(PVR), and mean right atrial pressure (mRAP) and inversely with cardiac index 
(CI). As PECAM is a surface marker that stains both endothelial cells and 
platelets, MPs with the heterodimeric integral membrane protein integrin alpha-
IIbIIIa (CD41; GPIIbIIIa) were identified to distinguish endothelial specific 
PECAM+/CD41- MPs. Microparticles have been characterised on the basis of the 
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many surface markers that exist on the cells of origin. Endothelial microparticles 
(EMPs) have been extensively studied in their role as mediators or biomarkers of 
various vascular diseases including vasculitis, sickle cell anemia, and 
endotoxemia (Brogan et al., 2004; Dignat-George and Boulanger, 2011). EMPs 
have been shown to contain endothelial-derived proteins such as vascular 
endothelial cadherin, platelet endothelial cell adhesion molecule (PECAM) -1, 
intercellular cell adhesion molecule (ICAM)-1, endoglin, E-selectin, melanoma 
cell adhesion molecule (MCAM) or αv integrin (Chironi et al., 2009; Dignat-
George and Boulanger, 2011). As aforementioned, since PECAM1 is expressed in 
both endothelial cells (ECs) and platelets, EMPs have specifically been defined by 
a CD31+/CD41- phenotype. CD41 is the platelet integrin glycoprotein IIBIIIa, a 
receptor for fibrinogen and von Willebrand factor (vWF) that is involved in 
platelet activation, although EMPs are also able to bind to vWF. Jimenez and 
colleagues conducted a study where growing renal and brain microvascular and 
coronary endothelial cells were deprived of growth factors to induce apoptosis 
(Jimenez et al., 2003).  
 
The types of proteins detected on the surface of MPs may provide information on 
the vasculopathy in disease conditions. Endoglin is an accessory protein for 
transforming growth factor -β (TGF-β) and its expression is upregulated in 
endothelial cells during cell proliferation (Nassiri et al., 2011). Endoglin therefore 
has been suggested to be a marker for tumour-related angiogenesis and 
neovascularisation. Endoglin expression appears elevated in ECs of neoplastic 
tissue, which are more proliferative than ECs isolated from normal tissue. Conley 
and colleagues reported that cultured human arterial smooth muscle cells (SMCs) 
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also express endoglin, predominantly the L-isoform (Conley et al., 2000). High 
endoglin expression was also observed on SMCs in atherosclerotic plaques in 
vivo, though little or no expression was seen in smooth muscle within normal 
arteries. PECAM-1 is another molecule expressed on ECs as well as on platelets 
and various leukocyte subtypes. It has been shown to play a role in the 
transmigration of monocytes, neutrophils, natural killer cells and some sub-sets of 
lymphocytes (Woodfin et al., 2007). ICAM-1 and VCAM-1 are molecules that are 
expressed in both ECs and SMCs (Braun et al., 1999; Dignat-George and 
Boulanger, 2011) and contribute to the adhesion of leukocytes to the activated 
endothelium. Through the binding of lymphocyte function-associated antigen 
(LFA)-1 (CD18/11a) or Mac-1 (CD18/CD11b), ICAM1 is able to mediate the 
adhesion of neutrophils, monocytes and lymphocytes to the endothelium. ICAM-1 
also acts as a receptor for fibrinogen and hyaluronic acid. VCAM-1 is able to bind 
to the very late antigen 4 (VLA4; integrin α4/β1) on monocytes and lymphocytes 
(Faruqi and DiCorleto, 1993). E-selectin is a member of the selectin family of 
glycoproteins and is an endothelial-specific adhesion molecule. Its expression is 
rapidly induced by inflammatory cytokines such as TNF-α and IL-1β and is 
involved in the initial cell attachment and rolling of leukocytes at sites of 
endothelial activation during inflammation (Rahman et al., 1998). Like E-selectin, 
VE-cadherin is also an endothelial specific marker that is located at junctions 
between ECs and plays a role in controlling vascular permeability and leukocyte 
extravasation (Vestweber, 2007). Another adhesion molecule that is present on 
both endothelial cells and vascular smooth muscle cells is MCAM, which plays a 
role in cell-cell adhesion as a component of the endothelial junction associated 
with the actin cytoskeleton (Guezguez et al., 2007). MCAM is also expressed on 
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activated T-cells and in lymphoid tissues including the thymus and spleen. Indeed, 
many surface markers used to identify endothelial-derived microparticles as 
biomarkers of vascular diseases are highly involved in inflammation. 
 
As medial thickening is the earliest known pathology in PAH, the identification of 
circulating smooth muscle MPs may be a valuable tool in prompting an earlier 
diagnosis of the disease. However, smooth muscle MPs have not been 
characterised unlike endothelial MPs. This may be due to the fact that SMCs in 
the past have classically been characterised by intracellular markers instead of 
surface markers. Thus, α-smooth muscle actin (αSMA) is frequently used to 
identify the smooth muscle phenotype, though it is not specific to SMCs as it is 
present in cultured fibroblasts as well (Hinz et al., 2001; Metz et al., 2012). Other 
intracellular markers of SMCs include myosin heavy chain, transgelin (SM22α), 
calponin, caldesmon, and the cytoskeletal protein smoothelin. SM22α is an 
intracellular SMC-specific protein that is related to the actin- and tropomyosin-
binding protein calponin (Li et al., 1996). Wang and colleagues demonstrated that 
smooth muscle progenitor cells (SMPCs) were positive for certain surface markers 
such as platelet derived growth factor receptor β (PDGFRβ), carboxipeptidase M 
(CPM) and low-density lipoprotein receptor-related protein 1 (LRP1) (Wang et 
al., 2012). PDGFR-α and -β are receptors for PDGF, a growth factor that is 
elevated in PAH. mRNA expression of both receptor isoforms have been shown to 
be increased in small pulmonary arteries from patients with IPAH compared to 
control subjects (Perros et al., 2008). Protein expression of PDGFRβ is 
significantly increased in disease as well. Both PDGFR-α and –β receptors largely 
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stained pulmonary arterial SMCs and to a lesser extent endothelial cells. CPM is a 
protein in the family of carboxypeptidases and has a wide variety of roles 
physiologically including the regulation of blood coagulation/fibrinolysis, 
inflammation, food digestion, neuropeptide and prohormone processing (Deiteren 
et al., 2009). Though expressed on smooth muscle cells, greater CPM activity has 
been shown in cultured endothelial cells when both cell types were isolated from 
hog aorta (Palmieri et al., 1986). LRP1 is a protein expressed in various tissues 
including smooth muscles and has been shown to inhibit PDGF-induced mitogen-
activated protein kinase (MAPK) activity and migration and proliferation of 
smooth muscles (Basford et al., 2009). It is also a clearance receptor for amyloid 
Aβ and has been shown to play a protective role in Alzheimer’s disease (Kanekiyo 
et al., 2012). 
 
Though smooth muscle microparticles have reportedly been identified in past 
studies, a full characterisation has not been initiated. Akker and colleagues 
showed that these MPs could bind potently to annexin V in the same manner as 
other microparticles, which allowed identification of the total MP count using 
flow cytometry (van den Akker et al., 2012). Essayagh and colleagues 
demonstrated that apoptotic rat aortic smooth muscle derived MPs were annexin 
V and expressed β3 integrin and contained low levels of tissue factor (Essayagh et 
al., 2005). Tissue factor on the surface of smooth muscle MPs were also 
confirmed by Brisset and colleagues, though this was also seen in endothelial MPs 
and monocytes (Jimenez et al., 2003; Stampfuss et al., 2006). In PH, circulating 
levels of PECAM+/CD41-, VE-cadherin+, and E-selectin+ EMPs as well as 
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CD45+ leukocyte derived MPs have been shown to be elevated compared with 
control subjects (Amabile et al., 2008). In PAH, Bakouboula and colleagues 
showed that procoagulant MPs bearing tissue factor and endoglin were elevated in 
patients and attributed it to endothelium damage (Bakouboula et al., 2008). With 
the intent of determining the level of smooth muscle MPs, I aimed to first 
characterise smooth muscle cells isolated from PAH cells and distinguish them 
from those from normal control SMCs and ECs. 
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3.2 Results 
3.2.1. Characterisation of smooth muscle cells 
Pulmonary arterial smooth muscle cells isolated from PAH patients expressed 
platelet derived growth factor receptor β (PDGFRβ), endoglin, neural glial antigen 
2 (NG2), intracellular cell adhesion molecule (ICAM) and mesenchymal cell 
adhesion molecule (MCAM) (Figure 12). The level of fluorescence intensity 
representing receptor expression of endoglin, NG2, and MCAM were significantly 
higher than that of the isotype control antibody (p=<0.001, p=<0.001, and p=0.05, 
respectively; n=3). Expression levels of PDGFRα, vascular cell adhesion molecule 
(VCAM) 1, E-selectin, platelet endothelial cell adhesion molecule 1 (PECAM-1), 
and the cytoskeletal markers α-smooth muscle actin (αSMA), and transgelin 
(SM22α) were not elevated when their intensity was compared to the control 
antibody. 
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Figure 12. Measurement surface marker expression on PASMCs isolated from PAH 
patients 
Measurement surface marker expression on pulmonary artery smooth muscle cells 
isolated from PAH patients and grown in 10% FBS. A) Histograms show flurescence 
intensity of surface markers platelet derived growth factor receptor-β (PDGFR-β), 
endoglin, neural glial receptor 2 (NG2), and platelet and endothelial cell adhesion 
molecule (PECAM-1). B) Data are presented as median fluorescence intensity ± S.E.M. 
(n=3); One-way ANOVA with Holm-Sidak’s multiple comparisons test, with a single 
pooled variance was used. 
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3.2.2. Visualisation of intact microparticles 
MPs were visualised in culture using green fluorescent probes and confocal 
microscopy (Figure 13). The fluorescent dye carboxyfluorescein succinimidyl 
ester (CFSE) was used to permeate patient-derived pulmonary artery smooth 
muscle cells (PASMCs). This dye covalently binds via its succimidyl group to 
intracellular molecules and stains the cytosol fluorescent green. These cells were 
able to release microparticles after stimulation with 20ng/ml PDGF and 10% FBS 
for 24 hours. These microparticles were subsequently visualised as green globules 
when administered to growing smooth muscle cells and left to attach for 4 and 24 
hours. The fluorescent staining of the MPs indicate that they are entities with 
intact membranes and are able to attach to the cell surface of PASMCs isolated 
from PAH patients and grown in culture. The number of visible particles was 
greater after 24 hours of administration to cells indicating that MPs are adhesive 
to cells and may be involved in the fusing of membranes and transporting 
intercellular material.  
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Figure 13. Green fluorescent staining of MPs attached to smooth muscle cells. 
A) PASMCs were grown in culture in the presence of the intracellular fluorescent 
dye carboxyfluorescein succinimidyl ester (CFSE) and then stimulated with 
20ng/ml PDGF-BB and 10% FBS to cause the release of MPs. MPs were isolated 
and subsequently administered to smooth muscle cells for 24 hours. Cells were 
stained (red) with α-smooth muscle actin primary monoclonal antibody (1:500 
dilution) and anti-mouse Alexa 555 (1:1000 dilution) and the nuclear marker 
DAPI (blue) and imaged via confocal microscopy. B) CFSE-stained MPs were 
administered to growing smooth muscle cells for 24 hours and imaged using a 
fluorescence microscope to assess level of attachment. DAPI was used for nuclear 
staining. Any un-attached MPs were washed away with PBS. 
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3.2.3. Microparticles derived from pulmonary artery smooth muscle cells 
The release of MP derived from PAH smooth muscle cells (n=3) was studied over 
48 hours (Figure 14). The level of MPs released gradually increased over time and 
was highest at 24 hours after stimulation with 10% serum and 20ng/ml PDGF-BB, 
declining  thereafter. Total MP release was 3 fold greater with a combination of 
PDGF-BB and serum at 24 hours compared to serum alone. This decline may 
have been due to MP degradation or uptake by growing cells. MP release was 
minimal with 0.1% FBS, which stabilised after 6 hours. Serum was able to induce 
greater MP release compared to serum starvation (0.1% FBS), with peak levels 
that were 2.5 fold greater at 6 hours, though this did not reach significance. 
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Figure 14. Time course of the total MPs released by SMCs isolated from PAH patients
Time course of the total MPs released by smooth muscle cells isolated from PAH patients 
and grown in culture with 0.1% FBS, 10% FBS, and 10% FBS + 20ng/ml PDGF-BB. Total 
MPs were Annexin+ and smaller than 1.1µm in size as assessed by side scatter using flow 
cytometry. Data is mean ± S.E.M. (n=3). Two-way ANOVA was conducted with Tukey’s 
multiple comparisons test, where ***=P<0.001 when compared to 10% FBS. 
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3.2.4. PDGF-BB induced smooth muscle microparticle release 
 
PDGF-BB induced MP release from SMCs isolated from PAH patients (n=3) in a 
dose-dependent manner (Figure 15). A visible, though not significant, increase 
was seen when 10-9 ng/ml PDGF-BB was administered with 10% FBS compared 
with serum alone. 3x108ng/ml PDGF-BB caused the highest level of MP release 
from smooth muscle cells which was 2-fold greater than that caused by serum 
alone (P<0.01; n=3). There was a slight decrease in MP number at the highest 
dose 1x107ng/ml, which could be due to PDGF-BB working via other pathways 
that counteract the MP shedding process. 
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Figure 15. Effect of platelet-derived growth factor-BB (PDGF-BB) on MP 
release from growing smooth muscle cells. 
PDGF-BB was administered for 24 hrs at concentrations 10-9g/ml, 3x10-9g/ml, 
10-8g/ml, 3x10-8g/ml, 10-7g/ml each in combination with 10% FBS and compared 
with 10% FBS and 0.1% FBS. Data are presented as mean ± S.E.M. (n=3). 
*=P<0.05; **=P<0.01; One-Way ANOVA with Tukey’s multiple comparisons test 
was conducted when compared to 0.1% FBS. 
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3.2.5. Characterisation of smooth muscle microparticles from PAH 
cells 
 
Pulmonary artery smooth muscle MPs from PAH cells (n=5) were further 
analysed and characterised. Cells were grown in 0.1% FBS, 10% FBS and 10% 
FBS with 20ng/ml PDGF-BB for 24 hours to stimulate MP release (Figure 16a). 
Low serum induced significantly less MP release compared to 10% FBS 
(p=<0.05), while 20ng/ml of PDGF-BB with serum induced significantly greater 
particle release (p=<0.05). For characterisation, MPs were co-stained for different 
cell surface markers (Figure 16b). High levels of PDGFRβ, endoglin, NG2, 
ICAM-1, and E-selectin positive MPs derived from smooth muscle (greater than 
20,000 MPs/ml/104 cells) were detected after PDGF-BB administration, with 
significantly less generated with serum alone (P=<0.05; n=5) and accounted for 
30%, 44%, 25%, 17% and 19% of the total MPs detected, respectively. 
Differences in the proportion of the MP subpopulations between treatments was 
not noticeable. Levels of PDGFRα+, MCAM+, +, αSMA+ and sm22α+ induced 
by PDGF were comparably lower, and few VCAM+-1 or PECAM-1+ MPs were 
detectable. 
  
139 
 
 
  
Figure 16. Characterisation of MPs released from cultured PASMCs isolated from 
PAH patients 
A) Total MPs released by cells incubated for 24 hrs in the presence of either 0.1% FBS, 
10% FBS   or 10% FBS in combination with 20ng/ml PDGF-BB as indicated. B) 
Characterisation of MPs released from cultured cells stimulated with 10% FBS in the 
absence or presence of 20ng/ml PDGF-BB for 24 hrs. All MPs were stained for annexin 
V and a single cell surface/cytoskeletal marker. Data are expressed mean ± S.E.M (n=5). 
*=P<0.05; **=P<0.01; ***=P<0.001; One-Way ANOVA with respect to 0.1% FBS for 
A and unpaired t-test with respect to 10% FBS for B.  
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3.2.6 Smooth muscle microparticles released from growing cells 
from PAH patients 
 
Levels of specific receptor positive MP subpopulations were studied over a 48 
hour period to investigate their release from cells in proportion to the total number 
of MPs released (Figure 17). All three PDGFRβ+, endoglin+, and NG2+ MP 
subpopulations increased over time, peaking at 24 hours, with a combination of 
20ng/ml PDGF-BB and 10% serum causing a significantly greater MP release 
than serum alone (**=P<0.01). During MP release over 24 hours, the proportion 
of the receptor positive subpopulations also increased relative to the total MP 
levels. At 6 hours and 24 hours respectively, the proportion of total MPs that were 
endoglin+ was 23.4% and 44.65%, for PDGFRβ+ was 15% and 32% and for 
NG2+ was 16% and 28%. At 48 hours, all three MP subpopulations decreased in 
number both in the presence of serum with and without PDGF-BB. 
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Figure 17. MPs released from growing PASMCs 
MPs released from PASMCs grown in 10% FBS with and without 20ng/ml PDGF-
BB over 48 hours. Smooth muscle MPs were stained for endoglin (A), PDGFRβ 
(B), and NG2 (C). Data are mean±S.E.M (n=5); *=P<0.05; **=P<0.01; 
***=P<0.001; ****=P<0.0001; Two-way ANOVA was conducted with Sidak’s 
multiple comparisons test when compared to 10% FBS. 
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3.2.7. Characterisation of smooth muscle microparticles from 
normal cells 
 
MPs released from control PASMCs (n=5) isolated from donor lungs were also 
analysed and characterised (Figure 18). 20ng/ml PDGF-BB in the presence of 
10% FBS also induced a significantly greater release of MPs at 24 hours 
compared to serum alone (P=<0.05). MPs released by either serum alone or in 
combination with PDGF-BB contained a similar marker profile to that observed in 
PAH cells with PDGFRβ+, endoglin+, NG2+, ICAM-1+ and E-selectin+ MPs 
being considerably higher than other markers (figure 6b). MPs positive for these 
markers were all detected at levels greater than 20,000 MPs/ml/104 cells. Though 
PDGFRβ+ MP release was significant, in the presence of PDGF-BB and serum, 
levels for the receptor specific subpopulation were not significantly higher 
compared to serum alone. Moreover, total MP release and receptor specific 
subpopulations from normal control donor cells were slightly though not 
significantly lower than MP levels from PAH cells. PDGFRβ+ and endoglin+ 
MPs accounted for 17% and 33% of the total MPs, which are considerably lower 
than that seen in PAH cell-derived MPs. In contrast, E-selectin+ MPs accounted 
for 35% of the total count, which is comparably higher than in MPs from PAH 
cells. PDGFRα+, MCAM+, VCAM+, αSMA+, and sm22α+ MP numbers were 
noticeably low before and after PDGF stimulation (ie. <10000 MPs/ml/104 cells), 
with PECAM-1+ MPs virtually undetectable. 
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Figure 18. Characterisation of SMMPs released by PASMCs isolated from normal 
donor lungs 
A) Total Annexin V+ MPs released by cells cultured in the following conditions: 10% FBS 
and 10% FBS + 20ng/ml PDGF-BB for 24 hours. Total MPs were positive for annexin V 
and smaller than 1.1µm in size. B) Annexin V+ MPs were also screened for cell surface and 
cytoskeletal markers. Data are expressed as mean±S.E.M. (n=5). Unpaired t-test was used 
when compared with 10% FBS. 
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Figure 19. Characterisation of MPs released from cultured PASMCs from control and 
PAH patients. 
A) Total Annexin V+ MPs released by cells cultured in the following conditions: 10% FBS 
and 10% FBS + 20ng/ml PDGF-BB for 24 hours. Total MPs were positive for annexin V 
and smaller than 1.1µm in size. B) Annexin V+ MPs were also screened for cell surface and 
cytoskeletal markers. Data are expressed as mean±S.E.M. (n=5). Two-Way ANOVA with 
Sidak’s multiple comparison’s test was used for A and One-way ANOVA with 
Tukey’smultiple comparison’s test was used to compare MP levels. 
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3.2.8. The effect of inflammatory and proliferative mediators on MP release 
from PAH cells 
 
I investigated the ability of different growth factors or proinflammatory cytokines 
that are known to be elevated in PAH. The efficacy of mediators causing smooth 
muscle MP release from PAH cells in the presence of 10% FBS was as follows: 
20ng/ml TNFα < 20ng/ml PDGF-BB < 5ng/ml TGF-β < 10nM ET-1 (Figure 20). 
After 24 hours of stimulation, all four agents were able to increase MP release 
over and above that induced by serum alone. 20ng/ml PDGF-BB was able to 
cause 2 fold of the number of MPs compared to serum alone, while 5ng/ml TGFβ 
induced a 2.5 fold increase. The addition of 10nM ET-1 to serum was the most 
potent agent as it caused a 3.5 fold elevation compared to serum alone.  
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Figure 20. Total MPs released from cultured PASMCs after stimulation 
with growth factors and cytokines. 
Growth arrested cells were stimulated with either 0.1% FBS  with and without 
20ng/ml TNFα, 20ng/ml PDGF-BB, 5ng/ml TGF-β, or 10nM ET-1 for 24 hours. 
Data are presented mean±S.E.M. (n=5). *=P<0.05; **=P<0.01; One-Way 
ANOVA with Bonferroni’s multiple comparisons test was conducted when 
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3.2.9. Characterisation of human umbilical cord vein endothelial cells 
 
Human umbilical cord vein endothelial cells (HUVECs) were isolated and 
characterised for the surface markers expressed (Figure 21). Similar to what was 
found in  smooth muscle cells, these endothelial cells expressed high amounts of 
endoglin antibody binding on their cell surface as determined by fluorescence 
intensity using flow cytometry (P<0.05; n=3). Cells also expressed ICAM1 and 
low levels of MCAM, though the fluorescence intensities were not significantly 
different from that of the isotype control antibody. Unlike smooth muscle cells, 
HUVECs did express high levels of PECAM-1 (P<0.05; n=3) but  did not express 
PDGFRβ, E-selectin  or NG2.   
148 
 
 
 
  
101 102 103 104 105
0
20
40
60
80
100
%
 
of
 
M
ax
101 102 103 104 105
Endoglin
0
20
40
60
80
100
%
 
of
 
M
ax
101 102 103 104 105
PECAM-1
0
20
40
60
80
100
%
 
of
 
M
ax
101 102 103 104 105
0
20
40
60
80
100
%
 
of
 
M
ax
PDGFRβ Endoglin 
PECAM-1 NG2 
A. 
B. 
Figure 21. Surface marker expression on HUVECs 
Measurement of surface marker expression on human umbilical cord vein endothelial cells 
isolated from female patients at term and grown in 10% FBS. A) Histograms show 
fluorescence intensity of surface markers in red for platelet derived growth factor receptor 
β (PDGFRβ), endoglin, neural glial receptor 2 (NG2), and platelet and endothelial cell 
adhesion molecule (PECAM-1). B) Data is presented as median fluorescence intensity ± 
S.E.M. (n=3) and analysed using one-way ANOVA with Holm-Sidak’s multiple 
comparisons test, with a single pooled variance. ****=P<0.001 when compared to isotype 
control antibody. 
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3.2.10. Characterisation of endothelial microparticles 
Endothelial microparticles were released from growing HUVECs in culture that 
were subjected to either of three conditions: 0.1% FBS, 10% FBS, or 10% FBS + 
10ng/ml TNFα (Figure 22). The presence of serum increased MP release though 
this was not significantly different from 0.1% FBS. On the other hand, TNFα 
caused a significant 2-fold increase in MPs released from endothelial cells 
compared to serum alone (p<0.01; n=3). Numbers of microparticles positive for 
endoglin, ICAM, and E-selectin were considerably elevated after TNFα treatment, 
with the latter reaching significance (p<0.01; n=5). Unlike smooth muscle 
microparticles, PDGFRβ+ and NG2+ microparticle levels were low (<10,000 
MPs/ml/104 cells). Interestingly, there was a high level of PECAM+ 
microparticles in the total endothelial microparticle population compared to the 
PECAM+ subpopulation that was almost undetectable in the smooth muscle 
microparticle population. Levels of PDGFRα+, αSMA+ and sm22α+ 
microparticles were also very low, while VCAM1+ MPS were significantly 
elevated by TNF-α (n=5).
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Figure 22. Characterisation of endothelial MPs released by HUVECs isolated 
from donor patients 
Cells were cultured under the following conditions: 0.1% FBS, 10% FBS and 10% 
FBS + 20ng/ml PDGF-BB for 24 hrs. A) Total EMPs positive for annexin V and 
smaller than 1.1µm in size. B) Annexin+ MPs were screened for different cell 
surface markers. Data are presented as mean±S.E.M. (n=3 for A; n=5); *=P<0.05 
and **=P<0.01; One-Way ANOVA was conducted when compared to to 0.1% FBS 
for A and unpaired t-test was conducted when compared to 10% FBS for B. 
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3.3. Discussion 
 
The aim of the current chapter was to characterise SMMPs and distinguish them 
from EMPs by determining the surface markers present on these MP subtype, I 
first characterised culture smooth muscle cells that were growing in 10% FBS. In 
conjunction with studying cell surface protein expression, I investigated the 
presence of these markers on MPs from both smooth muscle and endothelial cells 
to elucidate smooth muscle specific surface markers. 
 
Smooth muscle cell characterisation revealed high endoglin expression in growing 
cells in vitro, which was similarly seen in HUVECs. endoglin, a 95kDa 
homodimeric transmembrane glycoprotein, is classically known as a marker for 
angiogenesis that is abundantly expressed on actively proliferating endothelial 
cells (Conley et al., 2000). Observations of strong upregulation of endoglin in the 
endothelium of tumour tissues taken from the lung, breast, colon, brain, prostate, 
and cervical cancer, have suggested its involvement in tumour angiogenesis 
(Olsen et al., 2014). Loss of function in the human gene encoding for endoglin 
causes hereditary haemorrhagic telangiectasia (HHT1), a disease where abnormal 
formation of blood vessels in various organs including the skin and mucous 
membranes, lungs, liver and brain occurs (Li et al., 1999). In mice, loss of 
endoglin leads to disrupted angiogenesis and ultimately death, which is attributed 
to poor vascular smooth muscle development (Bourdeau et al., 1999; Conley et 
al., 2000). Expression of endoglin has been shown to be elevated in the smooth 
muscle of human atherosclerotic plaques and in smooth muscles responding to 
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vascular injury, though its expression in normal human carotid artery, as observed 
via immunohistochemistry, was minimal (Conley et al., 2000; Ma et al., 2000). 
Conley and colleagues demonstrated that the L-isoform of human endoglin was 
predominantly expressed in cultured vascular SMCs. Endoglin is an accessory 
receptor for the β1 and β3 isoforms of TGF-β, a multifunctional cytokine that is a 
part of a large superfamily of proteins that includes bone morphogenic proteins 
(BMPs) (Lebrin et al., 2004). The TGF-β family acts on a heterodimeric receptor 
complex comprised of a type II (TβR-II) and a type I receptor (TβR-I). There are 
two type I receptors: activin-like kinase 1 (ALK1), which is expressed in the 
endothelium, and ALK5, which is expressed ubiquitously (Lee et al., 2008). TβR-I 
is a superfamily serine/threonine kinase receptors that work downstream from 
TβR-II and phosphorylate effector proteins known as Smads. In endothelial cells, 
TGFβ can either signal through ALK1 to phosphorylate Smads1/5/8 and stimulate 
proliferation, migration and angiogenesis or signal through ALK5 to 
phosphorylate Smads2/3 and inhibit proliferation. Thus, endoglin can cause 
endothelial proliferation though TGFβ signalling via the ALK1 and also 
negatively regulate TGFβ/ALK5 signalling in the ECs (Goumans et al., 2002; 
Lebrin et al., 2004). In contrast, the bone morphogenic peptide (BMP) ligands 
such as TGF-β and BMP-2, 4 and 7 are able to activate the BMP recpeptor II 
(BMPR-II) receptor coupled with ALK1 to activate Smads 1, 5 and 8 to inhibit 
cell proliferation in normal PASMCs (Morrell et al., 2009). In contrast, TGFβ is 
able to bind TβR-II coupled to ALK5 which consequently can signal via Smads 
2/3 and induce proliferation particularly in PASMCs derived from PAH patients 
(Yang, 2005; Morrell et al., 2009; Morrell, 2010). In the presence of mutation 
within the BMP receptor in heritable PAH, TGFβ signalling via the Smad2/3 
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pathway is dominant, and thereby induces SMC proliferation. The role of 
endoglin in smooth muscle cells has not been firmly established, though its high 
expression in cultured PAH smooth muscle cells may suggest that it plays a part in 
the regulation of cell proliferation. Moreover, high levels of endoglin+ smooth 
muscle MPs were detected following PDGF-BB stimulation compared to other 
MP subpopulations in both PAH and control cells. This may indicate that 
endoglin+ MPs detected in patient plasma may be smooth muscle- derived and not 
entirely endothelial derived as was concluded by Bakouboula and colleagues 
(Bakouboula et al., 2008). 
The PASMCs also significantly expressed NG2, PDGFRβ, ICAM, and MCAM. 
NG2 is classically known as a pericyte marker. It is a membrane-spanning 
chondroitin sulfate proteoglycan expressed by mural cells during normal 
development and microvascular remodelling during tumour growth and wound 
healing. Murfee and colleagues demonstrated that NG2 expression was primarily 
confined to perivascular cells, including mature SMCs, immature SMCs and 
pericytes, along arterioles and capillaries but not along venules (Murfee et al., 
2005). In my experiments, NG2 expression was not present on the cell surface of 
growing HUVECs. In previous studies, treatment of vascular smooth muscle cells 
from rat aorta with anti-NG2 immunoglobulins decreased DNA synthesis and cell 
migration in response to PDGF-AA, but not to PDGF-BB (Grako and Stallcup, 
1995). Likewise, I also found high levels of NG2+ MPs were released by 
activated SMCs but only low levels by HUVECs following PDGF-BB and TNF-α 
stimulation, respectively. Thus, NG2+ MPs may account for smooth muscle 
derived microparticles from activated cells. 
154 
 
Similar to NG2, I demonstrated that PDGFRβ was expressed on the cell surface of 
smooth muscle cells and not on HUVECs, and that high amounts of PDGFRβ+ 
MPs were released by smooth muscle cells compared to HUVECs. PDGFRβ is 
known to be expressed by developing smooth muscle cells and pericytes, and 
plays a key role in the signalling of its ligand PDGF-B in inducing cell 
proliferation and migration (Hellström et al., 1999). Lack of signalling though this 
pathway leads to pericyte loss as well as changes to the endothelium leading to 
capillary dilatation and rupture. Upon ligand binding, the receptor is able to 
undergo phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis through 
phospholipase Cγ binding, and subsequently generate diacylglycerol and inositol 
triphosphate (IP3). Through IP3-mediated calcium release from intracellular 
compartments which increases intracellular calcium levels and mitogen activated 
protein kinase activation, PDGFRβ is able to promote cell proliferation (Bornfeldt 
et al., 1995). Additionally, transfection of Notch1 and Notch3 intracellular domain 
into primary human VSMCs has been shown to potentiate PDGF-induced 
activation of extracellular signal-regulated kinases (ERK1/2) and Akt, which leads 
cell proliferation. PDGF has also been shown to signal through the protein 
phosphatase calcineurin through its activation of transcription factor nuclear factor 
of activated T-cells (NFAT) leading to a proliferative phenotype in aortic smooth 
muscle cells (Jabr et al., 2007). Thus, increase in PDGFRβ+ MPs released from 
PASMCs may be an indicator of proliferating smooth muscles (Weber, 2008). 
ICAM expression was seen on both growing SMCs and HUVECs. The number of 
ICAM+ MPs released by SMCs from both PAH and control patients were high 
(>20,000 MPs/ml/10,000 cells) after PDGF-BB stimulation and high in HUVECs 
(>10,000MPs/ml/10,000 cells) following TNFα stimulation. ICAM is an 
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immunoglobulin-like cell adhesion molecule expressed by a variety of cells 
including endothelial cells, leukocytes and smooth muscle cells (Lawson and 
Wolf, 2009). It is involved in the transendothelial migration (diapedesis) of 
leukocytes to sites of inflammation and the interaction between antigen presenting 
cells and T lymphocytes (immunological synapse). Thus, it plays an important 
role in both the innate and adaptive immune responses. TNFα has been known to 
increase ICAM-1 expression on human vascular endothelial and lung epithelial 
cells in a tyrosine kinase-dependent manner (Burke-Gaffney and Hellewell, 1996). 
Combes and colleagues first demonstrated that the expression of ICAM-1 and the 
release of ICAM+ MPs could be elevated by administering TNFα to growing 
HUVECs, albeit by a high concentration (100ng/ml) of TNFα (Combes et al., 
1999). Moreover, TNFα- and interleukin 1-α-induced ICAM -1 expression was 
significantly upregulated by pretreatment of HUVECs with the adenylyl cyclase 
activator forskolin, thus indicating that TNFα may act via the adenylyl cyclase 
pathway during EC activation (Bernot et al., 2005). In other studies, ICAM-1 
mRNA was very low in cultured human aortic smooth muscle cells grown in the 
presence 5% foetal calf serum, but expression was induced (Couffinhal et al., 
1993) in a dose- and time-dependent manner following incubation with 10 ng/ml 
TNFα. Furthermore, administration of TNFα also increased adhesiveness of the 
SMCs to monocytes (Couffinhal et al., 1993). Thus, ICAM+ MPs may be 
indicative of an inflammatory activation of vascular cells. Although MCAM was 
expressed on the smooth muscle surface, MCAM+ microparticles derived from 
cultured smooth muscle cells were low in number after PDGF-BB stimulation. 
MCAM expression was also present on HUVECs, thereby confirming its lack of 
selectivity for smooth muscle cells. Though it is often associated as a constitutive 
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endothelial marker independent of vessel size or site, the transmembrane 
glycoprotein has been shown to be expressed on other cells such as smooth 
muscle cells, melanoma cells, follicular dendritic cells and subpopulations of 
activated T-lymphocytes (Schrage et al., 2008). Strong expression of MCAM on 
bone marrow mesenchymal stem cells was associated with vascular smooth 
muscle cell lineage commitment (Espagnolle et al., 2014). Thus, MCAM may be 
more of a marker of cell and vascular development than vascular pathology. 
Cultured smooth muscle cells under growing conditions did not express PECAM-
1, whereas growing HUVECs did express high levels. Likewise, PECAM-1+ MPs 
were not detected from SMCs following PDGF-BB stimulation, but was detected 
on EMPs after serum and TNF-α stimulation. PECAM1 is a member of the 
immunoglobulin gene superfamily comprised of 6 extracellular Ig folds, that has a 
molecular weight of 130kDa and is differentially glycosylated with N-linked and 
O-linked glycosylated sites (Woodfin et al., 2007). Ligands for the receptor 
include PECAM-1, as well as a ligand expressed on transfected L cells, the 
integrin αvβ3 (domains 1 and 3), ADP-ribose cyclase, and CD177 (domain 6) 
located on a subset of neutrophils (Deaglio et al., 1998; Woodfin et al., 2007). Its 
2 immunoreceptor tyrosine inhibitory motifs (ITIMs) in the cytoplasmic 
(intracellular) domain serve as docking sites for signalling molecules including 
protein tyrosine kinase phosphatases. PECAM1 ligation/dimerization of the 
protein can induce phosphorylation of the tyrosine and serine/threonine residues 
of the ITIMs, which leads to the recruitment of molecules including SH2-
containing phosphatases and C-γl that collectively lead to downstream signalling 
pathways. These intracellular events regulate PECAM-1-mediated responses such 
as leukocyte transmigration, endothelial cell motility and permeability, and the 
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expression and activation state of integrins (Newman, 2003). PECAM1 is 
expressed on the cell surface of haematopoietic and immune cells including 
endothelial cells, platelets, neutrophils, monocytes, megakaryocytes, natural killer 
cells and some subsets of T-lymphocyte. More recently, platelet PECAM has been 
found to be involved in the negative regulation of platelet aggregation in vitro and 
thrombus formation in vivo (Falati et al., 2008). 
A surprising finding of my current study was that a high number of E-selectin+ 
MP were released by both PAH and control patient derived cells. This occurred 
despite a lack of expression on the surface of SMCs. E-selectin is a 115-kDa cell 
surface glycoprotein expressed by cytokine-activated ECs and regulates the 
adhesion of neutrophils to the endothelial surface. It is a member of the selectin 
gene family which includes P-selectin and L-selectin, adhesion molecules 
expressed on platelets and leukocytes, respectively. The expression of E-selectin 
by endothelial cells can be rapidly induced using cytokines such as TNF-α in vitro 
reaching maximum expression at 4-6 hours of activation followed by a rapid 
decline (Leeuwenberg et al., 1992). Its inducible expression is similar to ICAM1, 
which reaches maximum expression for approximately 48 hours. This might 
explain why E-selectin was not expressed in growing HUVECs from control 
subjects without the administration of cytokine for stimulation. Though E-selectin 
expression is classically thought to be endothelial specific, Chen and colleagues 
demonstrated in vitro that human aortic SMCs do have the potential to express E-
selectin after TNF-α and lipopolysaccharide stimulation via nuclear factor κB 
signalling (Chen et al., 1997). To my knowledge, this was the first study to show a 
non-endothelial cell expressing E-selectin and suggests that smooth muscles have 
the capability of releasing MPs containing E-selectin. 
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PDGF-BB, TNFα, TGFβ, and ET-1, in the presence of 10% serum, significantly 
increased the level of total MPs released from PASMCs over and above that 
induced by serum alone. Perros and colleagues demonstrated that PDGF-A, 
PDGF-B, PDGFRα, and PDGFRβ mRNA expression was elevated in small 
pulmonary arteries from idiopathic PAH patients compared with control subjects 
(Perros et al., 2008). PDGF-BB is able to bind to both PDGFR-α and –β on SMCs 
to induce proliferation and migration, though the former was not found to be 
expressed on the smooth muscle cells derived from PAH patients. PDGF-BB was 
shown to upregulate the expression of phosphorylated c-Jun NH2-terminal kinase 
1/2 (JNK1/2), a member of the mitogen-activated protein kinases (MAPKs). 
Additionally, PDGF-BB-induced proliferation was weakened following 
antagonism of the JNK pathway or JNK knockdown by siRNA, thus suggesting 
that the mitogen may act via the JNK pathway (Zhao et al., 2014). 
In PAH, TNFα is elevated along with other pro-inflammatory cytokines and 
chemokines such as IL-1β, IL-6, IL-8, monocyte chemoattractant protein (MCP)-1 
and CCL5/RANTES (Rabinovitch et al., 2014). TNFα is mainly produced by 
macrophages but also by other cells including lymphoid cells, mast cells, 
endothelial cells, fibroblasts and neuronal tissue (Wajant et al., 2003). It can exert 
its effects through the TNF receptor family TNF receptor (TNF-R)1, which is 
constitutively expressed in most tissues. TNF-R2 on the otherhand  has a more 
restricted expression, typically being expressed in cells of the immune system. 
TNFα is able to signal via the nuclear factor kappa B (NFkB) transcription factors 
to activate inflammatory related genes, as well as cause cellular TNF-R1-mediated 
apoptosis (Wajant et al., 2003).  
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My experiments showed that TGF-β and endothelin are highly potent growth 
factors and induced the release of high levels of smooth muscle MPs. TGFβ is 
produced by macrophages as well as lymphocytes and dendritic cells (Letterio and 
Roberts, 1998). As aforementioned, due to the BMPRII mutation, TGFβ in PAH 
binds to TβR-II, which dimerises with ALK5 and signals through Smads2/3 to 
induce proliferation (Morrell, 2006). Endothelins are a family of naturally 
occurring peptides that consist of endothelin (ET)-1, ET2, and ET3 (Shao et al., 
2011). They are largely expressed by endothelial cells and to a lesser extent by 
smooth muscle cells, fibroblasts, macrophages, cardiac myocytes, airway 
epithelial cells, brain neurons, and pancreatic islet cells. By acting on two 
receptors, ETA and ETB, ET1 is able to act as a potent vasoconstrictor and 
mitogen, as well as a mediator of fibrosis and aspects of inflammation (Hall et al., 
2011). Thus, ET-1 plays a key role in vascular remodelling seen in PAH. 
Future experiments would be characterisation of endothelial microparticles 
isolated from pulmonary arterial endothelial cells as that would provide more 
accurate information as to pulmonary specific endothelial markers and their 
quantities.   
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Chapter 4 
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4.1 Introduction 
MPs are released by budding and fission of the plasma membrane of various cells 
including endothelial cells (ECs), smooth muscle cells (SMCs), leukocytes and 
platelets (Simak and Gelderman, 2006). They can be detected in a variety of 
biological fluids, peripheral blood, urine, asceptic fluids and synovial fluids 
(Budaj et al., 2012). The site and cellular origin of the MPs determine their 
biological function. For example, skeletal cell-derived MPs initiate bone 
mineralisation, whilst endothelial derived MPs (EMPs) have been associated with 
angiogenesis (Morel et al., 2004). The vesicularisation of MPs, known as 
blebbing, is triggered or enhanced during cellular activation or apoptosis during 
pathological conditions including inflammation, injury, vascular dysfunction, or 
cancer. The externalisation of phosphatidylserine (PS) to the outer membrane 
leaflet is specific to sites where MP shedding occurs while the topology of the 
membrane proteins remains intact (Hugel et al., 2005; Lima et al., 2009). As PS 
binds annexin V with high affinity, its externalisation is useful in detecting MPs 
and distinguishing them from exosomes, which are smaller vesicles (50-100 nm in 
diameter) and have no/low annexin V binding capacity as a result of very low 
levels of surface PS (Budaj et al., 2012). 
 
MPs have been detected via multiple methods including solid-phase capture assay, 
enzyme-linked immunosorbent assay (ELISA), and flow cytometry, the latter of 
which is the preferred method in the majority of studies. This is due to the ability 
of flow cytometry to quantitate MP number and multicolour analysis attributes, 
thus allowing simultaneous detection of several markers on the MP surface 
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(Chironi et al., 2009; Baj-krzyworzeka et al., 2013). Solid-phase capture assays 
rely on the fact that MP membranes contain externalised PS which can activate 
prothrombinase to generate thrombin. Thus, by measuring prothrombinase activity 
in the coagulation process, MP levels can be estimated (Hugel et al., 2004). 
ELISAs are able to accurately measure MP levels, though their lack of ability to 
detect multiple markers simultaneously, thus limiting their ability to provide 
information of specific MP subpopulations in the circulation (Nomura, 2004). 
The study of circulating MP in vivo from blood samples via flow cytometry 
involves several steps that ensure accuracy in MP measurement and 
characterisation. The determination of the centrifugation speed used to isolate 
MPs is an important step in MP collection. Prior to this, unwanted/contaminating 
cells from cells/tissue media or bodily fluids must be removed with an initial 
centrifugation speed of 200-500g for 5-20 minutes (Orozco and Lewis, 2010; Baj-
krzyworzeka et al., 2013). To obtain a MP pellet, centrifugation at 10,000-17,000g 
for 30 minutes to 1 hour is required. As exosomes are much smaller than MPs (50-
100nm as opposed to 100nm-1µm the  ultracentrifugation at 100,000-150,000g for 
1 hour is required (Baj-krzyworzeka et al., 2013; Colombo et al., 2014). The 
determination of total MPs is another step, and is made possible via the detection 
fluorescently conjugated annexin V bound to microparticles, whereas exosomes 
will not bind to annexin V because they have no/low externalised PS. 
Polychromatic flow cytometric analysis of MP subpopulations is the crucial step 
determining the cellular origin of the different circulating MPs. The final step in 
MP measurement is the enumeration of the particles. 
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In the past, endothelial cells have been characterised as expressing endoglin, 
intracellular adhesion molecule (ICAM-1), E-selectin, platelet endothelial cell 
adhesion molecule type 1 (PECAM-1), vascular cell adhesion molecule type 1 
(VCAM-1) and vascular endothelial (VE)-cadherin on their outer membrane 
surface (Chironi et al., 2009; van der Heyde et al., 2011). On the other hand, 
leukocytes express CD45, while monocytes express CD14 and CD11, 
granulocytes express CD66b, T helper cells express CD4, cytotoxic T cells 
express CD8, and B cells express CD20. CD4 has also been shown to be 
expressed on monocytes and CD11b on granulocytes. All platelets express 
CD41/CD61 (glycoprotein IIb/IIIa) on their surface (French and Seligsohn, 2000; 
van der Heyde et al., 2011). CD42a is also a ubiquitously expressed platelet 
marker (Van Velzen et al., 2012). CD42b is an activation marker that is 
proteolytically cleaved after platelet activation, while CD42c is a constitutively 
expressed. In addition to being expressed on endothelial cells, PECAM-1 is also 
expressed on platelets, so care must be taken to further characterise the origin of 
the cell type expressing this marker. Erythrocytes express glycophorin A (CD235) 
on their cell surfaces, which can be used to detect red blood cell-derived MPs. 
Using polychromatic flow cytometric analyses, different surface marker 
combinations have been used to more accurately characterise specific MP subsets. 
EMPs have been characterised as PECAM-1+/CD42b-, PECAM-1+/CD41-, 
PECAM-1+/CD62E+, endoglin+/CD45-, VE-cadherin+/endoglin+, and 
MCAM+/endoglin+  in a number of studies (Boulanger et al., 2007; Dey-Hazra et 
al., 2010; Dignat-George and Boulanger, 2011; Huica et al., 2011). Similarly, 
PMPs have been characterised using several marker combinations such as 
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CD31+/CD41+ and CD31+/CD42b+ (Chirinos et al., 2005; Angelillo-Scherrer, 
2012). 
 
Circulating MPs have been shown to be increased in animal models and patients 
with pulmonary hypertension. Total MPs were elevated two-fold in male Wistar 
rats exposed to chronic hypoxia for 3 weeks in a controlled hyperbaric chamber 
compared to normoxic rats  (Tual-Chalot et al., 2010a). Rats with PH had elevated 
PMPs (CD61+) and erythrocyte-derived MPs compared to normoxic rats, though 
no difference was seen in leukocyte (CD45+) and endothelial (CD54+) MPs 
(Tual-Chalot et al., 2010b). In contrast, MPs positive for the endothelial markers 
PECAM-1, VE-cadherin, E-selectin, and the leukocyte marker CD45 were 
significantly elevated in patients with pulmonary hypertension (n=24) compared 
to healthy age- and sex-matched controls (Amabile et al., 2008). This elevation 
was seen in total annexin V+ MPs as well as in PECAM+/CD41+ PMPs. 
Moreover E-selectin+ MPs positively correlated with high-sensitivity C-reactive 
protein, confirming that endothelial MPs may be a marker of inflammation in 
PAH (r=0.51, P=0.035). Both VE-cadherin+ and PECAM-1+ MPs positively 
correlated with haemodynamic measurements including mean pulmonary artery 
pressure (mPAP), pulmonary vascular resistance, cardiac index and right atrial 
pressure as well as haemoglobin levels in PH patients.  
 
In this chapter, I aimed to measure MP levels in plasma originating from a variety 
of cell types including smooth muscle cells, endothelial cells, leukocytes, and 
platelets in the venous blood from patients with pulmonary arterial hypertension 
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compared with sex- and age-matched controls. Additionally, I aim to determine 
whether these MPs could be used to determine therapeutic impact on disease. 
Finally, I aim to determine whether circulating MPs may be elevated in PAH and 
how levels might compare to other vasculopathies, potentially making MPs a 
viable biomarker to distinguish between PAH and other inflammatory disease 
states. 
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4.2. Results 
4.2.1. Total circulating annexin V+ microparticles in patients with 
pulmonary arterial hypertension 
 
Total annexin V+ microparticles (MPs) were measured from the forearm venous 
blood collected from patients (n=18) with pulmonary arterial hypertension and 
compared to age- and sex-matched controls (n=20) (Figure 23). In PAH patients, 
MP’s were assessed before and after treatment for a minimum and maximum of 4 
months and 18 months, respectively. The median total MP count in PAH was 
2.93x106 MPs/ml in PPP, which was significantly p<0.0001) higher (almost 100-
fold) than the median count observed in control subjects, 3.13x104 MPs/ml PPP. 
After long-term therapy for a minimum of 4 months, which consisted of either a 
prostacyclin analogue, phosphodiesterase (PDE)-5 inhibitor, endothelin-1 receptor 
antagonist (ETRA), calcium channel blocker, or combination therapy consisting 
of a PDE-5 inhibitor with an ETRA and/or a prostacyclin analogue, total MP 
count decreased by a third in pulmonary arterial hypertensive patients to a median 
of 2.13 x 106 MPs/ml PPP (P<0.01). 
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Figure 23. Total annexi V+ MPs in forearm venous blood taken from PAH 
patients before and after long-term drug therapy 
Total annexin V+ microparticle levels in forearm venous blood taken from 
pulmonary arterial hypertensive patients before and after drug therapy (n=18) for a 
minimum of 4 months, compared with and age- and sex-matched controls (n=18). 
The therapy consisted of prostacyclin analogues, phosphodiesterase (PDE)-5 
inhibitor, endothelin-1 receptor antagonist (ETRA), calcium channel blocker or 
combination therapy of PDE-5 antagonist with ETRA and/or a prostacyclin 
analogue. Data is presented median with interquartile range. **=P<0.01; 
*=P<0.0001; The Mann-Whitney test was performed. 
 
168 
 
4.2.2. Sensitivity/specificity analysis of total annexin V+ 
microparticles for identification of pulmonary arterial 
hypertension recurrence 
 
Receiver operator characteristic curve analysis was performed to examine the 
sensitivity and specificity of total annexin V+ microparticle quantification in 
diagnosing PAH in patients (figure 24). Total annexin MP levels in venous blood 
from patients with PAH were plotted alongside age- and sex-matched healthy 
controls. The diagnostic performance test of identification of disease recurrence 
was significant with an area under the curve (AUC) of 1, standard error of mean 
of 1.000-1.000 and P<0.0001. As the AUC is a measure of how well a parameter 
is able to distinguish between disease and control, this would suggest that total 
annexin V+ MPs are capable of PAH difference.  
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AUC: 1.000; SE: 0.0 
95% CI: 1.000 to 1.000 
P-value: <0.0001 
Figure 24. Receiver operator characteristic curve for total annexin V+ 
MPs for the identification of PAH recurrence 
(n=18 PAH vs n=18 controls). ROC analysis was significant with the area 
under the curve (AUC) of 1.000, confidence interval (CI) of 1.000-1.00, 
P<0.0001. 
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4.2.3. Circulating smooth muscle microparticles in pulmonary 
arterial hypertensive patients 
Smooth muscle microparticles (SMMPs) were measured in forearm venous blood 
collected from patients with PAH before and after long term therapy (n=18) and 
compared with normal control subjects (Figure 25). Polychromatic flow 
cytometric analysis was performed using four marker combinations to characterise 
the SMMPs. Platelet derived growth factor receptor β (PDGFRβ)+/PECAM-1-
/Annexin V+ SMMPs were significantly elevated in PAH with a median of 
median 1.38x105 MPs/ml of PPP compared to levels in control subjects with a 
median of 7.10x103 MPs/ml of PPP (P<0.0001). After therapy, these levels 
significantly reduced by half to 69580 MPs/ml PPP (P<0.01). 
Endoglin+/PECAM-1-/Annexin V+ MPs displayed a similar trend as their levels 
were elevated significantly in PAH patient blood (median 3.80x105 MPs/ml of 
PPP) compared to those seen in control subjects (median 1.49x104 MPs/ml of 
PPP; P<0.001). These levels reduced by 40% to a median of 2.64x105 MPs/ml of 
PPP after long-term therapy, though this difference was not significant. 
NG2+/PECAM1-/Annexin V+ SMMPs were also significantly elevated in PAH 
patients with a median of 2.31x105 MPs/ml PPP) compared to control subjects 
which were 10 fold lower with a median of 1.44x104 MPs/ml PPP (P<0.0001). 
The MP count dropped by 25% after long-term therapy to a median of 1.74x105 
MPs/ml PPP, though this was not significant. Levels of ICAM+/PECAM1-
/Annexin V+ SMMPs revealed significant elevation in PAH patients with median 
of 2.37x105 MPs/ml PPP compared to control subjects 1.28x104 MPs/ml PPP 
(P<0.0001) and a significant 48% decrease after lon
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Figure 25. Smooth muscle microparticle levels in forearm venous blood taken from AH 
patients before and after long-term therapy 
(n=18) for a minimum of 4 months, and healthy controls (n=18) were measured. The therapy 
consisted of prostacyclin analogues, phosphodiesterase (PDE-5) antagonist, endothelin-1 
receptor antagonist (ETRA), calcium channel blocker or combination therapy of PDE-5 
antagonist with ETRA and/or a prostacyclin analogue. Annexin V+ SMMPs were 
characterised as platelet derived growth factor receptor β (PDGFRβ)+/PECAM-1-, 
endoglin+/PECAM-1, neural glial antigen 2 (NG2)+/PECAM1-, and ICAM-1+/PECAM-1-.  
Data is presented as median with min and max. *=P<0.05; **=P<0.01; *=P<0.0001; The 
Mann-Whitney test were performed 
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4.2.2. Sensitivity/specificity analysis of smooth muscle 
microparticles for identification of pulmonary arterial 
hypertension recurrence 
 
Receiver operator characteristic curve analysis was performed to examine the 
sensitivity and specificity of annexin V+ SMMP quantification in diagnosing PAH 
in patients (figure 26). SMMP levels in venous blood from patients with PAH 
were plotted alongside age- and sex-matched healthy controls. The diagnostic 
performance test of identification of disease recurrence was significant for all four 
SMMP subpopulations: PDGFR+/PECAM- (AUC of 0.9907, standard error of 
0.01128 to 1.007, P<0.0001), endoglin+/PECAM-1- (AUC of 1.000 with standard 
error of 0.0, 95% CI of 1.000-1.000, and P<0.0001), NG2+/PECAM-1- (AUC of 
0.997 with a standard error of 0.0051, 95% CI of 0.969-1.013, and P<0.0001), and 
ICAM-1+/PECAM-1- (AUC of 0.9907 with a standard error of 0.0113, 95% CI of 
0.969 to 1.013, and P<0.0001). Thus, this would suggest that the SMMPs are 
capable of distinguishing PAH patients from normal subjects. 
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Figure 26. Receiver operator characteristic curve for smooth muscle annexin V+ 
MPs 
for smooth muscle annexin V+ MPs that were PDGFRβ+/PECAM-1-, 
Endoglin+/PECAM-1-, NG2+/PECAM-1-, and ICAM-1+/PECAM-1- for the 
identification of pulmonary arterial hypertension recurrence (n=18 PAH vs n=18 
controls). ROC analysis was significant for each SMMPs subpopulation as P<0.001 
and the area under the curve (AUC) with confidence interval (CI) were close to 1. 
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4.2.5. Circulating endothelial microparticles in pulmonary arterial 
hypertensive patients 
Endothelial microparticles (EMPs) in forearm venous blood collected from 
patients with pulmonary arterial hypertension before and after long term therapy 
(n=18) and normal control subjects (n=20) were measured (Figure 27). E-
selectin+/PECAM-1+/Annexin V+ EMPs were s elevated in PAH patients with a 
median of 1.83x105 MPs/ml PPP compared to control subjects with a median of 
8.22x103 MPs/ml PPP (P<0.001). Long-term therapy decreased these EMP levels 
by 24.5% to a median of 1.38x105 MPs/ml PPP, though this was not significant. 
Similarly, PECAM-1+/CD42a+/Annexin V+ levels were significantly higher in 
PAH patients with a median of 1.751x105 MPs/ml of PPP compared to control 
subjects with a median of 1.21x104 MPs/ml PPP. Long-term therapy decreased by 
these EMP levels by 27%, though not significantly. 
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Figure 27. Circulating endothelial MP levels in PAH patients before and after 
long-term therapy. 
Endothelial MP (EMP) levels in forearm venous blood taken from pulmonary arterial 
hypertensive patients before and after therapy (n=18) for a minimum of 4 months 
compared with healthy controls (n=18). The therapy consisted of prostacyclin 
analogues, phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor antagonist 
(ETRA), calcium channel blocker or combination therapy of PDE-5 antagonist with 
ETRA and/or a prostacyclin analogue. Annexin V+ EMPs were characterised as E-
selectin+/PECAM-1+ and PECAM-1+/CD42a-. Data is presented median with min 
and max****=P<0.0001; Mann-Whitney and Wilcoxen tests were performed. 
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4.2.6. Circulating leukocyte microparticles in pulmonary arterial 
hypertensive patients 
 
Leukocyte microparticles (LMPs) were measured in forearm venous blood 
collected from patients with pulmonary arterial hypertension before and after 
therapy (n=18) and from normal control subjects (Figure 28). Median 
CD66b+/Annexin V+ LMP levels in PAH were 1.0869105 MPs/ml in PPP, which 
was 24 fold greater compared to levels in control subjects who had a median of 
4.489x103 MPs/ml PPP (P<0.0001). These LMP levels decreased by 54% after 
long term therapy, though due to variability in patient levels of MPs this just 
failed to reach significance(P=0.072). Tissue factor+ LMP levels in PAH were 
also significantly elevated with median of 1.15x105 MPs/ml PPP compared to 
control subjects (P<0.001). These MP levels were maintained and did not decrease 
after long-term therapy. 
  
178 
 
 
  
M
P
 n
u
m
b
e
r/
m
l 
P
P
P
C
D
66
b+
Ti
ss
ue
 F
ac
to
r+
0
5.0 10 5
1.0 10 6
1.5 10 6
Normal
PAH Before Treatment
PAH After Treatment
**
**
Figure 28. Circulating leukocyte MPs in PAH before and after long-term therapy 
: Leukocyte MP levels in forearm venous blood was taken from pulmonary arterial 
hypertensive patients before and after therapy (n=18) for a minimum of 4 months 
compared to healthy controls (n=18). The therapy consisted of prostacyclin analogues, 
phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor antagonist (ETRA), 
calcium channel blocker or combination therapy of PDE-5 antagonist with ETRA and/or 
a prostacyclin analogue. Annexin V+ LMPs were characterised as CD66b+ and Tissue 
Factor+. Data is presented as median with min and max. *=P<0.05; ****=P<0.0001; 
Mann-Whitney were performed. 
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4.2.7. Circulating platelet microparticles in pulmonary arterial 
hypertensive patients 
Platelet microparticles (PMPs) were measured in forearm venous blood collected 
from patients with pulmonary arterial hypertension before and after long term 
therapy (n=18) and in normal control subjects not on any drug treatment (Figure 
29). Median CD42a+/Annexin V+ PMP levels were 100-fold greater in PAH 
patients with a median of 1.71x106 MPs/ml in PPP compared to control subjects 
who had a median of 1.704x104 MPs/ml PPP. PMP levels were not significantly 
different after long-term therapy in PAH patients. After therapy, though the 
median decreased to 1.49x106 MPs/ml PPP, the variability measured by the range 
in PMP levels increased by 2-fold in PAH patients.  
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Figure 29. Circulating PMP levels in PAH before and after long-term therapy 
Platelet MP levels in forearm venous blood taken from pulmonary arterial hypertensive 
patients before and after long term therapy (n=18) for a minimum of 4 months and 
compared with age- and sex-matched controls (n=18). The therapy consisted of 
prostacyclin analogues, phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor 
antagonist (ETRA), calcium channel blocker or combination therapy of PDE-5 
antagonist with ETRA and/or a prostacyclin analogue. LMPs were characterised as 
CD42a+. Data is presented as median with min and max. *=P<0.05; ****=P<0.0001; 
The Mann-Whitney test were performed. 
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4.2.8. Effect of drugs on circulating microparticle levels in pulmonary 
arterial hypertension 
The impact of different drug treatments over a minimum period of 4 months on 
the number of total circulating annexin V+ MPs released was assessed in PAH 
patients (figure 30). The median MP level in patients who were on a prostacyclin 
analogue (treprostinil or iloprost) with or without a phosphodiesterase (PDE)-5 
inhibitor (sildenafil or tadalafil; n=6) was 3.82x106 MPs/ml in PPP prior to 
treatment, which was significantly higher than in control subjects (n=18; 
P<0.001). After long-term therapy, total MP levels decreased significantly by 
44%. In patients who were on a PDE-5 inhibitor with or without an endothelin-1 
receptor antagonist (ETRA; bosentan or ambrisentan; n=6), the median MP level 
prior to long-term treatment was 2.00x106 MPs/ml PPP, which was significantly 
higher than we observed in control subjects (P<0.001). After therapy, the median 
MP count decreased by only by 12%. 
 
Patients under prostacyclin therapy of a prostacyclin analogue with or without a 
PDE-5 inhibitor also contained higher median levels of smooth muscle 
microparticles than in patients on PDE-5 inhibitor with or without ETRA therapy 
(Figure. 32). Prostacyclin therapy signficantly decreased levels of 
PDGFRβ+/PECAM1-, Endoglin+/PECAM1-, and NG2+/PECAM1- SMMPs by 
more than 50% after long-term therapy (P<0.05). Such a decrease was not seen 
after non-prostacyclin therapy.  Similarly, significant reductions were seen in E-
selectin+/PECAM1+ EMPs (P<0.05), CD66b+ LMPs (P<0.05), and CD42a+ 
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PMPs (P<0.0001) after long-term prostacyclin therapy, which was not seen after 
non-prostacyclin therapy (Figures 31 and 32). 
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Figure 30. Effect of different long-term PAH therapies on total annexin V+ MPs in PAH 
patients. 
Total annexin V+ MPs  were measured in blood taken the forearm vein of PAH patients 
before and after long term therapy (prostacyclin analogue with/without a phosphodiesterase 5 
(PDE5) inhibitor (n=6) and a PDE5 inhibitor with/without an endothelin-1 receptor antagonist 
(ETRA) (n=8). Microparticle levels of age- and sex-matched healthy controls were also used 
for comparison (n=18). Data is presented median with min and max. *=P<0.05; 
****=P<0.0001; The Wilcoxen and Mann-Whitney tests were performed.) 
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Figure 31. Effect of different long-term PAH therapies on total annexin V+ 
smooth muscle and endothelial MPs in PAH patients. 
Annexin V+ MPs derived from smooth muscle (SMMPs; top) and endothelial cells 
(EMPs; bottom)  were measured in blood taken the forearm vein of PAH patients 
before and after long term therapy (prostacyclin analogue with/without a 
phosphodiesterase 5 (PDE5) inhibitor (n=6) and a PDE5 inhibitor with/without an 
endothelin-1 receptor antagonist (ETRA) (n=8). Microparticle levels of age- and 
sex-matched healthy controls were also used for comparison (n=18). Data is 
presented median with min and max. *=P<0.05; ****=P<0.0001; The Wilcoxen and 
Mann-Whitney tests were performed. 
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Figure 32. Effect of different long-term PAH therapies on total annexin V+ 
smooth muscle MPs in PAH patients. 
Annexin V+ MPs derived from leukocytes (LMPs; top) and platelets (PMPs; 
bottom) were measured in blood taken the forearm vein of PAH patients before and 
after long term therapy (prostacyclin analogue with/without a phosphodiesterase 5 
(PDE5) inhibitor (n=6) and a PDE5 inhibitor with/without an endothelin-1 receptor 
antagonist (ETRA) (n=8). Microparticle levels of age- and sex-matched healthy 
controls were also used for comparison (n=18). Data is presented median with min 
and max. *=P<0.05; **=P<0.01; ***=P<0.001; ****=P<0.0001; The Wilcoxen and 
Mann-Whitney tests were performed. 
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4.2.9. Total Annexin V+ microparticles in patients with coronary artery 
disease 
The total number of annexin V+ MPs was assessed in patients with coronary 
artery disease (figure 33). Circulating total MPs in coronary arterial blood 
collected from patients with ST-elevated myocardial infarction (STEMI) was a 
median of 2.927x106 MPs/ml PPP, which was significantly higher than those from 
control subjects (P<0.0001) but significantly lower than those from PAH patients 
(P<0.05). Total MPs in coronary artery blood collected from patients with Non-
ST-elevated myocardial infarction (NSTEMI) was slightly lower than in STEMI 
with a median of 1.14x106 MPs/ml PPP, but was nonetheless still significantly 
higher than in control subjects (P<0.05). Forearm venous blood from STEMI 
patients had a median MP count of 1.02x106 MPs/ml PPP, which was significantly 
higher than in control subjects (P<0.01), and while lower than in coronary blood 
from STEMI patients,  was  not significantly different. Forearm venous blood 
from NSTEMI patients also contained a low median MP level of 1.32x106 MP/ml 
in PPP, this was not significantly higher than levels in control subjects. Thus, total 
MP levels in both coronary artery and venous forearm blood in both STEMI and 
NSTEMI patient groups were significantly lower than in PAH patients. 
 
Receiver operator characteristic curve analysis was performed to examine the 
sensitivity and specificity of annexin V+ quantification in distinguishing PAH 
from coronary artery disease in patients (figure 34). MP levels in venous blood 
from patients with PAH were plotted alongside coronary arterial blood from 
patients with STEMI. The diagnostic performance test of identification of PAH 
187 
 
recurrence was significant with an AUC of 0.739, a standard error of 0.104, a 95% 
CI of .534 to 0.944, and P=0.039. This would therefore suggest that measuring 
total annexin V+ MPs in forearm venous blood is capable of distinguishing PAH 
patients from STEMI patients. 
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Figure 33. Total circulating annexin V+ MPs in coronary artery disease 
Total Annexin V+ MP levels in coronary artery blood  (Cor) from patients with ST-
elevated myocardial infarction (STEMI; n=7), non-ST-elevated myocardial 
infarction (NSTEMI; n=5), and in forearm venous (FV) from STEMI patients (n=3) 
and non-STEMI patients were measured. MP values were compared with PAH 
patients before start of therapy (n=18). Data are presented as median with 
interquartile range. *=P<0.05; **=P<0.01; ****=P<0.0001; The Mann-Whitney test 
was performed. 
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AUC: 0.9907; SE: 0.01128 
95% CI: 0.9686 to 1.013 
P-value: <0.0001 
Figure 34. Receiver operator characteristic curve for total annexin V+ MPs for 
identification of PAH patients from STEMI patients 
Receiver operator characteristic curve for total annexin V+ MPs for the identification 
of patients with PAH (n=18) from patients with ST-elevated myocardial infarction 
(n=10). ROC analysis was significant with the area under the curve (AUC) of 0.739 
with a standard error (SE) of 0.104, a confidence interval (CI) of 0.534 to 0.944 and 
P<0.0001. 
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4.2.10. Smooth muscle microparticles in coronary artery disease 
SMMPs in CAD patient blood was measured and compared to healthy control 
subjects (Figure 35). PDGFRβ+/PECAM-1-/Annexin V+ MP levels in coronary 
arterial blood from STEMI and NSTEMI patients had a median of 1.48x105 
MPs/ml and 4.76x104, respectively in PPP, but were significantly higher than 
forearm venous blood from control subjects who had a median of 7.19x103 
MPs/ml of PPP (P<0.001 and P<0.01, respectively). Forearm venous blood 
collected from both STEMI and NSTEMI patients had low PDGFRβ+/PECAM1-
/Annexin V+ SMMP levels that were not significantly different from those in 
control subjects, with medians of 2.86x103 MPs/ml and 4.48x103 MPs/ml of PPP, 
respectively. These SMMPs were significantly elevated in STEMI patient-derived 
coronary blood compared to STEMI forearm blood (P<0.01) and NSTEMI 
coronary blood (P<0.01), suggesting the dependence of SMMP levels on disease 
severity and site of measurement. Levels of PDGFRβ+/PECAM1-/Annexin V+ 
SMMPs in PAH forearm venous blood (median of 1.38x105 MPs/ml PPP) was 
similar to STEMI coronary artery blood and significantly higher than in NSTEMI 
coronary blood (P<0.01). 
Endoglin+/PECAM-1-/Annexin V+ SMMPs from STEMI coronary artery blood 
was elevated to a median of 2.84x105 MPs/ml in PPP, which was very close to 
levels seen in PAH (median 3.00x105 MPs/ml PPP) but was ~20 fold higher than 
in forearm venous blood from control subjects (1.298x104 MPs/ml in PPP; 
P<0.001). SMMPs were also elevated in NSTEMI Coronary blood (1.63x105 
MPs/ml in PPP) compared to controls (P<0.01) but were significantly lower than 
PAH forearm blood (P<0.05). STEMI forearm venous blood contained 4.20x104 
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MPs/ml in PPP Endoglin+/PECAM1-/Annexin V+ SMMPs, which were higher 
than in control subjects though not significant. NSETMI forearm venous blood 
contained very low SMMPs with a median of 7.84x104 MPs/ml PPP, which was 
not significantly different from the number in controls. Though a trend was seen, 
there was no significant difference between coronary artery- and forearm-derived 
blood as well as between STEMI- and NSTEMI-derived blood. 
NG2+/PECAM1-/Annexin V+ SMMPs in STEMI coronary artery blood was 
significantly higher than in controls with a median of 1.91x105 MPs/ml PPP 
compared to 1.22x104 MPs/ml PPP, respectively (P<0.01). The SMMPs in 
NSTEMI coronary blood was lower, though not significantly, with a median of 
5.68x104 MPs/ml PPP and was also significantly higher than in controls (P<0.05). 
Forearm derived blood from STEMI patients had a low median of 5.33x103 
MPs/ml in PPP and were significantly lower than coronary derived blood 
(P<0.05). NSTEMI forearm blood also had a low median of 6.16x103 MPs/ml in 
PPP. STEMI and non-STEMI forearm bloods did not contain elevated 
NG2+/PECAM1-/Annexin V+ SMMPs compared to healthy control blood. 
ICAM+/PECAM-/Annexin V+ SMMPs was also elevated in STEMI coronary 
artery blood compared to controls with a median of 1.31x105 MPs/ml ien PPP 
compared to 1.163x104 MPs/ml PPP, respectively (P<0.001). Levels of these 
SMMPs were lower in NSTEMI coronary blood with a median of 4.22x103 
MPs/ml PPP (P<0.05), but was also significantly higher than in controls (P<0.01). 
In STEMI patients, the median ICAM+/PECAM-/Annexin V+ SMMPs in the 
forearm venous blood were 2.953x104 MPs/ml PPP and were also significantly 
lower than coronary artery blood (P<0.05). Similarly in NSTEMI patients, the 
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median SMMPs in the forearm venous blood with a median of 8.4x103 MPs/ml 
PPP were significantly lower than in coronary artery blood (P<0.05). The SMMPs 
levels in PAH venous blood containing a median of 1.238x105 MPs/ml PPP was 
significantly higher than in both forearm venous STEMI and STEMI blood 
(P<0.01). 
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Figure 35. Circulating smooth muscle microparticles in coronary artery disease 
patients 
SMMP levels in blood taken from the coronary artery of patients with ST-elevated 
myocardial infarction (STEMI; n=7), non-ST-elevated myocardial infarction (NSTEMI; 
n=5), and from the forearm vein from STEMI patients (n=3). SMMP values were compared 
in pulmonary arterial hypertensive patients before and after drug treatment (n=18) for a 
minimum of 4 months, and in age- and sex-matched controls (n=18). Therapy consisted of 
prostacyclin analogues, phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor 
antagonist (ETRA), calcium channel blocker or combination therapy of PDE-5 antagonist 
with ETRA and/or a prostacyclin analogue. SMMPs were characterised as platelet derived 
growth factor receptor β (PDGFRβ)+/PECAM-1-/Annexin V+, endoglin+/PECAM-1-
/Annexin V+, neural glial antigen 2 (NG2)+/PECAM-1-/Annexin V+, and 
ICAM1+/PECAM-1-/Annexin V+.  (*=P<0.05; **=P<0.01; Mann-Whitney and Wilcoxen 
tests were performed. Results are expressed as median and range.) 
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4.2.11. E-selectin+ microparticles in coronary artery disease 
E-selectin is classically known to be an endothelial surface marker and was used 
to label EMPs in blood from patients with coronary artery disease. E-selectin+ 
MPs were 106-fold higher in coronary blood from STEMI patients with a median 
of 8.87x105 MPs/ml PPP compared to venous blood in control subjects (8.351x103 
MPs/ml PPP; P<0.001; Figure 36). Coronary NSTEMI blood contained only 
35919 MPs/ml PPP, which was 96% less E-selectin+ MPs than coronary STEMI 
blood (P<0.01) and the MP count was not significantly different from that seen in 
controls (P=0.0553). E-selectin+ MPs in STEMI forearm venous blood were a 
median of 3.296x104 MPs/ml PPP and were significantly higher than in control 
subjects (P<0.05). NSTEMI forearm venous blood contained much lower levels of 
these EMPs (median of 1.12x104 MPs/ml PPP) which were comparable to levels 
in controls. E-selectin+ MP levels in PAH venous blood (median 4.00 x105 
MPs/ml PPP) was not significantly different from levels in STEMI coronary 
artery blood but was significantly higher than levels in NSTEMI coronary artery 
blood (P<0.01). 
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Figure 36. Circulating E-selectin+ microparticles from CAD patients 
E-selectin MP levels in blood taken from the coronary artery of patients with ST-
elevated myocardial infarction (STEMI; n=7), non-ST-elevated myocardial infarction 
(NSTEMI; n=5), and from the forearm vein from STEMI patients (n=3). SMMP 
values were compared with pulmonary arterial hypertensive patients before and after 
long term therapy (n=18) for a minimum of 4 months and compared to age- and sex-
matched controls (n=18). The therapy consisted of prostacyclin analogues, 
phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor antagonist (ETRA), 
calcium channel blocker or combination therapy of PDE-5 antagonist with ETRA 
and/or a prostacyclin analogue. MPs were E-selectin+/Annexin V+.  (**=P<0.01; 
***=P<0.001; ****=P<0.0001; Mann-Whitney and Wilcoxen tests were performed. 
Results are expressed as median and range.) 
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4.2.12. Leukocyte microparticles in coronary artery disease 
STEMI coronary artery blood contained very high levels of CD66b+ leukocyte 
MPs (LMPs; 1.32x105 MPs/ml PPP), which were significantly greater than in 
control venous blood (P<0.0001) and more than two-fold greater than in PAH 
venous blood (6.07x104 MPs/ml PPP; P<0.05; Figure 37). Levels of CD66b+ MPs 
in NSTEMI coronary artery blood was had a median of 2.53x104 MPs/ml in PPP, 
which was significantly lower than in STEMI coronary artery blood (P<0.05) and 
but higher than in control venous blood (P<0.05). Forearm venous blood from 
both STEMI and NSTEMI patients did not contain CD66b+ levels that were 
significantly different from levels seen in control venous blood (3.62x103 MPs/ml 
PP and 1.12x103 MPs/ml PP, respectively). CD66b+ were significantly higher in 
PAH forearm venous blood compared to NSTEMI forearm venous blood 
(P<0.01). 
TF+ MPs were elevated in STEMI coronary artery blood (median of 4.34x105 
MPs/ml PPP) compared to control venous blood (P<0.01) and STEMI venous 
blood (median of 1.103x105 MPs/ml PPP; P<0.05), and was three-fold higher than 
in PAH venous blood (1.41x105 MPs/ml PPP; P<0.05). NSTEMI coronary artery 
blood contained significantly less TF+ MPs compared to STEMI coronary artery 
blood with a median of 1.103x105 MPs/ml PPP (P<0.05). Levels of TF+ MPs in 
the forearm venous blood from STEMI and NSTEMI patients were low and not 
significantly different from control subjects (2.477x103 MPs/ml PPP and 
3.920x103 MPs/ml PP, respectively). Forearm venous blood from PAH patients 
contained significantly higher levels of TF+ MPs than in forearm venous blood 
from STEMI and NSTEMI patients (P<0.01 and P<0.001, respectively). 
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Figure 37. Circulating leukocyte microparticles in blood taken from CAD patients 
LMP levels in blood taken from the coronary artery of patients with ST-elevated myocardial 
infarction (STEMI; n=7), non-ST-elevated myocardial infarction (NSTEMI; n=5), and from 
the forearm vein of STEMI patients (n=3). SMMP values were compared with pulmonary 
arterial hypertensive patients before and after therapy (n=18) and age- and sex-matched 
controls (n=18). The drug therapy consisted of prostacyclin analogues, phosphodiesterase 
(PDE-5) antagonist, endothelin-1 receptor antagonist (ETRA), calcium channel blocker or 
combination therapy of PDE-5 antagonist with ETRA and/or a prostacyclin analogue. LMPs 
were characterised as CD66b+/Annexin V+ and TF+/Annexin V+.  (*=P<0.05; Mann-
Whitney and Wilcoxen tests were performed. Results are expressed as median and range.) 
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4.2.13. Platelet microparticles in coronary artery disease 
CD42a+ platelet MPs (PMPs) were elevated 100 fold in STEMI coronary artery 
blood (median 1.57 x 106 MPs/ml PPP) compared to control venous blood 
(median 1.704x104 MPs/ml PPP; P<0.0001; Figure 38). STEMI coronary artery 
blood contained levels similar to PAH forearm venous blood (median 1.651x106 
MPs/ml PPP) and was significantly higher than STEMI forearm venous blood 
(median 1.555x105 MPs/ml PPP; P<0.05). NSTEMI coronary artery blood 
contained significantly higher PMP than control venous blood but lower CD42a+ 
PMPs (median 3.962x105 MPs/ml PPP) than control venous blood, though this 
difference did not reach  significance. Forearm venous blood from STEMI and 
NSTEMI patients (median 1.12x105 MPs/ml PPP) contained lower PMPs 
compared to coronary artery blood samples, but were both found containing PMPs 
significantly higher than in control venous blood (P<0.05 and P<0.01, 
respectively). 
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Figure 38. Circulating platelet microparticles in coronary artery disease 
PMP levels in blood taken from the coronary artery of patients with ST-elevated 
myocardial infarction (STEMI; n=7), non-ST-elevated myocardial infarction 
(NSTEMI; n=5), and from the forearm vein from STEMI patients (n=3). SMMP 
values were compared with pulmonary arterial hypertensive patients before and after 
therapy (n=18) and age- and sex-matched controls (n=18). The therapy consisted of 
prostacyclin analogues, phosphodiesterase (PDE-5) antagonist, endothelin-1 
receptor antagonist (ETRA), calcium channel blocker or combination therapy of 
PDE-5 antagonist with ETRA and/or a prostacyclin analogue. PMPs were 
characterised as CD42a+/Annexin V+.  (****=P<0.0001; Mann-Whitney and 
Wilcoxen tests were performed. Results are expressed as median and range.) 
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4.2.14. Total circulating annexin V+ microparticles in human 
immunodifficiency virus infected patients 
Total circulating annexin V+ MP levels in forearm venous blood from Malawian 
patients with human immunodeficiency virus (HIV) were a median of 2.11x105 
MPs/ml of PPP and were not significantly different from Malawian control 
patients (median 2.66x105 MPs/ml of PPP), though the range of MPs in HIV 
blood was broader and had a higher maximum count (1.03x106 MPs/ml of PPP) 
compared to controls (6.224x105 MPs/ml PPP; Figure 39). Both Malawian patient 
and control bloods contained significantly higher levels of total MPs than in 
control subjects from the UK who had a median of 3.13x104 MPs/ml in PPP 
(P<0.001). Total MPs in forearm venous blood from PAH patients were 
significantly higher levels than blood from HIV-infected (P<0.0001) and non-
infected controls from both Malawi (P<0.0001) and the UK (P<0.0001). 
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Figure 39. Total circulating microparticles in human immunodeficiency virus-
infected patients 
Total annexin V+ MPs were measured in blood samples from HIV infected Malawian 
patients (n=24), HIV non-infected Malawian control subjects (n=25), and control British 
subjects (n=18). (***=P<0.001; ****=P<0.0001; The Wilcoxen test was performed. 
Results are expressed as median and interquartile range.) 
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4.2.15. Smooth muscle microparticles in human immunodifficiency 
virus infected patients 
PDGFRβ+/PECAM-/Annexin V+ SMMPs were significantly lower in HIV 
venous blood (median 4.34x103 MPs/ml of PPP) than in Malawian venous 
controls (median 1.00x104 MPs/ml of PPP; Figure 40). Venous blood from UK 
control subjects contained these SMMPs at levels that were lower than Malawian 
control venous blood by 28% (median of 7.19x103 MPs/ml of PPP) but not 
significantly different from Malawian control and HIV bloods. 
Endoglin+/PECAM-1-/Annexin V+ SMMPs was ~5-fold lower in HIV venous 
blood (median 5.47x103 MPs/ml PPP) compared to both Malawian control venous 
blood (1.251x104 MPs/ml PPP) and UK controls (1.423x104 MPs/ml PPP; both 
P<0.001). Levels of these SMMPs were not significantly different between 
Malawian and UK control bloods. 
NG2+/PECAM-1-/Annexin V+ SMMPs were lower, though not significantly 
(P=0.0604) in HIV venous blood (median of 3.478x103 MPs/ml PPP) compared to 
Malawian control blood (median of 9.067x104 MPs/ml PPP) and UK control 
blood (median of 1.22x104 MPs/ml PPP). Though the range of these SMMP 
counts was wider, and the maximum level higher in the Malawian control blood 
(median of 1.83x105 MPs/ml PPP) compared to UK controls (median of 5.04x104 
MPs/ml in PPP), the latter had a higher median, though the difference was not 
significant. 
ICAM1+/PECAM-/Annexin V+ SMMPs levels in HIV venous blood (median of 
4.18x103 MPs/ml of PPP) was significantly lower than in Malawian (median of 
9.85x103 MPs/ml of PPP) by 57% and UK venous control bloods (median of 
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1.25x104 MPs/ml in PPP) by 66% (P<0.01 and P<0.001, respectively).  There was 
no significant difference in the SMMP counts between Malawian and UK control 
bloods. 
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Figure 40. Circulating smooth muscle microparticles in HIV-infected patients 
SMMPs were measured in blood samples from HIV infected Malawian patients (n=24), 
HIV non-infected Malawian control subjects (n=25), and control British subjects 
(n=18). SMMPs were characterised as platelet derived growth factor receptor β 
(PDGFRβ)+/PECAM1-/Annexin V+, endoglin+/PECAM1-/Annexin V+, neural glial 
antigen 2 (NG2)+/PECAM1-/Annexin V+, and ICAM1+/PECAM1-/Annexin V+. 
(***=P<0.001; ****=P<0.0001; The Wilcoxen test was performed. Results are 
expressed as median and range.)  
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4.2.16. Endothelial microparticles in human immunodifficiency virus 
infected patients 
 
Levels of E-selectin+ MPs in HIV patients were slightly though not significantly 
higher than in UK controls and 67% lower than in Malawian controls though this 
was not significant (Figure 41). E-selectin+ MPs were significantly higher in 
Malawian control blood compared to UK controls. 
Circulating levels of PECAM-1+/CD42a- EMPs in HIV patients (median of 
2.85x103 MPs/ml PPP) were 64% lower than in Malawian controls (median of 
7.97x103 MPs/ml PPP) and 76% lower than in control subjects (1.21x104 MPs/ml 
PPP; P<0.001 and P<0.01, respectively). There was no significant difference in 
PECAM1+/CD42a- EMP levels between Malawian and UK control blood 
samples.  
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Figure 41. Circulating endothelial microparticles in HIV-infected patients 
EMPs were measured in blood samples from HIV infected Malawian patients 
(n=24), non-infected Malawian control subjects (n=25), and non-infected British 
subjects (n=18). EMPs were characterised as E-selectin+/PECAM-1+/Annexin 
V+ and PECAM-1+/CD42a-/Annexin V+. (*=P<0.05; ***=P<0.001; 
****=P<0.0001; The Wilcoxen test was performed. Results are expressed as 
median and range.) 
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4.2.17. Leukocyte microparticles in human immunodifficiency virus 
infected patients 
Circulating CD66+ LMP levels in HIV patients measured at 2.46x103 MPs/ml in 
PPP and were lower than, though not significantly different, from levels in control 
venous blood from both Malawian (median of 5.63x103 MPs/ml PPP) and UK 
(median of 4.49x103 MPs/ml PPP) subjects (Figure 42). However, there was no 
difference in the levels of LMPs between the two control groups. 
HIV venous blood contained significantly lower amounts of TF+ MPs (median of 
1. 6x104 MPs/ml in PPP) compared to Malawian controls (median of 3.86x104 
MPs/ml in PPP; P<0.01) but were similar to levels in UK controls (median of 
1.13x104 MPs/ml in PPP). Circulating TF+ MPs were significantly higher in 
Malawian controls than in UK controls (P<0.05). 
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Figure 42. Circulating leukocyte microparticles in IHV-infected patients 
LMPs were measured in blood samples from HIV infected Malawian patients 
(n=24), non-infected Malawian control subjects (n=25), and non-infected British 
subjects (n=18). LMPs were characterised as CD66b+/Annexin V+, tissue 
factor+/Annexin V+, CD16+/Annexin V+, and CD14+/Annexin V+. (**=P<0.01; 
The Wilcoxen test was performed. Results are expressed as median and range.) 
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4.2.18. Platelet microparticles in human immunodifficiency virus 
infected patients 
Circulating CD42a+ PMPs were elevated, two-fold in HIV venous blood (median 
6.75x104 MPs/ml in PPP) compared to Malawian control venous blood (median 
3.533x104 MPs/ml in PPP) though this was not significant (Figure 43). However, 
PMPs were significantly higher in HIV patients compared to UK control venous 
blood (median 1.70x104 MPs/ml PPP; P<0.05). There was no difference in 
CD42a+ PMP levels between the two control groups.  
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Figure 43. Circulating platelet microparticles in HIV-infected patients. 
PMPs were measured in blood samples from HIV infected Malawian patients 
(n=24), non-infected Malawian control subjects (n=25), and non-infected British 
subjects (n=18). PMPs were characterised as CD42a+ /Annexin V+. Results are 
expressed as median and interquartile range; and the Wilcoxen test performed 
where *=P<0.05.) 
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Figure 44. Summary of total Annexin V+ in PAH, CAD, and HIV 
Summary of total annexin V+ microparticle levels in forearm venous blood taken from 
pulmonary arterial hypertensive patients before and after drug therapy (n=18) compared with  
age and sex-matched controls (n=18). The therapy consisted of prostacyclin analogues, 
phosphodiesterase (PDE-5) antagonist, endothelin-1 receptor antagonist (ETRA), calcium 
channel blocker or combination therapy of PDE-5 antagonist with ETRA and/or a prostacyclin 
analogue. MP levels were also measured in blood taken from the coronary artery of patients 
with ST-elevated myocardial infarction (STEMI; n=7), non-ST-elevated myocardial infarction 
(NSTEMI; n=5), and from the forearm vein of STEMI patients (n=3). Total Annexin V+ MPs 
were measured in blood samples from HIV infected Malawian patients (n=24), HIV non-
infected Malawian control subjects (n=25), and non-infected British subjects (n=20).. Results 
are expressed as median and interquartile range. The Mann-Whitney and Wilcoxen tests were 
performed with *=P<0.05 and ****=P<0.0001;) 
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4.3. Discussion 
In this chapter I have shown that circulating total annexin V+ MPs were 
significantly elevated in PAH patients compared to healthy control subjects and 
that these levels were considerably higher in PAH than in other diseases affecting 
the vasculature such as coronary artery disease and HIV. Total MP levels in 
forearm venous blood in PAH were more than two-fold greater compared to 
coronary artery blood of patients with STEMI and almost 3-fold greater compared 
to coronary artery blood from patients with NSTEMI. This may suggest a higher 
level of vascular damage, cell activation and apoptosis in PAH than in other 
vascular diseases such as myocardial infarction. A study conducted in 2008 by 
Amabile and colleagues also showed that total annexin V+ MP levels in PH 
patients were higher than in healthy controls though a significant difference was 
not seen (Amabile et al., 2008). In this study, the level of annexin V+ MPs were 
considerably elevated in control subjects compared to diseased, potentially 
indicating pre-existing cellular activation and underlying inflammation within the 
vasculature (Amabile et al., 2008). A lower total MP count would presume to 
reflect a healthier control group. Hong et al. showed this as their control group, 
consisting of both adults and children contained, less than 105 MPs/ml PPP in 
venous blood, which was more similar to my results (Hong et al., 2012). The 
method needed only 100µl of platelet poor plasma for the flow cytometric 
analyses to determine that MPs in venous blood were considerably higher in PAH 
than in coronary artery blood in coronary artery disease. This suggests that MPs 
may be a viable biomarker to use for PAH screening as a less invasive procedure 
compared to right heart catheterisation that requires minimal sample collection. 
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Through detecting MPs, I was also able to assess the severity of cell activation in 
coronary artery blood and forearm venous blood samples from STEMI and 
NSTEMI patients. The level of circulating annexin V+ MPs detected in blood 
from the different vascular complications in order of least to higher magnitude 
was as follows: HIV forearm venous<NSTEMI forearm venous<STEMI forearm 
venous<NSTEMI coronary artery<STEMI coronary artery<PAH forearm venous.  
 
Smooth muscle MPs were defined as PDGFRβ+/PECAM-1-, endoglin+/PECAM-
1-, NG2+/PECAM-1- and ICAM1+/PECAM-1-. All four MP subpopulations 
were significantly elevated in PAH venous blood significantly compared to 
normotensive control venous blood samples, coronary artery disease coronary and 
forearm venous blood, and HIV venous blood, possibly as a result of increased 
hyperproliferation and activation of smooth muscle cells in PAH. Of the four 
SMMPs sub-populations analysed in PAH blood samples, PDGFRβ+/PECAM1- 
MPs had the lowest median while endoglin+/PECAM- MPs had the highest 
median Nevertheless, all SMMP subpopulations were all significantly elevated in 
STEMI coronary artery-derived and NSTEMI coronary artery-derived blood 
compared to healthy controls, but not in forearm venous blood from STEMI and 
NSTEMI patients. In PAH forearm venous blood as well as STEMI and NSTEMI 
coronary artery blood, the endoglin+/PECAM1- and NG2+/PECAM1- SMMP 
subpopulations were detected at higher levels compared to PDGFRβ+/PECAM1- 
and ICAM1+/PECAM1-, with levels of endoglin+/PECAM1- being the highest. 
Increased circulating endoglin+ MPs in PAH compared to healthy controls have 
been reported though levels were higher in the pulmonary artery compared to the 
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jugular vein (Bakouboula et al., 2008). PDGFRβ+/PECAM- SMMPs were 
elevated significantly higher in STEMI coronary blood compared to NSTEMI 
coronary and STEMI forearm venous blood, thereby suggesting that the level of 
circulating SMMPs present is affected by disease severity and site of blood 
sampling. The difference in coronary arterial and forearm venous blood was 
further seen as the former had significantly higher levels of NG2+/PECAM-1- and 
ICAM-1+/PECAM- SMMPs. A similar trend was seen of endoglin+/PECAM- 
SMMPs, though the difference was insignificant. Unlike in PAH and CAD, HIV 
forearm venous blood contained lower SMMPs of each of the four supopulations 
compared to both control subjects from Malawi and the UK.  
 
Other MPs such as endothelial, leukocyte and platelet MPs were also studied 
alongside smooth muscle MPs in PAH, coronary artery disease and HIV. E-
selectin+/PECAM-1- and PECAM-1+/CD42a- EMPs were significantly elevated 
in PAH venous blood compared to controls with levels in the similar range as for 
SMMPs, though the range of total  SMMPs was wider for the 
endogolin+/PECAM- subtype as opposed to the PECAM+/CD42a subtype. E-
selectin+ MPs were highly elevated in STEMI coronary blood compared to 
NSTEMI coronary blood and such levels were comparable with levels in PAH 
venous blood. That levels of E-selectin+ MPs were significantly elevated in 
STEMI coronary and forearm bloods and non-significantly elevated in NSTEMI 
coronary and forearm bloods may result from coronary endothelial damage in 
coronary (Mutin et al., 1999). Indeed, elevated CD31+/Annexin+ microparticles, 
thought to be an indicator of endothelial damage correlated with impairment of 
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coronary endothelial dilatation as assessed by measuring the coronary luminal 
diameter (Werner et al., 2006). Though this would go against the current dogma 
my results presented in the previous chapter, which provide evidence that the 
increase of E-selectin+ MPs may result from activated smooth muscle cells.  
 
CD66b+ LMPs were significantly elevated in PAH compared to normotensive 
controls indicating increased leukocyte activation in the disease though total 
numbers of these LMPs were lower than SMMPs and EMPs. TF+ MPs were also 
significantly elevated, as reported by Bakouboula and colleagues(Bakouboula et 
al., 2008). These LMPs may be viable biomarker for severe coronary artery 
disease as their levels in STEMI coronary blood were significantly elevated 
compared to NSTEMI coronary blood. Interestingly, TF+ leukocyte-derived MPs 
values were also significantly higher than I found in PAH venous samples, 
suggesting that leukocyte involvement maybe more active in coronary artery 
disease within the disease site compared to PAH. However we cannot rule out that 
MP levels in PAH patients would be higher if pulmonary artery blood samples 
were taken instead of venous blood, although MP numbers were considerably 
higher in PAH venous blood than in venous blood from patients with coronary 
artery disease. Levels for both CD66b+ and TF+ MPs were half as low in HIV 
patients compared to Malawian non-infected control groups. Tissue factor may 
also be expressed in multiple cell types including smooth muscle cells and 
activated monocytes and endothelial cells, thus the number of TF+ MPs may 
reveal a broader picture of disease pathophysiology than just leukocyte activation 
(Steffel, 2006). Indeed, agents elevated in PAH such as platelet derived growth 
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factor and TNFα have been shown to increase TF levels in the medium of growing 
smooth muscle cells (Schecter et al., 2000). In other studies, it has been reported 
that CD4+ lymphocyte microparticles and CD11a+ monocytic MPs released from 
human atherosclerotic placques also expressed TF on the surface of MPs thus 
adding to the dynamic role of the TF molecule in different vasculopathies (Mallat 
et al., 1999). 
 
CD42a+ platelet microparticles were elevated in PAH forearm venous blood, 
STEMI coronary and forearm venous blood, and NSTEMI coronary and forearm 
venous blood compared to control venous blood. Platelets were highly elevated in 
PAH and represented 57% of the total Annexin V+ MPs. Nadaud and colleagues 
showed increased levels of CD31+/CD41+ PMPs in idiopathic, heritable, and 
associated PAH though to a similar extent in each distinct form of PAH (Nadaud 
et al., 2013). The CD42a+ PMP levels in coronary blood of STEMI patients were 
significantly higher than in NSTEMI patients, potentially indicating enhanced 
platelet activation within the coronary arteries during disease.  
 
The effect of drug therapy on circulating MP count of PAH patients was 
examined. This study revealed that patients who underwent long-term therapy for 
a minimum of 4 months (consisting of various combinations of prostacyclin 
analogues, PDE-5 inhibitor, ETRA or calcium channel blocker) had significantly 
decreased total annexin V+ MP count compared to prior to therapy. The median 
levels after therapy were 27% lower than before therapy, but still significantly 
higher than in control venous blood. Despite this, the lowering of the MP count 
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still allowed the assessment of the impact of therapy on the patients of different 
sub-populations. Isolated SMMPs showed there to be a similar trend, with 
PDGFRβ+/PECAM1- and ICAM1+/PECAM1- SMMP levels being significantly 
decreased after long-term therapy. This might be expected given that prostacyclin 
analogues, PDE5 inhibitors and ETRAs have been shown to inhibit PASMC cell 
proliferation in various studies (Wang et al., 2008; Davie et al., 2009; Falcetti et 
al., 2010). The number of E-selectin+/PECAM-1- and PECAM-1+/CD42a- EMPs 
also lowered after therapy. Consistent with this, prostacyclin, and in particular 
iloprost, is capable of inhibiting the expression of selectins (P and E) and the 
adhesion molecules ICAM and VCAM in endothelial or inflammatory cells of 
patients with PAH, systemic sclerosis and peripheral vascular disease (Sakamaki 
et al., 2000; Zardi et al., 2005; Rehberger et al., 2009). Though the decreases in 
my studies were not significant, it may lack power due to a limited sample size. 
Likewise, the CD66+ LMPs and CD42a+ PMPs count decreased after long-term 
therapy but did not reach significance. This may also have been due to a limited 
sample size. Interestingly, the level of tissue factor+ MPs remained the same after 
long-term therapy. The level of CD42a+ PMPs also decreased by 34% after long-
term therapy, though this was non-significant. Tamburrelli et al. have shown than 
the eproprostenol was able to inhibit CD42b PMP release after a stimulating blood 
with a mixture of collagen and ADP. The synthetic prostacyclin was also capable 
of inhibiting the formation of platelet mixed conjugates with polymorphonuclear 
or monocytes as well inhibiting the expression of the adhesion molecule P-selectin 
and PAC-1 (activated glycoprotein IIb/IIIa) on platelets (Tamburrelli et al., 2011). 
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Taking a closer look at the specific therapies, prostacyclin analogue treatment 
with/without a PDE-5 inhibitor induced a significant 44.5% reduction in the level 
of total annexin V+ MPs, whilst a PDE-5 inhibitor with/without an ETRA induced 
17% reduction that was not significant. To note, patients on a prostacyclin 
analogue with/without a PDE-5 inhibitor had a higher median MP level of 
3.826x106 MPs/ml PPP compared to patients on a PDE-5 inhibitor with/without 
an ETRA (median of 2.003x106 MPs/ml PPP). The addition of the PDE-5 
inhibitor sildenafil to long-term intravenous epoprostenol therapy in patients with 
PAH was studied in the PACES trial, which resulted in greater changes in mean 
pulmonary arterial pressure, cardiac output, and shorter time to clinical worsening 
compared to epoprostenol monotherapy (Simonneau et al., 2008). Thus patients 
with this combination therapy may have resulted in a further decline in MP levels 
after long-term therapy. 
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Chapter 5 
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5.1. Introduction 
MPs are submicron vesicles shed into the circulation from the plasma membrane 
of a variety of cells, including platelet, endothelial, leukocyte and smooth muscle 
cells, in response to cell activation, injury and/or apoptosis (Simak and 
Gelderman, 2006; Chironi et al., 2009; Amabile et al., 2013). They were first 
described as “platelet dust” and were found to be capable of inducing thrombin 
generation in a similar manner to platelets (Wolf, 1967).  MPs are able to have a 
role in coagulation within the vasculature as their phospholipid surface is rich with 
phosphatidylserine (PS), a procoagulant anionic aminophospholipid, which is 
translocated to the external leaflet of the MP membrane during MP formation 
(Morel et al., 2006). PS is able to activate circulating blood factors, including 
enhancing the activity of tissue factor (TF; CD142), the main cellular initiator of 
blood coagulation. Shielding phosphatidylserine rich surfaces decreases the 
catalytic efficiency of both extrinsic tenase and prothrombinase complexes by 200 
and 1000-fold, respectively (Nesheim et al., 1979; Ruf et al., 1991; Morel et al., 
2006). 
 
The coagulation cascade is a series of stepwise enzymatic conversions involving 
the activation of inactive precursors called zymogens required for the formation of 
fibrin, the ultimate product in the process (Adams and Bird, 2009; Figure 1). 
There are two pathways involved in the cascade that later converge downstream to 
produce coagulation: the intrinsic and extrinsic pathways. The intrinsic pathway is 
dependent on contact activation by a negatively charged surface that is seen on 
damaged areas within the vasculature and involves coagulation factors XII, XI, 
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IX, VIII and V. This pathway starts with the formation of factor XIIa, which can 
cleave prekallikrein to produce kellikrine (McLaughlin et al., 2009). This in turn 
activates factor XII, which becomes activated when it comes in contact with 
negatively charged damaged surfaces by  undergoing a conformational change to 
generates factor XIIa (Long et al., 2015). Factor IIa, in the presence of high 
molecular-weight kininogen, converts factor XI to factor XIa, which then is able 
to convert factor IX to factor IXa. In presence of calcium and membrane 
phospholipids, factor IXa binds its cofactor protein factor VIIIa to form the tenase 
complex (Adams and Bird, 2009), which activates factor X to Xa. Factor Xa is 
able to bind to its cofactor protein factor Va in the presence of calcium to form the 
prothrombinase complex and convert prothrombin (factor II) to thrombin (factor 
IIa), which is the essential component that converts fibrinogen (factor I) to fibrin 
(factor Ia). The extrinsic pathway also leads to the production of thrombin, but 
also initiates the expression of TF following vascular trauma. TF is an intrinsic 
membrane protein located on a variety of cells such as monocytes, endothelial 
cells, and smooth muscle cells. It is a 47 kDa cell-bound membrane glycoprotein, 
a member of the class II cytokine superfamily, and functions as both a receptor 
involved in downstream signalling promoting inflammation, apoptosis, embryonic 
development and cell migration well as a cofactor for the factors, VII/VIIa (Key et 
al., 2007; Adams and Bird, 2009). The TF/VIIa complex is able to activate factor 
X to Xa as well as activate factor IX to IXa (Ruttmann, 2006), thus promoting the 
generation of thrombin, and ultimately fibrin. Thrombin is able to rapidly convert 
soluble plasma fibrinogen to an insoluble fibrin polymer as well as activate 
plasma tranglutaminase (factor XIII), which after being converted to factor XIIIa 
cross links the fibrin polymers to form a fibrin clot (Lewis et al., 1985). 
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The generation of thrombin is a central biochemical reaction that is important in 
the normal homeostasis of the blood and during thrombosis. The thrombin 
produced can engage in a positive feedback loop where it amplifies its own 
generation through multiple mechanisms. It can activate factor XI upstream in the 
intrinsic pathway and generate small amounts of factor XIa which can amplify 
through its own positive feedback mechanism and increase coagulation. 
Activation of factor XIa plays an important role when the initiation phase of 
thrombin generation is prolonged due to low TF levels or elevated levels of 
coagulation inhibiting proteins (Cawthern et al., 1998). Thrombin can also 
activate factor VIII, which can be converted to factor VIIIa and form a tenase 
complex with factor IXa. The tenase complex activates factor X at a 50-100-fold 
higher rate than the TF/factor VIIa complex, thus giving rise to a “thrombin burst” 
(Lawson and Mann, 1991). Both thrombin and factor Xa, with the latter being 40-
fold more potent, are also able to activate factor VII in the extrinsic pathway, 
thereby further driving the coagulation process (Radcliffe and Nemerson, 1975). 
Thrombin is also able to activate factor V, which is important for both extrinsic 
and intrinsic pathways, further potentiating its generation. Factor V has shown to 
play an important physiological role as deficiency in platelet factor V is associated 
with decreased factor Xa binding and bleeding diathesis (Tracy et al., 1984). 
 
There are two types of inhibition that exist for the regulation of thrombin. The 
first is circulating levels of activated inhibitors of thrombin such as antithrombin 
III (ATIII), α2-macroglobulin, and Protein C. ATIII inhibits target enzymes by 
forming complexes and blocking the active site of the enzyme. These target 
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enzymes including factors like IXa, Xa, Xia and XIIa. α2-macoglobulin is also 
able to inhibit multiple serine proteases such as thrombin, factor Xa, plasmin and 
kallikrein. Protein C, a vitamin K-dependent protein that is generated when 
thrombin is converted to activated protein C is also a coagulation inhibitor. The 
second type of inhibition is a negative feedback mechanism that involves the TF 
pathway inhibitor (TFPI), an important regulator of serine proteases that inhibits 
factor Xa and the factor VIIa/TF/Factor Xa complex (Broze et al., 1988). 
 
MPs contain multiple functional membrane or cytoplasmic effectors such as 
selectins, glycoprotein IIIa, glycoprotein IIb, von Willebrand factor, arachidonic 
acid and thromboxane A2, which can promote pro-thrombotic pathways (Morel et 
al., 2006). The presence of microparticles as well as activated endothelial cells 
and other cells enables the formation of the tenase complex, which in turn is able 
to activate factor X at a high rate, resulting in a thrombin burst (Lawson and 
Mann, 1991). Furthermore, endothelial MPs have been shown to interact with 
monocytes and promote TF mRNA expression and TF-dependent procoagulant 
activity, suggesting that MPs are also able to transfer their procoagulant potential 
to target cells (Sabatier et al., 2002). Thus, MPs are able to activate both intrinsic 
and extrinsic pathways in the coagulation cascade as well as pathways involving 
other target cells, which give rise to their procoagulant phenotype. 
 
MPs induce inflammation in the vascular wall through contact with vascular cells 
and can upregulate cytokine expression in monocytes and endothelial cells as well 
as promote leukocyte recruitment and aggregation (Forlow et al., 2000; Nomura et 
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al., 2001). Consequently, leukocyte MPs can activate endothelial cells to release 
interleukin-6 and MCP-1 as well as upregulate tissue factor expression through 
the JNK-1 signalling pathway (Mesri and Altieri, 1998, 1999). In conditions of 
oxidative stress, EMPs contain oxidised phospholipids that can promote 
monocyte-endothelial interactions (Huber et al., 2002). PMPs have also been 
shown to increase adhesion and interactions between the endothelial layer and 
monocytes (Barry et al., 1998). Of note, PMPs have also been shown to contain 
IL-1β, which contributes to endothelial inflammation (Lindemann et al., 2001). In 
addition to providing a proinflammatory stimulus, PMPs have been shown to 
induce angiogenesis in vitro and in vivo (Brill et al., 2005). Moreover, PMPs are 
able to deliver platelet adhesion receptors to hematopoietic stem cells, promoting 
chemotaxis towards endothelial cells, thereby causing cell adhesion, proliferation 
and survival (Baj-Krzyworzeka et al., 2002).  
 
Several therapies for cardiovascular disorders in past studies have shown to 
decrease the level of circulating MPs in disease. Statins have shown to be able to 
target MPs. Previous studies in vitro showed that fluvastatin reduced EMP release 
on growing human coronary artery endothelial cells stimulated with TNF-α, 
partially via inhibiting Rho the small GTPases that regulate cytoskeletal 
remodelling (Tramontano et al., 2004). In patients with type 2 diabetes mellitus, 
pravastatin caused the decrease of glycoprotein IIb/IIIa (GPIIbIIIa)+ PMPs 
(Sommeijer et al., 2005). In hypertensive patients, co-administration of 
simvastatin and the angiotensin II receptor antagonist, losartan, reduced levels of 
monocyte-derived MPs (Nomura et al., 2004). Anti-platelet treatments such as 
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GPIIbIIIa antagonists (i.e. abciximab and eptifibatide) and thienopyridines 
(adenosine diphosphate receptor inhibitors) have shown to lower circulating PMP 
levels (Goto et al., 2003).  
 
Classically, PGI2 acts through the membrane prostacyclin (IP) receptor, which is 
expressed on multiple tissues including blood vessels, leukocytes and 
thrombocytes (Anderson and Nawarskas, 2010). This  receptor is coupled to the G 
stimulatory protein, Gs, which through the activation adenylyl cyclase can 
generate cyclic adenosine monophosphate (cAMP). This second messenger can 
exert multiple biological effects, with protein kinase A being a major target 
protein. PGI2 and its stable analogues are able to induce vasodilatation, inhibit 
platelet activation and inhibit cell proliferation, giving a strong rational for using 
this class of drugs to treat PAH patients (Takubowski et al., 1994; Montani et al., 
2013; Clapp and Gurung, 2015; Galie et al., 2015b). 
 
Whilst the mechanism behind the anti-proliferative effects of PGI2 analogues on 
normal smooth muscle cells are driven by the cAMP pathway, the anti-
proliferative effects of these agents on idiopathic PAH cells were shown to be 
driven in a cAMP independent manner and seemingly not involving the IP 
receptor (Falcetti et al., 2010). A 2007 study from our laboratory demonstrated 
that PGI2 analogues could inhibit cell proliferation in human embryonic kidney 
293 (HEK-293) cells by signalling through the IP-receptor and activating the 
peroxisome proliferator-activated receptor γ (PPARγ) pathway (Falcetti et al., 
2007). Moreover, the PPARγ antagonist GW9662 was able to significantly reverse 
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the inhibition of proliferation caused by the prostacyclin analogue treprostinil in 
normal PASMCs but to a greater extent in cells derived from IPAH patients 
(Falcetti et al., 2010). PPARs are a family of nuclear transcription factors, of 
which there are three isoforms (α, β, and γ), that are commonly activated by 
binding to ligands including prostaglandins (ie. 15-Deoxy-delta 12, 14-PGJ2), 
fatty acids, lipoxygenase metabolites and a variety of synthetic ligands (Forman et 
al., 1997). Classically, PPARs are known to bind to retinoid X receptor (RXR) 
and form a heterodimer which can associate with coactivators and bind to 
peroxisome proliferator response elements (PPRE) in the nucleus to regulate the 
expression of target genes involved in cell processes such as inflammation, cell 
growth and cell differentiation (Nisbet et al., 2007). In addition to directly 
regulating gene expression, PPARγ is also able to transrepress transcription 
factors like nuclear factor-κB (NFκB), activated protein-1 (AP-1), nuclear factor 
of activated T-cells (NFAT) and signal transducer and activator of transcription 
(STAT) (Abdelrahman et al., 2005). Precipitation experiments in T-cells revealed 
a direct interaction between NFAT and PPARγ, which led to the suppression of T 
cell proliferation and activation (Yang, 2000). NFAT is activated by binding to the 
heterodimeric serine/threonine phosphatase enzyme calcineurin, which is 
dependent on elevated intracellular calcium for its activation. Upon activation, the 
NFAT/calcineurin complex is able to translocate into the nucleus and initiate 
transcription of genes that regulate smooth muscle and cardiac muscle, the 
immune response and allergic pulmonary inflammatory response (Said et al., 
2010). The calcineurin Aβ (CnAβ) isoform was shown to be activated by PDGF-
BB and to contribute to smooth muscle cell proliferation in rat aorta by inducing 
calcineurin-dependent translocation of NFATc3 into the nucleus from the cytosol 
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(Jabr et al., 2007). PDGF-induced CnAβ activation/nuclear translocation and 
smooth muscle proliferation were abrogated by the adenylyl cyclase activator 
forskolin, suggesting that cAMP may also be involved in regulating the 
NFAT/calcineurin activation (Jabr et al., 2007). Thus, I aimed to investigate 
whether the mechanism underlying the antiproliferative effects of prostacyclin 
analogues involved activation of PPARγ and the subsequent inhibition of the 
translocation of calcineurin Aβ to the nucleus because of its ability to inactivate 
(transrepress) NFAT. 
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Results 
5.2.1. Thrombin generation by MPs in plasma from healthy patients 
Thrombin generation induced by microparticles in healthy microparticle-free 
plasma was measured over a period of 90 minutes (Figure 45). MPs were isolated 
from 100µl of platelet poor plasma obtained from treatment naïve patients with a 
diagnosis of PAH (n=7) or who subsequently had been treated with a combination 
of a prostacyclin with/without a phosphodiesterase-5 (PDE-5) inhibitor (n=4), 
PAH patients treated with a PDE-5 inhibitor with/without an endothelin-1 
antagonist (n=4). Effects on thrombin generation were compared against MPs 
isolated from patients with non-ST-elevated myocardial infarction (NSTEMI) and 
from healthy control subjects (n=10). Peak thrombin levels caused by MPs from 
PAH treatment naïve patients and from control subjects was 225 nM (range 123-
428nM) and 38 nM (range 19-190nM, respectively (P<0.001). Thrombin levels in 
PAH patients after long-term treatment with PGI2 analogue ± PDE-5 inhibitor 
151.8nM (85-173nM; P<0.05) and NSTEMI patients 151.8nM (103-222nM; 
P<0.05) were lower than MPs from PAH. Treatment of PAH patients with a PDE-
5 inhibitor±ETRA 170nM (114-186nM) caused lower peak thrombin levels 
compared to treatment naïve PAH patients, though failed to reach significance 
(P=0.07). There was a trend to increased thrombin levels with MPs derived from 
the venous blood with NSTEMI compared to control subjects, though this was not 
significant (P=0.08). 
 
The endogenous thrombin potential (ETP) as measured by the area under the 
curve (AUC) was elevated significantly by MPs from PAH treatment naïve 
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patients 3.72 x 104 nM x min (2.3-4.4x104nM x min) compared to MPs from 
control subjects 2.08 x 104 nM x min (0.90-3.06 x 104 nM x min; P<0.0001) and 
PAH patients treated with prostacyclin analogue therapy 2.9 x104nM x min (1.77-
3.13 x104nM x min; P<0.05). MPs derived from Non-STEMI patients 2.9 x104nM 
x min (2.43-4.13 x104nM x min) also had significantly elevated ETP compared to 
control subjects (P<0.01), though this was significantly less than in PAH 
treatment naïve patients (P<0.05). MPs derived from PAH patients treated with a 
PDE-5 inhibitor ± ETRA 3.22x104nM x min (2.45-3.58x104nM x min) also had 
decreased ETP compared to PAH naïve, though this was not significantly 
different, largely due to the increase in length of time thrombin remained elevated 
under these conditions (P=0.119). 
 
The time taken to reach the peak level of thrombin generated was significantly 
lower with  MP samples taken from treatment naïve PAH compared to control 
subjects patients being 25 minutes (15.5-28.5 min) to peak as opposed to 31.8 
minutes (28.5-41 min; P<0.0001). After treatment, the time taken for thrombin 
generation to reach peak levels in both treatment groups of PAH patients treated 
with either a PGI2 mimetic ± PDE-5 inhibitor 152 minutes (85.2-173.4 min; 
P<0.01) or PDE-5 inhibitor ± ETRA 170 minutes (114.6-185.5 min; p<0.05) was 
lengthened. The peak time was significantly greater for MPs from non-STEMI 
patients 33.5 minutes (28.5-38.5 min) compared to PAH patients (P<0.0001). 
 
The rate of thrombin generated in healthy plasma was elevated 3 fold for MPs 
from PAH treatment naïve patients 32.13nM/min (14.89-91.21nM/min) compared 
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to control subjects 10.28nM/min (3.75-26.52nM/min; P<0.001) and was double 
that seen with MPs isolated from non-STEMI patients (P<0.001). In MPs isolated 
from PAH patients treated with PGI2 mimetic ± PDE-5 inhibitor therapy, this 
significantly fell to 14.67nM/min (10.66-20nM/min; P<0.05) compared to 
untreated PAH patients. While the rate of thrombin generation for MPs isolated 
from PAH patients after long-term PDE-5 inhibitor ± ETRA therapy also fell to 
20.02nM/min (12.19-21.36nM/min; P<0.001), this decrease just failed to reach 
significance (P=0.055). The velocity index for MPs derived from the venous 
blood of non-STEMI patients was not significantly different from control subjects 
(P=0.313). 
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Figure 45. Representation of thrombin generation curves induced by circulating 
MPs 
Representation of thrombin generation curves induced by microparticles derived from the 
venous blood of patients with pulmonary arterial hypertension (naive or treated) and non-
ST-elevated myocardial infarction (STEMI). Isolated microparticles were administered in 
equal volume (100 µl plasma) to microparticle-removed plasma from healthy volunteers. 
Thrombin generation (nM) measured over 90 minutes using a calcium fluorogenic 
substrate which is cleaved during thrombin generation and detected using a fluorescence 
reader. Therapy included 1) a prostacyclin mimetic with/without a phosphodiesterase-5 
inhibitor (PDE-5i), or 2) a PDE-5i with/without an endothelin-1 receptor antagonist 
(ETRA). Data is presented as mean values. 
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Figure 46. Analysis of circulating microparticle-induced thrombin generation in PAH 
and Non-STEMI patients 
Microparticle-induced thrombin generation in patients diagnosed with pulmonary arterial 
hypertension (n=7) and non-ST-elevated myocardial infarction (STEMI; n=7). Microparticles 
were isolated from the venous blood and administered to microparticle-free plasma obtained 
from healthy volunteers (n=10). Thrombin generation (nM) was measured over 90 minutes. 
Therapy included 1) an prostacyclin analogue with/without a phosphodiesterase-5 (PDE-5i; 
n=4), or 2) a PDE-5i with/without an endothelin-1 receptor antagonist (ETRA; n=4). Levels of 
peak thrombin (nM), endogenous thrombin potential (AUC), time to peak (minutes) and 
velocity index (nM x min-1) were recorded and analysed. Data are represented as median; 
*=P<0.05; **=P<0.01; ***=P<0.001, with Mann-Whitney U Test. 
233 
 
5.2.2. Sensitivity/specificity analysis of peak thrombin and endogenous 
thrombin potential for identification of pulmonary arterial hypertension 
recurrence 
 
Receiver operator characteristic curve analysis was performed to examine the 
sensitivity and specificity of peak thrombin and endogenous thrombin potential 
(ETP) of patient-derived microparticles in the diagnosis of pulmonary arterial 
hypertension (Figure 47). Peak thrombin and ETP levels of microparticles from 
PAH patients (n=13) were compared with healthy controls (n=10). The diagnostic 
performance test for identifying disease recurrence with peak thrombin levels was 
significant with area under the curve (AUC) 0.9385, standard error (SE) 0.0469, 
95% confidence interval (CI) 0.846-1.031, and P=0.0004. The diagnostic 
performance test for identifying disease recurrence was with endogenous 
thrombin potential levels was significant with area under the curve (AUC) 0.9592, 
standard error (SE) 0.031, 95% confidence interval (CI) 0.9092-1.029, and 
P=0.0001567. 
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Figure 47. Receiver operator characteristic curve for peak thrombin 
and endogenous thrombin potential for identification of PAH 
recurrence 
Receiver operator characteristic curve for peak thrombin and endogenous 
thrombin potential for the identification of pulmonary arterial 
hypertension recurrence (n=13 PAH vs n=10 controls). ROC analysis was 
significant for endogenous thrombin potential  with the area under the 
curve (AUC) = 0.9692, standard error (SE) = 0.031, 95% CI = 0.9020-
1.029, and P=0.0001567. The ROC analysis was also significant for peak 
thrombin with the AUC = 0.9385, SE=0.04697, 95% CI = 0.8464-1.031, 
and P=0.0004. 
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5.2.3. Peak thrombin and endogenous thrombin potential correlated with 
total number of annexin V+ microparticles 
 
Peak thrombin and endogenous thrombin potential levels of PAH patient-derived 
microparticles were correlated with total annexin V+ MP numbers (n=13; Figure 
48). Peak thrombin levels positively correlated with total annexin V+ MP levels 
and was significant with r=0.705 and p<0.0137 using the Spearman correlation 
test. The ETP of total microparticles also correlated positively and was significant 
with r=0.5714 and p<0.045.  
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Figure 48. Total annexin V+ microparticles correlated with peak thrombin and 
endogenous thrombin potential in PAH 
Levels of peak thrombin (top) and endogenous thrombin potential (bottom) of 
microparticles from patients with pulmonary arterial hypertension (n=13) plotted against 
total annexin V+ microparticle number. There was a significant positive correlation 
between peak thrombin and total microparticle number (r=0.75 and P<0.0137 using the 
Spearman correlation test). The endogenous thrombin potential, measured as the area 
under the curve of the thrombin generation profile was also significantly correlated with 
total microparticle number with r=0.57 and p<0.045. 
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5.2.4. Generation of thrombin in healthy plasma by smooth muscle 
microparticles and human umbilical cord vein endothelial cell microparticles 
 
Thrombin generation was compared between a fixed number of microparticles 
(105 MPs) derived from cultured smooth muscle cells isolated from PAH patients 
and from human umbilical vein endothelial cells (HUVECs). The peak thrombin 
level, total thrombin generated over time (endogenous thrombin potential), time 
taken to reach peak thrombin levels (peak time) and rate of thrombin generation 
(velocity index) were measured. The PAH patient derived SMMPs caused a 
significantly greater (by 31%) peak thrombin level (203±15.54nM) compared to 
the endothelial microparticles (140.3 ± 3.31nM; P<0.05). SMMPs had 
significantly elevated endogenous thrombin potential (2515±77.29 nM x min) 
compared to the EMPs (2103 ± 53.11nM x min; P<0.05). The time taken to reach 
peak levels was also significantly lower in SMMPs (8. 7±0.601 min) than EMPs 
(16.3 ±0.667 min). The rate of thrombin generation caused by SMMPs 
(47.38±9.68 nM x min-1) was two-fold higher compared to that of EMPs 
(21.72±2.60 nM x min-1).  
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Figure 49. Analysis of thrombin generation by SMMPs from PAH cells and 
EMPs from HUVECs 
Thrombin generation was compared between smooth muscle cells of PAH patients 
and human umbilical vein endothelial cells (HUVECs). The peak thrombin level 
(nM), total thrombin generated over time (endogenous thrombin potential), time 
taken to reach peak thrombin levels (peak time), and rate of thrombin generation 
(velocity index) were measured. (Data is represented as mean±S.E.M; *=P<0.05; 
**=P<0.01; n=3.) 
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5.2.5. Prostacyclin analogue-mediated inhibition of microparticle release by 
pulmonary arterial smooth muscle cells 
 
Given that certain growth factors and cytokines are elevated in PAH which lead to 
raised MP levels, I wished to assess the impact of antiproliferative prostacyclin 
analogue treprostinil on inhibiting MP. Smooth muscle cells were grown in 
culture until about 70% confluence and were then stimulated with 20ng/ml PDGF-
BB, 20ng/ml TNF-α, 5ng/ml TGF-β, and 10nM ET-1 alone and in combination 
with 1µM treprostinil. Cells were stimulated for 24 hours in growth media 
containing 10% foetal bovine serum plus growth factors and drugs, the 
supernatants collected, and total annexin V+ MPs measured. 1µM treprostinil was 
able to inhibit microparticle release by smooth muscle cells induced by various 
growth factors though the degree to which it did, depended on the growth stimulus 
(Figure 50). 
The addition of 20ng/ml PDGF-BB to 10% serum significantly increased SMMP 
numbers (142670±20046 MPs/ml/104 cells) compared to serum alone 
(66521±6958 MPs/ml/104 cells; P<0.01; n=4). Treprostinil completely abolished 
the PDGF-BB and 10% FBS-induced MP release to 49062±8005 MPs/ml/104 
cells (P<0.01; n=4) back to slightly below levels seen by serum alone. 
Administration of 20ng/ml TNF-α to growing cells caused ~1.75-fold increase in 
MP number (117306±18731 MPs/ml/104 cells) compared to serum alone 
(66521±6958 MPs/ml/104 cells), though this failed to reach significance. 
Treprostinil inhibited the TNF-induced release by 44% to 77741±27363 
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MPs/ml/104 cells, though the difference was not significant due to a large 
variation in the response to treprostinil. 
5ng/ml TGF-β in combination with serum significantly increased MP number by 
3-fold (216879±2554 MPs/ml/104 cells) compared to serum alone (69572±8844 
MPs/ml/104 cells; P<0.001; n=3). This increase was significantly inhibited by 
1µM treprostinil by 56% (121705±18518 MPs/ml/104 cells).10nM ET-1 in the 
presence of 10% serum caused nearly a 3.5-fold increase in MP count 
(235522±32627 MPs/ml/104 cells) compared to serum alone (66521±6958 
MPs/ml/104 cells; P<0.01; n=4). The addition of 1µM treprostinil significantly 
inhibited the release MPs by 66% to 102469±25833 MPs/ml/104 cells (P<0.01; 
n=4). 
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Figure 50. The prostacyclin analogue treprostinil inhibited microparticle release 
by PASMCs from PAH patients after cell stimulation. 
Smooth muscle cells were grown in culture until 70% confluence and were stimulated 
with 20ng/ml PDGF-BB, 20ng/ml TNF-α, 5ng/ml TGF-β, and 10nM ET-1 alone and in 
combination with 1µM treprostinil in growth media with 10% foetal bovine serum. 
Cells were stimulated for 24 hours, supernatants were collected, and total annexin V+ 
MPs were measured. (Data is represented as mean±S.E.M (n=3-4); **=P<0.01; 
***=P<0.001; One-way ANOVA was performed. 
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5.2.6. Dose-dependent of treprostinil on smooth muscle microparticle release 
 
The prostacyclin analogue treprostinil inhibited MP release by PDGF-BB in a 
dose-dependent manner (Figure51). Pulmonary artery smooth muscle cells from 
PAH patients were grown in culture until 70% confluent and stimulated for 24 
hours with 0.1% foetal bovine serum (FBS), 10% FBS ± 20ng/ml platelet-derived 
growth factor (PDGF) with increasing concentrations of treprostinil). Supernatants 
were collected and total annexin V+ MPs were measured and normalised to cell 
number. 
 
Total annexin V+ SMMP levels were 3-fold higher after 10% serum stimulation 
compared to 0.1% serum (77329±15097 MPs/ml/104 cells). The total SMMP 
number significantly increased by 2-fold after the administration of 20ng/ml 
PDGF+10% FBS to 152672±102677 MPs/ml/104 cells compared to serum alone 
(77329 MPs/ml/104 cells; P<0.01). The SMMP number started to decline at 
concentrations above 1nM and this increased in a dose-dependent manner. Co-
administration of 100nM treprostinil significantly (P<0.05, n=5) decreased SMMP 
numbers (92767±12886 MPs/ml/104 cells) by 39% compared to 20ng/ml 
PDGF+10% FBS The addition of 1µM treprostinil induced the greatest inhibition 
in MP release by 61% (59916±18896 MPs/ml/104 cells) compared to 20ng/ml 
PDGF+10% FBS (P<0.001). Unexpectedly, SMMP levels were higher in the 
presence of 10µM treprostinil compared to lower (0.03-1µM), indicating a weaker 
inhibition in SMMP release at this higher concentration, perhaps indicative of 
activation of opposing pathways.   
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Figure 51. The prostacyclin analogue treprostinil inhibits microparticle release by 
PDGF-BB in a dose-dependent manner. 
Pulmonary artery smooth muscle cells from PAH patients were grown in culture until 
70% confluent and stimulated for 24 hours with 0.1% foetal bovine serum (FBS), 10% 
FBS ± 20ng/ml platelet-derived growth factor (PDGF) with increasing concentrations of 
treprostinil (0.001-10µM). Supernatants were collected and total annexin V+ 
microparticles were measured. Data is presented as mean ± S.E.M. *=P<0.05; 
**=P<0.01; ***=P<0.001; ****=P<0.0001, one-way ANOVA with Holm-Sidak’s 
multiple comparisons test with respect to 20ng/ml PDGF+10% FBS (n=5). 
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5.2.10. Smooth muscle microparticle-induced proliferation of normal 
smooth muscle cells 
 
Next I wished to assess if microparticles could stimulate or enhance the 
proliferation of PASMCs derived from control patients. 105 MPs derived from 
PASMCs from PAH patients were used to stimulate 104 growth arrested cells per 
well in a 96-well plate. 
 
10% FBS induced a two-fold increase in proliferation of smooth muscle cells 
compared to 0.1% FBS (P<0.0001; Figure 52). Likewise 20ng/ml PDGF-BB 
significantly increased cell proliferation compared to 0.1% FBS alone by 80% 
(P<0.0001). The addition of smooth muscle MPs significantly increased cell 
proliferation by 37% compared to 0.1% FBS (P<0.05), though to a lesser extent. 
In contrast, administration of TGF-β plus 0.1 FBS% did not induce cell 
proliferation over and above what was observed under  basal conditions (0.1% 
FBS).  
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Figure 52. Smooth muscle MPs induced PASMC growth in vitro. 
: A fixed number (105) of MPs  derived from cultured PASMCs of PAH patients 
induced proliferation of growth arrested PASMCs from healthy donors. PASMCs 
were plated into a 96-well plate at a density of 105 cells/ml, arrested in 0.1% FBS 
for 48 hours and treated with 0.1% FBS, 10% FBS, 0.1% FBS+20ng/ml PDGF-BB, 
0.1% FBS+ PAH MPs, and 0.1%+5ng/ml TGF-β. The cells were left to grow for 
96 days and the % proliferation with respect to 0.1% FBS was measured. Data are 
presented as mean ± S.E.M. *=P<0.05; ****=P<0.0001, with respect to 0.1% FBS 
(One-way ANOVA with Holm-Sidak’s multiple comparisons test was used; n=3 
patient isolates with 5 repeats). 
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5.2.7. Effect of prostacyclin receptor and prostaglandin E2 receptor 
antagonists prostacyclin-mediated inhibition of microparticle release 
 
Treprostinil is known to potently bind, not only to the IP receptor, but EP2 
receptors as well (Whittle et al., 2012), with both receptors shown to contribute to 
the antiproliferative effects of treprostinil (Falcetti et al., 2010; Patel et al., 2015). 
Thus microparticle release was examined in PASMCs isolated from PAH patients 
that were grown in culture until 70% confluent and stimulated for 24 hours with 
10% foetal bovine serum (FBS) alone and with 20ng/ml (PDGF in combination 
with 100nM treprostinil, 1µM of the IP receptor antagonist (IPRA), R01138452, 
1µM of the EP2 receptor antagonist (EP2RA), PF04418948 or a combination of 
the two antagonists. The supernatants were collected, and total annexin V+ 
microparticles measured. Inhibition of PDGF and serum-induced microparticle 
release by 100 nM treprostinil was reversed with either a prostacyclin or a 
prostaglandin EP2 receptor (Figure 53). Microparticles release was increased 2-
fold by the addition of 20ng/ml PDGF-BB and 10% FBS compared to serum 
alone. The addition of 100nM treprostinil significantly inhibited MP release 
caused by 20ng/ml PDGF+10% FBS (P<0.05). When treprostinil and 1µM IPRA 
was added in combination with 20ng/ml PDGF with 10% FBS, it reversed the 
inhibitory  effects of treprostinil on MP release, though this just failed to reach 
significance (P=0.074). Likewise, the EP2RA at 1µM reversed the effect of 
treprostinil, though not significantly (P=0.251). The combination of both 
antagonists did however significantly (P<0.01) reverse the inhibitory effects of 
treprostinil on MP release.  
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Figure 53. Treprostinil-induced smooth muscle microparticle release 
inhibition through the IP2 and EP2 receptors. 
The inhibitory effects of treprostinil on PDGF-mediated microparticle release, was 
reversed by a combination of a prostacyclin and prostaglandin EP2 receptor 
antagonist. Pulmonary artery mooth muscle cells from PAH patients were grown in 
culture until 70% confluent and stimulated for 24 hours with 10% foetal bovine 
serum (FBS) alone and with 20ng/ml platelet-derived growth factor-BB (PDGF) in 
combination with 100nM treprostinil in the absence and presence of 1µM 
R01138452 (IP receptor antagonist; IPRA), 1µM PF04418948 (EP2 receptor 
antagonist; EP2RA) and a combination of both antagonists. Cell culture 
supernatants were collected and the total annexin V+microparticles were 
measured. Data are presented as mean±S.E.M.  **=P<0.01, ***=P<0.001 (n=4). 
One-way ANOVA with Dennett’s multiple comparisons test was used with respect 
to 100nM Trep+20ng/ml PDGF-BB+10% FBS 
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5.2.8. Expression and activation of calcineurin Aβ in pulmonary arterial 
smooth muscle cells 
 
Calcineurin-Aβ (CnAβ) activation plays an important role in driving PASMC 
proliferation and is known to be inhibited by PPARγ signalling. As prostacyclin 
has been shown to act through PPARγ to inhibit cell growth, I wanted to 
investigate whether the prostacyclin analogue treprostinil may be signalling 
through PPARγ to inhibit CnAβ, and in turn suppress PASMC proliferation. The 
expression and nuclear translocation in PASMCs from PAH patients was 
investigated. Cells were growth arrested for 48 hours and treated for 24 hours with 
0.1% foetal bovine serum (FBS), 10% FBS alone and in combination with 1µM 
treprostinil, the PPARγ activator,  rosiglitazone  (1µM) and the PPARγ 
antagonists GW9662 (1µM)  and T00701 (1µM) as shown (Figure 54). 
 
The expression of CnAβ as assessed by the intensity of fluorescent staining 
outside the nucleus was increased after treatment with 10% FBS, as was the 
presence of CnAβ within the nucleus. The addition of the PPARγ antagonist 
GW9662 at 1µM increased the nuclear presence of CnAβ compared to 10% FBS, 
as did 1µM of the selective PPARγ antagonist T00701 though to a slightly lesser 
extent. 1µM treprostinil treatment abolished the effect of serum and dropped 
CnAβ expression and its nuclear presence to levels lower than by 0.1% FBS. 
Blockade of PPARγ by GW9662 and T00701 increased the CnAβ expression and 
nuclear presence, though not to levels of the antagonists alone. CnAβ expression 
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was slightly lower with 1µM rosiglitazone compared to serum alone, as were its 
presence in the nucleus. 
The nuclear occupancy was quantified through confocal image analysis to study 
calcineurin activation in the PASMCs (n=3; 24 cells total per treatment; Figure 
55). Nuclear occupancy of CnAβ was increased in cells growing in 10% FBS 
(22.64%) compared with cells grown in 0.1% serum (11.06%) for 24 hr. 1µM 
treprostinil significantly (P<0.01) reduced the nuclear occupancy by 67% (7.53%) 
compared to 10% serum. Rosiglitazone also reduced nuclear occupancy to 15%, 
though not significantly. There was some increase in CnAβ nuclear occupancy 
with GW9662 (30.17%) compared to 10% serum alone, suggesting basal PPARγ 
activity maybe affecting calcineurin activation. Co-administration of 1µM 
GW9662 and 1µM treprostinil significantly reversed the effect of treprostinil by 
doubling the nuclear occupancy to 20.77% (P<0.05). Similarly, 25.14% he 
combination of T00701 and 1µM treprostinil significantly reversed the effect of 
treprostinil by increasing the nuclear occupancy to 19.79% (P<0.05), slightly 
below that observed in the presence of T00701 alone (25.1%). 
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0.1% FBS 10% FBS 1µM Trep+FBS  1µM Rosi 
1µM GW9662 1µM GW9662 + Trep 1µM T00701  1µM T00701+ Trep 
Figure 54. Calcineurin Aβ exression and activation in PASMCs from PAH patients 
by treprostinil involves activation of the PPARγ pathway. 
Cells were plated in 8-well chambered and growth arrested for 48 hours, then treated for 
24 hours with 0.1% foetal boviane serum (FBS), 10% FBS alone and in combination with 
1µM treprostinil, 1µM rosiglitazone, 1µM GW9662±1µM treprostinil and 1µM 
T00701±1µM treprostinil. Cells were immunostained for calcineurin Aβ and imaged via 
confocal microscopy. The images were analysed using the ImageJ software and the % of 
nuclear occupancy of calcineurin Aβ representing calcineurin-Aβ activation was 
calculated. (Data is represented as mean±S.E.M; *=P<0.05; **=P<0.01; One-way 
ANOVA with Tukey’s multiple comparisons test was used; n=3). 
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Figure 55. Analysis of nuclear occupancy of Calcineurin Aβ in PASMCs from 
PAH patients by treprostinil 
Inhibition of calcineurin-Aβ expression and activation in pulmonary arterial smooth 
muscle cells from PAH patients by treprostinil involves activation of the PPARγ 
pathway. Cells were plated in 8-well chambered and growth arrested for 48 hours, then 
treated for 24 hours with 0.1% foetal boviane serum (FBS), 10% FBS alone and in 
combination with 1µM treprostinil, 1µM rosiglitazone, 1µM GW9662±1µM 
treprostinil and 1µM T00701±1µM treprostinil. Cells were immunostained for 
calcineurin Aβ and imaged via confocal microscopy. The images were analysed using 
the ImageJ software and the % of nuclear occupancy of calcineurin Aβ representing 
calcineurin-Aβ activation was calculated. (Data is represented as mean±S.E.M; 
*=P<0.05; **=P<0.01; One-way ANOVA with Tukey’s multiple comparisons test was 
used; n=3). 
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5.2.9. Inhibition of proliferation of pulmonary arterial smooth muscle cells by 
treprostinil and cyclosporine A 
 
Given the above results showing that treprostinil inhibited not only CnAβ 
expression but its nuclear translocation, I wished to assess the role of calcineurin 
in regulating cell proliferation in in PASMCs isolated from PAH patients. 
Proliferation induced by serum in the presence of DMSO was significantly and 
similarly inhibited by 100 nM treprostinil or by the calcineurin inhibitor, 
cyclosporine A at 1µM (Figure 56). When the two agents were combined, cell 
proliferation was further inhibited, though not significantly. At the higher dose of 
treprostinil (1µM),  a greater inhibition of cell proliferation was observed with 
further inhibition when combined with cyclosporine. The enhanced 
antiproliferative effects of treprostinil in the presence of cyclosporine were 
however less than the effect of either agent alone, suggesting some crossover of 
mechanism of inhibition of cell growth.  
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Figure 56. : Proliferation of PASMCs from PAH patients was inhibited by 
treprostinil and the calcineurin inhibitor cyclosporin A. 
Cells were plated at 104 cells/ml density and growth arrested for 48 hours, then 
treated with 0.1% foetal boviane serum (FBS), 10% FBS alone and in combination 
with 1µM treprostinil (Trep), 100nM treprostinil+1µM cyclosporine A (CsA), 
1µM treprostinil+1µM cyclosporine A, 1µM cyclosporine A, and 0.02% DMSO as 
the solvent control. (Data is represented as mean±S.E.M; *=P<0.05; **=P<0.01; 
***=P<0.001, with respect to 0.1% FBS in graph A and with respect to 10% FBS 
in graph B; One-way ANOVA with Tukey’s multiple comparisons test was used; 
n=6). 
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5.3. Discussion 
A major finding of the current finding was that MPs isolated from the plasma of 
PAH patients induced a higher peak thrombin level compared to both controls and 
NSTEMI patients. Given that the same volume of plasma was used in this study, 
suggests this was caused by the significantly higher number of MPs. Furthermore, 
peak thrombin levels, endogenous thrombin potential, and the rate of thrombin 
generation were lower in MPs isolated from PAH patients after therapy, being 
more reduced in PAH patients treated with PGI2 analogue with/without a PDE-5 
inhibitor compared to treatment with a PDE-5 inhibitor with/without an ETRA. 
Thrombin generation was also significantly higher for MPs from NSTEMI 
patients compared to control subjects, though these levels were still lower 
compared to MPs from PAH patients. As MP number positively correlated with 
peak thrombin and endogenous thrombin potential in PAH patients, the high total 
number of MPs seen in PAH patients is likely to account for higher thrombin 
levels generated compared to that seen in NSTEMI patients. As total MPs in the 
forearm blood in PAH patients were 13–fold higher than in the forearm of 
NSTEMI patients, but I observed only a 33% higher median peak thrombin level 
and a 21% higher median ETP, may indicate that the thrombin generation 
potential per MP is lower in PAH than in NSTEMI. This could be due to a greater 
thrombogenicity of the MPs in myocardial infarction or that the maximum 
thrombin generation was reached by PAH MPs. For clinical relevance, a fixed 
volume of MPs of 100µl plasma was able to show that MPs in PAH potentiate 
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greater coagulation than MPs in NSTEMI and that this could be damaging 
throughout the vasculature. This was confirmed by ROC analyses for peak 
thrombin and ETP between PAH and NSTEMI were significant. 
MP elevation in myocardial infarction was shown in the previous chapter and has 
also been shown in past studies. Elevated circulating procoagulant platelet and 
endothelial PECAM-1+ and glycoprotein Ib+ MPs have been reported in ST-
elevated myocardial infarction (STEMI) compared to healthy volunteers (Morel et 
al., 2005). Elevated MP levels have also been indicated in other thromboembolic 
diseases such as thrombocythemia and acute pulmonary embolism (Trappenburg 
et al., 2009; Bal et al., 2010). Essayagh and colleagues reported that patients with 
acute myocardial infarction, who had undergone thrombolysis treatment, had 
lower levels of TFPI on TF+ MPs compared to before treatment, though such a 
decrease was not seen in TF+ MP levels in the patient groups who had undergone 
stenting (Essayagh et al., 2005). The high amounts of thrombin produced by MPs 
in the blood from PAH patients may be partially due to SMMPs from being highly 
thrombogenic compared to endothelial MPs. Indeed, SMMPs induced a higher 
peak thrombin, ETP and velocity index and a lower peak time compared to EMPs 
from HUVECs, suggesting SMMPs may cause greater coagulation and damage to 
the vasculature. This may be due to greater numbers of SMMPs being TF+ as TF 
is expressed constitutively in smooth muscle cells as opposed to being induced 
with an  inflammatory stimulus in endothelial cells (Zwicker et al., 2011). 
 
Treprostinil was effective at inhibiting the release of MPs caused by growth 
factors and pro-inflammatory agents elevated in PAH in combination with serum. 
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Treprostinil was particularly effective at decreasing MP levels induced by 
20ng/ml PDGF-BB. Such results may not be surprising, given that previous 
studies in normal human PASMCs have shown that PGI2 analogues can inhibit the 
mitogenic responses to PDGF and serum in a largely cAMP-dependent manner 
(e.g. Wharton et al, 2000; Clapp et al, 2002). Furthermore, PGI2 itself is known to 
be a potent inhibitor of growth factor released from platelets and leukocytes, in 
particular platelet-derived growth factor (PDGF), a key driver of smooth muscle 
cell proliferation and neointimal formation in atherosclerosis (Fredrich and 
Muller, 1992) as well as in PAH (Hassoun, 2009;  Clapp & Gurung, 2015). 
 
MP levels were not elevated as much by TNFα, and the administration of 
treprostinil while not significantly lowering total MP levels, a trend was 
nonetheless visible. A number of studies have shown that PGI2 analogues can 
downregulate pro-inflammatory cytokine production (e.g. TNF-α, IL-1 IL-6 and 
interferon-γ) in a variety of inflammatory cells types via suppression of NF-κB 
activity (see Clapp & Gurung) and studies in patients show iloprost to inhibit 
plasma TNFα levels in critical limb ischemia (Di Renzo et al., 2005). 
 
Treprostinil significantly lowered the release of MP levels caused by TGFβ and 
was even more effective in lowering  ET-1-induced MP release How treprostinil 
may reduce MP release induced by these two mitogens is unclear. PGI2 analogues 
have been reported to reduce ET-1 synthesis stimulated by mitogens in PASMCs 
(Wort et al., 2001; Davie et al., 2002) and to reduce elevated ET-1 plasma levels 
in patients with systemic sclerosis (Rehberger et al., 2009). Furthermore, 
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treprostinil inhibited the proliferative effects of TGF-β in PASMCs harbouring a 
BMPRII mutation cells by reducing SMAD3 phosphorylation (Ogo et al., 2013). 
 
Based on the effects of two relatively selective IP (Falcetti et al., 2007) and EP2 
receptor antagonists (Birrell and Nials, 2011), treprostinil is likely to be working 
via the activation of both these receptors to inhibit MP release by PASMCs 
derived from PAH patients. When 1µM of the IP receptor antagonist was used in 
combination with treprostinil, MP release was restored to levels similar to that by 
PDGF-BB with serum. Similarly, blocking with the EP2 antagonist also reversed 
the inhibiting effects of treprostinil on MP release by smooth muscle cells. 
Interestingly, the combination of both increased the MP number to levels higher 
than by 20ng/ml PDGF-BB and serum. This may suggest that treprostinil may 
have another target that increases MP release. That treprostinil is likely to have 
functional effects at other prostanoid receptors besides the IP receptor was 
confirmed in functional assays where this agent was assessed as a vasorelaxant in 
several isolated smooth muscle preparations. In such studies, it was found to be 
equipotent with PGE2 against EP2 receptors (EC50 4-5 nM) in mouse trachea and 
only 3–4 times less potent than PGD2 at DP1 receptors in rabbit saphenous vein 
and vena cava (Syed et al, 2015). 
 
The impact on normal smooth muscle proliferation by smooth muscle MPs from 
PAH patients was assessed. 0.1% FBS instead of 10% FBS was used as the 
control for these experiments as we were interested in subtle changes in 
proliferation. A fixed number of MPs (100,000 MPs) were able to stimulate cells 
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and increase proliferation by 37% over four days, with the ratio of MPs to cells 
being 10 MPs:1 cell. In contrast, 5ng/ml TGF-β was not able to stimulate any 
growth, confirming that the normal cells, unlike diseased, were unresponsive in 
proliferation to TGF-β, suggesting a functional BMP/BMPRII/Smad1/Smad5/Id 
gene axis that is growth suppressive (Morrell, 2010). This increase in proliferation 
seen caused by SMMPs was similarly seen suggest that the MPs may play a role 
in the remodelling seen in PAH. Similarly, PMPs have been shown to increase 
proliferation, adhesion and survival of normal stem cells and progenitor cells, and 
activate various intracellular cascades including MAPK p42/44, PI3-AKT, and 
STAT proteins and other extracellular kinases (Kim et al., 2002). With the 
addition of being able to activate the coagulation cascade due to its high 
phosphatidylserine and tissue factor rich surface, smooth muscle MPs may play an 
important role in driving inflammation and remodelling in PAH. 
 
Calcineurin Aβ expression and activation in pulmonary arterial smooth muscle 
cells were assessed using confocal microscopy. CnAβ expression and nuclear 
translocation was low in arrested cells, while 10% serum was able to increase 
expression and nuclear translocation. Treprostinil decreased both the expression 
and nuclear translocation of CnAβ to levels lower than seen with 0.1% FBS, while 
rosiglitazone did not affect the expression of CnAβ but did reduce nuclear 
translocation, though the difference did not reach significance Both PPARγ 
antagonists GW9662 and T00701 increased nuclear translocation compared to 
10% serum, suggesting that the PPARγ pathway may be active in growing 
PASMCs from PAH patients.. Indeed, PPARγ expression was enhanced in the 
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medial layer of distal pulmonary arteries taken from the lungs of children with 
endstage PAH (Falcetti et al, 2010). Furthermore, PPARγ expression was reported 
to be increased in the smooth muscle layers from asthmatic patients (Benayoun et 
al., 2001) as well as in atherosclerotic lesions (Hamblin et al., 2009). 
 
Blocking PPARγ with both GW9662 and T00701 when given in combination with  
treprostinil significantly reversed the effect of treprostinil and increased CnAβ 
nuclear translocation. However, nuclear occupancy levels were still lower when 
the PPARγ antagonists were given in combination with treprostinil than 
treprostinil treatment alone. These results may suggest that treprostinil may be 
partially acting via PPARγ and inhibiting CnAβ activity. Consistent with this 
notion, PPARγ negatively regulates store-operated Ca2+entry through the down 
regulation TRPC1 and TRPC6 (Wang et al, 2013), which in turn is likely to 
reduce calcineurin activity and thus its interaction with NFAT. Administration of 
GW9662 has been shown to reverse the effects of the prostacyclin analogue 
cicaprost inhibiting PDGF-induced cell proliferation (Falcetti et al., 2010).  
Protein kinase A has been reported to be able to phosphorylate and activate 
PPARγ, suggesting a potential cross-talk between PPARγ and prostacyclin 
(Hamblin et al., 2009). However, the activation of the ligand binding domain of 
PPARγ by prostacyclin analogues has been shown to be independent of the cAMP 
pathway (Falcetti et al., 2007). 
 
The CnAα and CnAβ isoforms of calcineurin have been shown to contain very 
different cellular distribution of expression in rat aortic smooth muscle cells. 
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CnAα was found to be evenly expressed throughout the nucleus and cytosol, while 
CnAβ was scarce in the nucleus and predominantly expressed in the perinuclear 
region of the cytosol in growth arrested cells (Jabr et al., 2007). PDGF-BB was 
able to induce nuclear translocation of CnAβ and NFATc3 but not CnAα or 
NFATc1. This may suggest that PDGF may be a common pathway for CnAβ and 
NFATc3 in driving the proliferative phenotype. CnAα may still play a role in 
SMC proliferation as it can activate calcium-dependent Cl- channels and inhibit 
ATP-sensitive K+ channels, which are also both involved in promoting agonist 
induced and/or spontaneous vascular smooth muscle contractions (Greenwood et 
al., 2004; Orie et al., 2009; Chan et al., 2012). NFATc2 levels have been shown to 
be increased in PASMCs in IPAH patients, while NFATc3 levels and smooth 
muscle actin, a marker for cell proliferation, were increased by chronic hypoxia in 
mice. This was thought to be calcium/calcineurin driven as cyclosporine A was 
able to inhibit NFATc3 nuclear translocation and smooth muscle actin expression 
(de Frutos et al., 2007b). 
 
Treprostinil was able to decrease proliferation significantly compared to serum 
alone. The calcineurin inhibitor, cyclosporine A was also able to decrease 
proliferation compared to serum alone. As 100nM treprostinil concentration is 
considered just within therapeutic range, that cyclosporine A was able to decrease 
proliferation to levels similar levels may indicate that calcineurin activation may 
play a role. The combination of 1µM treprostinil and cyclosporine A caused an 
increased inhibition of cell proliferation, which may indicate that treprostinil may 
also be acting via another pathway, such as downstream the EP2 receptor. 
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Treprostinil could have been inhibiting calcineurin activation and suppressing 
PASMC proliferation through the cAMP-driven pathway, as it has shown to 
increase cAMP production by 2-3-fold in PASMCs derived from both IPAH and 
normal cells (Davie et al., 2002; Falcetti et al., 2010). Cyclic AMP is able to 
decrease intracellular calcium levels through a variety of mechanisms that may 
lead to decreased activation of calcineurin/NFAT. cAMP could inhibit the 
formation of inositol-1,4,5-triphosphate (IP3) through inhibiting phospholipase 
Cβ, causing the inhibition calcium release from the sarcoplasmic reticulum, as 
well as inhibiting calcium entry into the cell and stimulating calcium uptake and 
extrusion (Cogolludo et al., 2007). Two major types of calcium channels have 
been demonstrated to be responsible for the regulation of calcium influx: 1) 
voltage-dependent calcium channels (VDCC), such as the L-type calcium channel, 
and 2) voltage-independent calcium channels, such as the receptor-operated 
channels and store operated calcium channels. Prostacyclin analogues have also 
been shown to act via plasma membrane potassium channels to reduce vascular 
tone (Schubert et al., 1996, 1997; Clapp et al., 1998). These channels are powerful 
and sensitive regulators that are able to inhibit VDCC-mediated calcium entry. In 
normal PASMCs, such potassium channels include the TASK1 channel, which is 
inhibited by hypoxia and endothelin-1, and the large conductance calcium 
activated potassium channel (BKCa) (Li et al., 2012). The ATP-sensitive 
potassium channel (KATP) and the calcium activated potassium channel (KCa) were 
also found to play a role in iloprost-mediated pulmonary vessel dilatation in rat 
lung (Dumas et al., 1997).  
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The store operated calcium entry (SOCE) appears to play an important role in 
PAH as calcium influx through this mechanism is enhanced in both humans and 
animal models. The transient receptor potential channels (TRPC) 3 and 6 were 
reported to be upregulated in pulmonary arterial smooth muscle cells from IPAH 
patients compared to healthy, normotensive, and non-PH patients (Zhang et al., 
2007). Moreover, iloprost was shown to be able to decrease TRPC3 expression 
and SOCE-associated calcium influx, while the adenylyl cyclase activator, 
forskolin was able to inhibit IPAH smooth muscle proliferation. This may help 
explain the observed decrease in PASMC proliferation and calcineurin activity 
caused by treprostinil. 
 
Future experiments that would be useful to understand the impact on 
inflammatory cells by the SMMPs would be to conduct experiments measuring 
the levels of cytokines (eg. IL-1β, TNFα, IL-6) after stimulating cells such as 
pulmonary arterial endothelial cells as well as to measure adhesion molecules 
expressed (eg. ICAM-1 and E-Selectin). I also would like to measure ROS 
production by cells after being treated with MPs. Platelet aggregation assays 
would provide further information on the effect of SMMPs on coagulation as it 
would be interesting to see if it correlates with thrombin generated in normal MP 
free blood. 
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Chapter 6 
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6 General Discussion and Conclusion 
Pulmonary arterial hypertension (PAH) is a debilitating and fatal disease with 
nonspecific presenting symptoms, making diagnosis often delayed for two or 
more years, during which time the disease becomes irreversible (Galie et al., 
2015b). Untreated, median survival is 3 years in adults and 10 months in children, 
highlighting the particularly aggressive nature of this disease in children 
(D’Alonzo et al., 1991; Takatsuki and Ivy, 2013). The diagnostic approach for 
PAH is based on the patient’s history and physical exam screened by 
echocardiogram and confirmed by right heart catheterisation (RHC), which is 
considered the gold standard for haemodynamic evaluation although it is highly 
invasive (Bazan and Fares, 2015). Although echocardiography is less invasive, it 
has limited accuracy for estimating hemodynamic measures such as pulmonary 
artery pressure (Fisher et al., 2009). When considering treatment decisions for 
PAH, echocardiography alone is not sufficient and RHC is required (Galie et al., 
2015b). Thus, biomarkers detecting early disease through less invasive means but 
with high accuracy for disease severity and assessment of therapeutic impact 
would prompt more immediate intervention with the hope of stabilizing and 
possibly reversing the disease. 
 
Various biomarkers that are closely associated with cardiovascular injury have 
been established for PAH but are not used clinically for the purpose of diagnosis 
and assessing treatment. Brain natriuretic peptide (BNP) and NT-pro-BNP have 
been confirmed as biomarkers for PAH relating to ventricular dysfunction but are 
"late" markers relating to ventricular dysfunction (Warwick et al., 2008). Cardiac 
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troponins are biomarkers of myocardial injury that are also elevated in PAH but 
do not represent a sensitive marker of early disease (Neuhold et al., 2008). 
 
PAH initially develops from endothelial damage, which is set off by sheer stress, 
hypoxia and genetic factors. As a result, the adhesion and migration of circulating 
inflammatory cells leads to the structural remodelling of small blood vessels, 
which is characteristic of the disease (Rabinovitch, 2008; Hassoun et al., 2009). 
Thus, inflammation coupled with vascular remodelling thus play important roles 
in driving the progression of the disease. Indeed, levels of numerous cytokines 
including interleukin (IL)-1β, -6, -8, monocyte chemoattractant protein (MCP)-1, 
fractaline, CCL/RANTES, and tumour necrosis factor (TNF)-α are abnormally 
elevated in pulmonary hypertension, some of which correlate with clinical 
worsening (Rabinovitch et al., 2014). 
 
As markers of both inflammation and vascular remodelling, microparticles (MPs) 
have shown to be increased in a variety of cardiovascular diseases including acute 
coronary syndrome, venous thromboembolism and pulmonary embolism (Chironi 
et al., 2009). These MPs in the circulation are elevated in PAH and appear to 
correlate with severity of disease, though their origin has only been characterised 
for endothelial cells and leukocytes (Amabile et al., 2008, 2013). As the earliest 
pathology is medial thickening involving the abnormal proliferation of smooth 
muscle cells, I took a special interest in smooth muscle derived MPs as potential 
early markers of PAH. During disease progression, as the proliferation of the 
adventitial and intimal layers take over, the formation of plexiform lesions also 
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start to appear (Rabinovitch, 2012). The endothelial damage and formation of 
vascular lesions could potentially allow blood to come into direct contact with the 
smooth muscle layer, thereby allowing smooth muscle MPs (SMMPs) to be 
released into the pulmonary circulation. Through this body of work, I aimed to 
show how elevated MPs derived from various cells, with a particular interest to 
SMMPs, may be used as biomarkers for early PAH diagnosis, disease severity, 
and assessment of therapeutic impact. 
 
6.1. Characterisation of smooth muscle microparticles 
The characterisation for SMMPs had not been extensively investigated prior to my 
work in this project. Brisset and colleagues reported that Fas ligand was able to 
induce annexin V+ MPs from rat aortic smooth muscle cells growing in culture, of 
which 26.6±5.8% were positive for TF (Brisset et al., 2003). Similarly, TF+ MPs 
were also shown by Schecter and colleagues to be released by smooth muscle 
cells from human coronary artery grown in 10% foetal bovine serum (FBS) and 
concentrated on a 60% sucrose bed (Schecter et al., 2000). The α5 and β1 integrin 
subunits were also found on the SMMP surfaces as well as on the smooth muscle 
cells plasma membrane. Both tissue factor and the integrin subunits are expressed 
in multiple cell types apart from smooth muscle cells, including endothelial cells 
and leukocytes, and even satellite/skeletal muscle cells, carcinoma cells and 
nervous tissue for the latter (Hirsch et al., 1994; Dingemans et al., 2010; van der 
Flier et al., 2010; Wang et al., 2011; Zwicker et al., 2011). Thus, the challenge of 
characterising SMMPs was to identify combinations of cell surface markers that 
could allow detection of specific SMMPs subpopulations in blood. 
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Classical markers of smooth muscle cells include α-smooth muscle actin, 
transgelin (sm22α), smooth muscle-myosin heavy chain, smoothelin A/B, smooth 
muscle calponin, and H-caldesmon which are all intracellular markers involved in 
either cytoskeletal support, cell proliferation or cellular contraction (Rensen et al., 
2007). Because MP detection using flow cytometry relies on the externalised 
plasma membrane markers on the MP surface, other less classical markers had to 
be investigated. In order to determine the specificity of markers on pulmonary 
arterial smooth muscle cells (PASMCs), their expression was also examined on 
growing human umbilical vein endothelial cells. PASMCs isolated from PAH 
patients and normal donors expressed platelet derived growth factor receptor-β 
(PDGFR-β), endoglin, neural glial antigen 2 (NG2), and intracellular adhesion 
molecule-1 (ICAM-1), which were also present on their MPs. It must be noted 
that high amounts of SMMPs positive for E-selectin was also detected via flow 
cytometry, though the adhesion molecule was not detected on the smooth muscle 
surface. Classically, endothelial cells are known to express endoglin, ICAM-1, E-
selectin and PECAM-1, which was confirmed by my experiments. These markers 
were also present in a high proportion of endothelial MPs. 
 
Though endoglin is classically thought to be expressed primarily on endothelial 
cells (ECs), expression of endoglin on growing human aortic smooth muscle cells 
in culture has also been seen in past experiments (Conley et al., 2000). High 
expression was also seen in human atherosclerotic plaques following vascular 
injury. In contrast to my results, Gore and colleagues reported that cultured 
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pulmonary arterial smooth muscle cells from IPAH patients had low endoglin 
expression, while pulmonary endothelial cells expressed it at high levels (Gore et 
al., 2014). Elevated levels of TGF-β and ALK-5 mRNA levels were also seen in 
PASMCs and pulmonary ECs (PECs). As endoglin is a transmembrane accessory 
protein for TGF-β, the TGF-β/ALK1/endoglin signalling pathway may be 
important in the endothelial activation seen in PAH. Through this axis, the 
activation of smooth muscle cells may also occur as the incubation of PECs with 
TGF-β led to Smad1/5/8 phosphorylation and fibroblast growth factor 2, PDGFb 
and ET-1 expression, all of which promote smooth muscle proliferation. Endoglin 
may also play a role in TGF-β signalling via ALK-5 and Smads 2/3 to induce 
smooth muscle cell proliferation (Morrell, 2010). This could be supported by 
reported data showing that endoglin deficiency in mice was found to be protective 
during hypoxic conditions (Gore et al., 2014). Soluble endoglin has also been 
shown to be elevated in PAH compared to controls and was shown to predict 
survival and functional class (Malhotra et al., 2013). Thus, endoglin+ smooth 
muscle MPs may be an important indicator of vascular remodelling and disease 
severity in PAH. 
 
PDGFRβ+ and NG2+ smooth muscle MPs may also indicate the 
hyperproliferative phenotype seen in PAH. PDGF receptors are made of two 
receptor subunits, α and β, that homo- (αα or ββ) or hetero-dimerise (αβ) to form a 
functional receptor for PDGF (dimeric isoforms PDGF-AA, -BB, -AB, CC, and –
DD). Mice experiments have shown that most mutations in PDGFRβ involve the 
disruption of phosphoinositide 3 (PI3)-kinase and phospholipase C kinase 
270 
 
pathways which lead to reduced vascular smooth muscle development in various 
tissues, while mutations in PDGFR-α lead to defects in the function of a wide 
variety of cells including chondrocytes, neural crest cells, leydig cells, intestinal 
mesenchymal cells, and kidney interstitial fibroblasts (Tallquist and Kazlauskas, 
2004). Expression of PDGFRβ has been shown to be significantly higher in PAH 
lungs compared to healthy donors (Schermuly et al., 2005). Additionally, the 
addition of the PDGFR inhibitor imatinib reversed advanced pulmonary vascular 
disease in monocrotaline-induced PH in rats and hypoxia-induced PH in mice. 
Similarly, NG2 has also been shown to be involved in the proliferation of smooth 
muscles. Schatteman and colleagues demonstrated that microvascular smooth 
muscle cells expressing PDGFRα depended on NG2 to potentiate cellular 
responses to PDGF-AA and progress in cell development (Stallcup, 2002; 
Schatteman et al., 2005). NG2 blockage using antibodies also inhibited PDGF-
AA-induced cell mitosis and migration (Grako and Stallcup, 1995). 
 
The increase of ICAM-1+ and E-selectin+ microparticles released from SMCs 
may be indicative of SMMPs as inflammatory markers. The role of inflammation 
on SMMP release was further supported by increased MP numbers following 
TNFα stimulation. Rolfe and colleagues showed that ICAM-1 expression was 
very low in rat aortic smooth muscle cells and increased with stimulation with 
cytokine IL-1β (Rolfe et al., 2000). Though I did not observe E-selectin 
expression on smooth muscle cells, E-selectin+ MPs were detected after PASMC 
stimulation with PDGF-BB. Although classically E-selectin is known to be 
expressed on endothelial cells, aortic SMCs have also shown to have the 
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capability of E-selectin expression. Nuclear factor kappa B was shown to be 
involved in the expression of E-selectin by human aortic SMCs, as its inhibitor 
pyrrolidinedithiocarbamide was able to prevented a protein synthesis inhibitor, 
cyclohexamide, from inducing a TNF-α- and LPS-mediated E-selectin 
upregulation (Chen et al., 1997). It may be possible that E-selectin+ MPs may be 
located on selective cell surface areas of the MP blebbing process after cell 
activation, though more studies would have to take place to confirm this. 
 
Validation experiments were also carried out in vitro to test whether the smooth 
muscle MPs detected represented markers of cell activation and inflammation. 
The MPs were quickly released by growing cells after PDGF-BB stimulation, with 
maximum levels reached after approximately 24 hours, in a dose-dependent 
manner. Apart from PDGF-BB, other agents elevated in PAH also were capable of 
increasing MP levels, with the order of potency being: TNFα<PDGF-BB<TGF-
β<ET-1. The activation of PASMCs by TGF-β would support the role of TGF-β 
as a mitogen in PAH due to the activation of the TGF/Alk5/Smads 2 and 3 
signalling (Morrell, 2006). As the most potent vasoconstrictor and mitogen for 
smooth muscle cells, ET-1 can act on endothelin receptors A and B to induce the 
phenotypic response (Cacoub et al., 1997; Dupuis and Hoeper, 2008). 
Interestingly, ET1-1 requires the presence of serum for its proliferative impact to 
be effective (Lambers et al., 2013). As an inhibitor of cAMP production via ETB 
receptors, ET-1 may have inhibited the cAMP-mediated suppression of 
intracellular calcium levels, thereby leading to a large increase in MP release 
(Davie et al., 2002). It has also been reported that TGF-β and ET-1 in PAH appear 
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to have a synergistic effect on PASMC proliferation as they both work via the 
ERK1/2 MAPK pathway (Lambers et al., 2013). Weigand and colleagues showed 
that ET-1-induced contractions in chronic hypoxic rats was mediated by the 
activation of Rho-kinase, which is also crucially involved in the process of 
blebbing during MP release (Weigand et al., 2006). 
 
6.2. Circulating microparticles in PAH 
Having characterised smooth muscle microparticles, they were measured in blood 
taken from the forearm vein of patients with PAH that were treatment naïve and 
after long-term therapy. Smooth muscle microparticles were defined as 
PDGFRβ+/PECAM-1-, Endoglin+/PECAM-1-, NG2+/PECAM-1-, and 
ICAM+/PECAM-1-. These SMMPs as well as total, EMPs, LMPs, PMPs and TF+ 
MPs were all increased significantly in PAH compared to age- and sex-matched 
control venous blood. Total MP levels in normal blood was very low, confirming 
low inflammation and cellular activation and apoptosis. After long-term therapy 
of a minimum of 4 months, all microparticle subpopulation levels except TF+ 
MPs were decreased compared to prior to therapy. Prior to going on long-term 
therapy, PAH patients about to go on prostacyclin therapy with/without a 
phosphodiesterase (PDE-5) inhibitor had higher total MP levels than patients 
about to go on therapy with PDE-5 inhibitor with/without endothelin receptor 
antagonist. The former group had a significantly decreased total annexin V+ MP 
level post-long-term therapy, while the latter group did not. 
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The increased MP levels in PAH may be due to high amounts of pro-
inflammatory cytokines and mitogens within the circulation as well as blood 
vessel damage. As explained above, the combination of highly potent proliferative 
agents such as TGF-β and ET-1 may partially help explain the extremely high 
levels of MP levels seen in PAH compared to healthy controls and even coronary 
artery disease and HIV. Additionally, the vascular injury and remodelling caused 
by high blood pressure, increased coagulation, medial thickening, endothelial 
damage and the formation of plexiform lesions may account for the increased 
number of both smooth muscle MPs and endothelial MPs. Increased CD66b+ MPs 
in PAH was be indicative of activated eosinophils and neutrophils in severe 
inflammation compared to control patients. Similarly, increased TF+ MPs in PAH 
would be indicative of three major processes: 1) the inflammatory status, as it 
would signify monocyte and macrophage activation and their release of cytokines 
including TNF-α and IL-1, 2) vascular remodelling, as TF+ MPs may represent 
increased smooth muscle and endothelial activation/proliferation, and 3) 
coagulation, as TF is the key player in the intrinsic coagulation pathway. As 
coagulation increases, the increase in thrombin would help stimulate large 
numbers of already activated and aggregating platelets, thereby leading to high 
amounts of platelet microparticles being released in the circulation. My results 
showed that TF+ MP levels did not decrease after long-term PAH therapy. This 
was not dissimilar to the findings of Steppich et al. who observed that TF+ MPs in 
patients with acute myocardial were unchanged after thrombolytic treatment and 
stenting (Steppich et al., 2005). 
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The decrease in circulating MPs after long-term therapy may be due to a variety of 
factors including, largely involving the decrease in cell proliferation. Indeed, all 
three major classes of drugs, prostacyclin analogues, endothelin antagonists, and 
PDE-5 inhibitors) have shown to decrease smooth muscle proliferation (Rhodes et 
al., 2009; Galie et al., 2015b). However, only prostacyclin analogues are also anti-
inflammatory and powerful inhibitors of platelet aggregation, which may help 
explain why microparticles were lower in PAH treated with prostacyclin analogue 
with or without an PDE-5 inhibitor compared to non-prostacyclin therapy. 
Inhibition of platelet aggregation by prostacyclin has been shown to be cAMP 
driven (Kelton and Blajchman, 1980). The combination of prostacyclin analogue 
with a PDE-5 inhibitor may also be an effective combination therapeutically as the 
PACES trial revealed that the addition of sildenafil to long-term intravenous 
epoprostinil therapy on patients with PAH resulted in greater mean pulmonary 
artery pressure, cardiac output, and longer time to clinical worsening compared to 
epoprostinil treatment on its own (Simonneau et al., 2008). 
 
Total annexin V+ MP levels were significantly higher in PAH venous blood than 
in STEMI coronary blood, which contained the highest number of MPs among the 
acute coronary syndrome groups. Coronary blood contained higher SMMPs, 
EMPs, LMPs, and PMPs than forearm venous bloods in STEMI and non-STEMI 
patients, possibly indicating the high level of inflammation present within the 
coronary vasculature. In coronary blood, STEMI patients had significantly higher 
circulating MPs of all subpopulations compared to non-STEMI, which may be an 
indication that MPs may be markers of disease severity. However, in venous 
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blood, the difference in MP levels was not as evident, as noticeable differences 
were seen only in SMMPs and not on other MP subpopulations. Interestingly, 
LMPs and TF+ MPs were elevated in STEMI coronary artery blood to levels 
higher than in PAH venous blood. The origination of SMMPs in myocardial 
infarction may come from thrombus formation as well as vascular damage. Indeed 
smooth muscle cells may be exposed to the blood, particularly during and after 
plaque rupture though the presence of more metalloproteinase-secreting 
macrophages appears to be more prominent during plaque development (Davies et 
al., 1993; Filardo et al., 2000). This may help explain elevated TF+ MPs and 
SMMPs. The elevation of CD66b+ MPs may be explained by the activation of 
neutrophils as they have been shown to accumulate in ischemic and reperfused 
myocardium after acute myocardial infarction and release thromboxane B2 and 
leukotriene B4 and induce vasoconstriction and platelet aggregation 
(Frangogiannis et al., 2002). The significantly higher levels of PAH venous blood 
compared to STEMI and non-STEMI venous blood suggests that MP 
measurement may be a biomarker that involves a quick, convenient, and far less 
invasive method compared to right heart catheterisation to aid in the early 
diagnosis of PAH. Though MP detection may not lead to direct diagnosis of the 
disease, it may help in the initial screening of patients who are more likely to 
suffer from PAH. 
 
The presence of microparticles was also investigated in venous blood from HIV-
infected Malawian patients and compared with blood from control subjects to 
study the effects of chronic inflammation. The level of total annexin V+ MPs in 
276 
 
HIV blood were not significantly different compared to Malawian age- and sex-
matched controls, though they were higher than in British healthy controls. 
SMMPs, EMPs and LMP levels were lower in HIV-infected patients than in 
Malawian control subjects, with British control subjects having higher MP 
numbers of the three groups. This was contrary to past work performed by da 
Silva et al. who showed that CD51+ EMPs were elevated compared to controls 
(da Silva et al., 2011). I did observe that E-selectin MPs were slightly elevated in 
HIV compared to British controls, though this difference was not significant. 
Mayne and colleagues reported that TF+ microparticles were also elevated, which 
was not seen in my results (Mayne et al., 2012). However, similar to the latter 
study, my results in chapter 4 showed that PMP levels in HIV-infected patient 
blood was higher than in Malawian controls, and was lowest in British controls. 
This may suggest that MPs may be a specific indicator of increased risk of 
thrombosis predisposed to HIV infected patients than inflammation at a wide 
spectrum. Several difficulties were faced when measuring HIV-infected blood 
samples. The measurement of samples using the only flow cytometer located in 
Blantyre, Malawi where I collected blood samples meant that I had to 1) use a 
different FACS machine with a different software, 2) could not process samples in 
the same way as my other PAH and coronary artery disease samples, and 3) had to 
use Malawian subjects for HIV non-infected controls, many who also likely had 
other inflammatory conditions. 
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6.3. Microparticle function and response to pulmonary arterial 
hypertension therapy 
 
MPs from a fixed volume of plasma from PAH patients were highly thrombogenic 
compared to microparticles from control patients and non-STEMI patients. 
Thrombin generation by MPs in PAH were lower after long-term therapy than 
prior to treatment. Thrombin generation was inhibited to a greater extent in 
patients treated with prostacyclin analogues with/without a PDE-5 inhibitor than 
in patients treated with a PDE-5 inhibitor with/without ET-1 antagonists. The 
correlation between thrombin generation and total MP count may suggest that the 
degree of thrombin generation may be, in part, due to number of MPs. A large part 
of the high thrombogenicity seen in PAH-derived MPs may also be due to 
elevated SMMP levels as my in vitro experiments showed that they were able to 
significantly induce greater amounts of thrombin in a shorter amount of time 
compared to EMPs from HUVECs. SMMPs Smooth muscle have also been 
shown to express CD154, which when bound to its receptor CD40 on leukocytes 
can also induce greater TF expression (Schonbeck et al., 2000). During 
coagulation, SMCs can be stimulated by thrombin and PDGF and in response 
release IL-6 (Libby and Simon, 2001). In response, IL-6 is able to increase plasma 
fibrinogen, plasminogen activator inhibitor-1 as well as the inflammation marker 
C-reactive protein. To add, were also found to be proliferation-inducing in normal 
smooth muscle cells, indicating that they may promote the pro-proliferative 
disease phenotype and may be involved to some degree in the remodelling that 
occurs within disease. 
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The impact of drug treatment on MP release by smooth muscle cells was also 
assessed in vitro. Treprostinil was able to decrease levels of MP release during 
cell activation after stimulation by platelet derived growth factor-BB (PDGF-BB), 
tumour necrosis factor-α (TNF-α), transforming growth factor –β (TGF-β), and 
endothelin-1 (ET-1). Moreover, the inhibition of treprostinil on PDGF-BB-
induced MP release was dose-dependent and appeared to act through both the 
prostacyclin and prostaglandin E2 receptors. It has been shown that prostacyclin 
can act via the cAMP-driven pathway in reducing intracellular calcium levels 
(Clapp et al., 2002). I wanted to investigate whether it could also be working via 
another pathway, the PPARγ pathway involving calcineurin/NFAT signalling 
which may be activated during vascular remodelling. Calcineurin Aβ expression 
and activation as measured by nuclear occupancy after translocation from the 
cytosol was decreased slightly with rosiglitazone and significantly with 
treprostinil. The partial reversal of the effect of treprostinil by the PPARγ 
antagonist GW9662 as well as the PPARγ-selective antagonist T00701 suggest 
that treprostinil may be working partially via the PPARγ-calcineurin/NFAT 
pathway. Indeed, inhibiting calcineurin with cyclosporin did cause an inhibition in 
cell proliferation compared to serum alone. When treprostinil was administered in 
combination with cyclosporin, proliferation was significantly lower, though this 
difference was not additive suggesting that treprostinil and cyclosporine may be 
working via a common pathway. Still other pathways may be involved in 
prostacyclin signalling. In human PASMCs, prostacyclin has shown to also 
activate the TWIK-related acid-sensitive K channel 1 (TASK1) and calcium-
dependent potassium channel (KCa), which may also account for the 
vasorelaxation effect of prostacyclin (Li et al., 2012). Similarly, the Kv1.5 channel 
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may be involved in the apoptotic-resistant pro-proliferative phenotype of smooth 
muscles in PAH as the calcineurin inhibitor cyclosporine A and NFAT blocker 
VIVIT were able to restore reduced Kv1.5 expression and function in PAH cells 
(Bonnet et al., 2007). Protein kinase A has been shown to be able to phosphorylate 
NFAT, thus there may also be an integration of the cAMP and NFAT/calcineurin 
pathways (Chow et al., 1999). 
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Figure 57. Calcineurin/NFAT activation 
Calcineurin (CaN) activates nuclear factor of activated T-cells (NFAT) through 
dephosphorylates and allows its nuclear translocation where it can bind to 
specific regions of the DNA and induce the expression of pro-proliferative and 
pro-inflammatory mediators. CaN/NFAT is phosphorylated by kinases such as 
protein kinase A (PKA) causing it to return from the nucleus. 
Abbreviations: Ca2+=calcium; PPARγ=peroxisome proliferator activated 
receptor γ; IL-6=interleukin 6; ET-1=endothelin-1; Kv1.5=Volage gated 
potassium channel 1.5; TRPC6= transient receptor potential cation channel 6 
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The Rho kinase pathway plays an important role in the formation of EMPs 
(Distler et al., 2005; Dignat-George and Boulanger, 2011). Rho GTPases (RhoA, 
B, and C) are intracellular signalling molecules that play a role in actin 
cytoskeletal regulation (Distler et al., 2005). After activation, Rho proteins can 
exchange GDP for GTP and signal to downstream effector proteins, and finally 
hydrolyse the bound GTP to return to its inactive GDP-bound state. Coleman and 
colleagues showed that the Rho-associated kinase I (ROCK-1) as an important 
element in Rho signalling that causes myosin light-chain phosphorylation and 
coupling of actin-myosin filaments to the plasma membrane, which contributes to 
the cytoskeletal restructuring leading to MP blebbing from mouse fibroblasts 
(Coleman et al., 2001). The small molecule inhibitor of ROCK activity Y-27632 
reduced of myosin light-chain phosphorylation and MP formation caused by 
TNFα. Additionally, the caspase inhibitor z-VAD-fmk blocked the cleavage of 
ROCK-I and MP release, suggesting that caspases could play a role in ROCK-I 
activation. Similarly, in vitro experiments showed that the cholesterol lowering 
drug fluvastatin was also shown to decrease TNFα-induced endothelial MP 
release from human coronary artery endothelial cells in a Rho-kinase mediated 
fashion (Tramontano et al., 2004). Another study showed that simvastatin could 
also inhibit chronic hypoxia-induced PAH and ROCK I and II expression (Girgis 
et al., 2007). 
 
The rho-kinase pathway may play a role in the pro-proliferative phenotype of 
PASMCs in PAH, vascular remodelling and pulmonary vascular contraction 
(Fukumoto et al., 2007). ROCK inhibition attenuates chronic hypoxia-induced 
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PAH in mice and rats, monocrotaline and high flow-induced PAH in rats, reduces 
susceptibility to PAH in fawn-hooded rats, and plays a role in the beneficial 
vasodilating effect of the PDE-5 inhibitor sildenafil in PAH (Abe, 2004; Fagan et 
al., 2004; Hyvelin, 2005; Nagaoka et al., 2006). The ROCK inhibitor fasudil has 
shown to decrease pulmonary artery pressure and pulmonary vascular resistance 
in PH patients (Ishikura et al., 2006; Xiao et al., 2015). Interestingly, prostacyclin 
does not regulate pulmonary vasodilatation through ROCK inhibition, though the 
combination of the prostacyclin analogue beraprost with fasudil has shown to be 
more effective than monotherapy with either drug (Abe et al., 2005). In bovine 
PASMCs, Rho kinase may be activated by the serotonin receptor 5-HT1B and 
mediate the nuclear translocation of phosphorylated ERK1/2  (Lee et al., 1999). 
These can in turn increase DNA binding of transcription factors including 
GATA4, Elk-1, Egr-1 and express proteins involved in cell proliferation, though 
the phosphorylation and nuclear translocation mechanism for ERK1/2 may be 
different for humans (Liu et al., 2004; Dempsie and MacLean, 2008). The 
vasoconstricting agent and mitogen serotonin that is elevated in PAH is able to 
signal via the 5-HT1B receptor on smooth muscle cells and fibroblasts and induce 
proliferation through signalling involving reactive oxygen species and ERK1/2 
mediated pathways, and may be working via ROCK as well (Dempsie and 
MacLean, 2008). ROS generation may also be a result of serotonin breakdown 
shown in human PASMCs or serotonin-induced NADPH oxidase activation 
shown in bovine PASMCs (Liu and Folz, 2004; Dempsie and MacLean, 2008).  
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My experiments showed that PDGF-BB induced MP release from smooth muscle 
cells, which may have possibly been through the Rho/Rho kinase pathway 
amongst others. Indeed, PDGF-BB is able to upregulate Rho A expression in 
vascular SMCs (Kamiyama et al., 2003). Moreover, inhibiting Rho kinase using 
Y-27632 suppresses PDGF-BB-induced ERK1/2 activation and SMC 
proliferation, suggesting that Rho A may be an important mediator of SMC 
activation and MP release. Apart from Rho, PDGF has shown to promote the 
proliferation of cells via the activation of calcineurin/NFAT (Jabr et al., 2007). 
Additionally, calcineurin was shown to be inhibited by the protein kinase A 
activator forskolin, suggesting how the cAMP pathway may be capable of 
antagonising the action of PDGF-BB. Bonet et al. has shown that PASMCs from 
PAH cells and lungs unlike normal contained activated NFATc2 (Bonnet et al., 
2007). NFATc3 is also increased in hypoxia-induced pulmonary hypertensive 
adult and neonatal mice but not in NFATc3 knockout adult mice, suggesting its 
significance in vascular remodelling (Bierer et al., 2011). To add, elevation of the 
highly potent vasoconstrictor and mitogen endothelin-1 was seen in PAH may 
also activate NFATc3 dependent on ROCK activation (de Frutos et al., 2011). 
Like PDGF, TNFα has also been shown to act via the rho kinase pathway in 
activating pulmonary microvascular endothelial cells to release JNK-mediated 
interleukin-6 secretion (Mong et al., 2007). However, unlike in SMCs, the 
Rho/ROCK pathway does not seem to play a role in endothelial contraction 
(Hunter et al., 2003; Garofalo and Surmacz, 2006). Another cytokine as well as a 
growth factor, TGFβ activity which has been implicated as an important driver of 
the remodelling process in PAH has also been shown to be regulated to an extent 
by Rho. Deficiency of the prostaglandin E3 receptor, which normally mediates 
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vasoconstriction of human arteries and is upregulated in human and mouse 
PASMCs in response to hypoxia, was shown to attenuate PH through suppression 
of TGFβ signalling via Rho/ROCK signalling. Thus, understanding the role of 
Rho in the pathogenesis of PAH and development of MPs may help explain why 
MPs may be a valuable marker for PAH. 
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  Figure 58. TGFβ, PDGFRβ, Rho, and PPARγ pathways in smooth muscle 
Schematic of the transforming growth factor β (TGFβ), platelet derived 
growth factor receptor β (PDGFRβ), Rho, and peroxisome proliferator 
activating receptor γ (PPARγ) pathways in smooth muscle 
Abbreviations: ROCK=rho associated kinase; ALK=activing like kinase; 
ERK=extracellular signal regulated kinase; RTK=receptor tyrosine kinase; 
BMP=bone morphogenetic protein; BMPRII=bone morphogenetic protein 
type 2 
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Another pathway that may also be involved in the activation of cells and release of 
MPs is the NOTCH pathway, which is involved in various aspects of vascular 
development such as vascular remodelling, angiogenesis, vascular SMC 
development and differentiation (Weber, 2008). As shown by Jin and colleagues, 
notch receptor activation leads to upregulation of PDGFRβ expression and activity 
in vascular SMCs, which would lead to increased cellular development and 
proliferation (Jin et al., 2008). TGFβ administered to mesenchymal stem cells was 
shown to induce expression of the Notch ligand Jagged 1 and SMC markers such 
as α-smooth muscle actin, calponin 1 and myocardin, which were dependent on 
Smad3 and Rho kinase activity (Kurpinski et al., 2010). Moreover, notch 
activation led to decreased endothelial markers PECAM-1 and VE-cadherin, 
suggesting that notch signaling via TGFβ may induce differentiation of 
mesenchymal stem cells into SMCs. Li et al reported greater levels of NOTCH3 
mRNA and protein levels in PASMCs from PAH patients compared to 
normotensive controls (Li et al., 2009). Constitutive expression of NOTCH3 by 
cultured PASMCs increased proliferation, while knocking out NOTCH3 in mice 
led to resistance in PH development. 
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Future studies 
• The characterisation of pulmonary artery endothelial cells and their 
microparticles after stimulation by pro-inflammatory agents such as TNFα 
would help clarify the distinction between smooth muscle and endothelial 
MPs involved in PAH. 
• Using multiple pro-inflammatory and/or pro-remodelling agents to stimulate 
cells and measure their impact on different receptor expression on the cell 
surface as well as on microparticle surface may help identify specific MP 
subpopulations that may act as viable markers in certain disease conditions. 
• Comparing levels of pro-inflammatory cytokines (e.g. IL-1, TNFα, and IL-6) 
and circulating endothelial cells in the plasma of PAH patients and controls 
could serve as indicators of vascular inflammation and damage. Levels in 
patients could subsequently be used to correlate with microparticle levels in 
patients to assess inflammatory status. 
• The inflammatory impact of SMMPs on activating vascular cells such as 
smooth muscle and endothelial cells could be investigated in vitro by 
measuring the release of proinflammatory cytokines and expression of 
adhesion molecules such as ICAM-1 and E-selectin by cells in culture. 
• ROS production by pulmonary artery smooth muscle cells after treatment 
with microparticles could also be measured in vitro using the indicator 
H2DCFDA, which can be converted to fluorescent 2’, 7’-di-chlorofluorescein 
(DCF) after oxidation and intracellular removal of acetate groups. 
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• The role of PPARγ in its ability to inhibit MP release in smooth muscle cells 
could be further studied. Using the PPARγ agonist rosiglitazone, the 
inhibition of SMMP release could be studied in vitro.  
• Other PPARs (α and β) in their ability to inhibit pulmonary artery smooth 
muscle proliferation and contribute to the anti-proliferative effect of 
treprostinil could be investigated. 
• Platelet aggregation assays could be performed to provide further information 
on the effect of SMMPs on coagulation and assess correlation with thrombin 
generation in normal MP-free blood. The role of Rho kinase pathway in 
SMMP formation in vitro could be identified. The small molecule inhibitor of 
ROCK activity Y-27632 could be used to study MP release inhibition by 
cells. The activation of ERK1/2 by RhoA could also be studied after the 
stimulation of smooth muscle cells by PDGF-BB in inducing MP release. The 
activation of NFAT by ROCK activation could also be studied in the process 
of cell proliferation and the release of SMMPs. 
• The notch pathway is implicated in various vascular processes such as 
vascular remodelling, angiogenesis and smooth muscle development and 
differentiation, and may be a novel pathway worth investigating in the 
mechanism of MP release. The activation of the notch pathway may 
potentially be a common pathway shared by multiple stimulants such as 
PDGF-BB and TGF-β leading to MP release. 
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6.4. Conclusion 
I propose that my work supports the innovation in quantifying microparticles for 
the detection of early PAH in patients. This body of work shows that MPs derived 
from smooth muscle cells classified as PDGFRβ+/PECAM1-, 
Endoglin+/PECAM1-, NG2+/PECAM1-, and ICAM1+/PECAM1- are elevated in 
PAH compared to healthy controls as well as other vascular diseases such as 
myocardial infarction and HIV. This was similarly seen in levels of microparticles 
derived from endothelial cells, leukocytes and platelets as well. As prothrombotic, 
pro-inflammatory, and pro-proliferative mediators, SMMPs could be an important 
player in the development of vascular remodelling. Furthermore, MPs may be able 
to allow assessment of the impact of therapy on PAH patients, making it a 
valuable tool in studying disease progression and patient clinical status. 
Prostacyclin was shown to be a potent inhibitor of smooth muscle microparticle 
release in vitro, and was also potent in reducing smooth muscle, endothelial, 
platelet and leukocyte circulating microparticles in PAH patients. Right-heart 
catheterisation may still be the gold-standard in PAH diagnosis but MP detection 
could potentially improve early patient screening for later more invasive 
diagnostic testing. Thus, as microparticles are a marker of disease severity and a 
quick, cost-effective, and less invasive alternative to the current diagnostic 
methods, this work could make a valuable contribution to the research of early 
biomarkers in PAH.  
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